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CHAPTER 1: Introduction
 
1.1 Obesity 
 Obesity, along with its related innumerable health problems, is increasing 
worldwide, decreasing quality of life and increasing mortality (Allison, Fontaine, 
Manson, Stevens, & VanItallie, 1999; Heo, Allison, Faith, Zhu, & Fontaine, 2003; 
Jensen, 2000; K.M. Flegal, 2002; K.R. Fontaine, 2003; Taegtmeyer, 2003). Obesity, 
declared to be disease by the American Medical Association in their 2013 annual 
meeting, generates a large portion of medical and health care costs, crossing $100 billion 
mark, particularly in the United States where two-thirds of the population is either 
overweight or obese (Ogden, Carroll, Kit, & Flegal, 2014; Tsai, Williamson, & Glick, 
2011). Obesity goes hand in hand with many fatal co-morbidities including 
cardiovascular diseases and metabolic syndrome that can then result in other disorders 
(Haslam, 2005; Sheehan & Jensen, 2000). Related to this, metabolic flexibility refers to a 
capacity to utilize lipid and carbohydrate fuels and to transit between them, depending on 
the individual’s energy needs (Kelley, He, Menshikova, & Ritov, 2002). The condition 
wherein there is a failure in this transition is termed metabolic inflexibility, which can 
lead to diabetes and obesity in affected individuals. This flexibility is difficult to achieve 
in individuals with low fat oxidation, low energy expenditure (EE), and low sympathetic 
activity, and this explains the tendency of those individuals to gain weight (Galgani & 
Ravussin, 2008).  
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Obesity, being a complex disease, is affected by genetic predisposition along with 
a multitude of factors that contribute to an individual’s likelihood of becoming obese. 
Factors that predispose an individual to be obese or resistant to obesity in an obesogenic 
environment are not fully explained. While the preponderance of data points to the 
interaction between genetic predisposition and obesogenic environment as a cause for 
obesity in the current environment, a significant fraction of people remain lean posing the 
question what is different about them?  
 
1.2 Physical activity, energy expenditure, and obesity  
Obesity is an outcome of disruption in energy balance homeostasis, which is 
strongly influenced by both genetic and environmental factors including a sedentary 
lifestyle (sitting or lying down for most part of the day (Sedentary Behaviour Research, 
2012)) and a western diet (D.W. Brown, 2004; Klein, 2004). The decline in daily 
physical activity levels is related to increased prevalence of obesity (Church et al., 2011). 
Both sedentary lifestyle and being physically inactive increase risk of metabolic 
syndrome and metabolic inflexibility, diabetes, and other cardiovascular diseases 
(George, Rosenkranz, & Kolt, 2013; Hu, 2001; Warren et al., 2010) leading to the phrase 
“sitting is the new smoking” (George et al., 2013). On average, physically inactive people 
have a life span that is 5 years shorter than that of physically active people (Pedersen, 
2011). It is well known that physical inactivity and poor physical fitness, independently 
of body mass index (BMI), are associated with an increased risk of cardiovascular 
diseases, type 2 diabetes, and mortality (Pedersen, (2009b)). This suggests that the health 
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consequences of physical inactivity and abdominal adiposity are similar and that physical 
inactivity could be a key factor in the development of abdominal adiposity.  
  
The World Health Organization recommends a minimum of 150 minutes per 
week of moderate to vigorous physical activity a healthy adult which improves their 
metabolic profile and life expectancy (D.W. Brown, 2004; Moore et al., 2012; Teske, 
Billington, Kuskowski, & Kotz, 2012). A sedentary lifestyle can decrease EE and other 
related mechanisms (Hamilton, 2008) affecting body weight and health (D.W. Brown, 
2004; Klein, 2004). The levels of physical activity or tendency to be physically active 
varies greatly between individuals and this variation is biologically regulated and is 
mostly inherited (Garland et al., 2011; Novak & Levine, 2007). Little is known regarding 
the molecular or physiological mechanisms underlying differences in physical activity, 
although the links between physical activity levels and obesity propensity are evident 
(Levine, Eberhardt, & Jensen, 1999; Levine et al., 2005). Genetic studies on obesity have 
identified a broad range of genes that are involved in obesity or are known to promote the 
obese phenotype by altering individual’s energetics. Some of these genes are involved in 
changing EE by affecting their activity energy expenditure (Novak CM, 2009; Novak et 
al., 2010). The underlying mechanisms of this alteration are unknown, however.  
 
Non-exercise activity thermogenesis (NEAT) is defined as the energy expended 
during the day by an individual outside of volitional exercise, sleeping, eating, and/or 
sport activities (Levine, 2002; Levine et al., 2005). EE associated with both voluntary 
exercise and NEAT are vital contributors to both weight maintenance and weight loss 
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(Levine et al., 1999).  NEAT accounts for the bulk of activity-associated EE in most 
individuals and is involved in body weight maintenance (Levine & Kotz, 2005). The 
ability to increase NEAT during overfeeding prevents fat gain in non-obese individuals, 
demonstrating the influence of NEAT on body weight regulation (Levine et al., 1999). 
Compared to the obese or overweight subjects, lean subjects tend to spend more time 
standing rather than sitting (Levine et al., 1999; Levine et al., 2005). Even relatively 
small amounts of weight loss can have beneficial effects on health and metabolic 
disorders (G. A. Bray, Ryan, & Harsha, 2003; LaMonte, Blair, & Church, 2005). 
Altogether, these studies show that NEAT varies considerably between individuals and 
can explain to some extent the variance among individual propensity to be lean or obese. 
Even though NEAT plays an important role in overall EE, little is known about the 
molecular and neural mechanisms that are involved in the variance among individuals. 
Thus, there is a need to understand the mechanisms involved in altering EE which 
influence weight gain and obesity propensity. 
 
1.3 Animal model for leanness and obesity 
The use of animal models to study mechanisms that underlie obesity – genetic, 
physiological, epigenetic, and environmental – as well as potential treatment strategies, 
have provided abundant of information related to obesity and its associated co-
morbidities. Most animal models of obesity are small rodents (rats or mice), but as is the 
case with most mammals, when maintained in closed enclosures with free access to food, 
obesity develops (Lutz & Woods, 2012). The most commonly used animal models of 
obesity are probably the leptin-deficient ob/ob mouse, the leptin receptor deficient db/db 
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mouse and its rat counterpart the Zucker rat, the melanocortin 4 receptor-deficient 
animals, and models of diet-induced obesity (Lutz & Woods, 2012). Approximately 20 
different genes have been implicated in monogenic causes of obesity; however, they 
account for a fewer than 5% of all severe obesity cases (Ranadive & Vaisse, 2008). This 
suggests the importance of polygenic mechanisms in the development of obesity. Diet-
induced obese animals are believed to better mimic the state of common obesity in 
humans than most of the genetically modified models and may be the best choice for 
testing prospective therapeutics (Lutz & Woods, 2012). Transgenic models or models 
with spontaneous mutations may be used in the evaluation of a prospective therapies to 
determine whether they engage a specific target or pathway in vivo or to explore the role 
of specific molecular targets and pathways in the physiology of food intake and their 
potential role in obesity (Lutz & Woods, 2012). 
 
Physical activity levels vary widely between individuals in both humans and 
rodents, and daily physical activity level is an inherited trait (Joosen, Gielen, Vlietinck, & 
Westerterp, 2005; Levine & Kotz, 2005; Levine et al., 2005). A key trait that predicts 
high physical activity is intrinsic aerobic capacity; this holds true for both humans and 
rodents where high aerobic capacity strongly predicts a favorable metabolic profile 
(Aspenes et al., 2011; M. S. Bray, 2000; Koch & Britton, 2001; Kodama et al., 2009; 
Novak CM, 2009; Zhan et al., 1999). Aerobic capacity, even in the absence of exercise, 
consistently predicts health and longevity (Kokkinos P, 2008; Myers J, 2002). To answer 
the question why some fraction of people remains lean in this obesogenic environment, I 
investigated a rat model that reproduces human leanness to greater degree. Rats that have 
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been selectively bred for high endurance capacity (HCR) are more physically active than 
their counterparts with low endurance capacity (LCR). The HCR have a low risk of 
obesity, have high EE and physical activity (independent of differences in body weight), 
and live significantly longer than LCR (Koch, Britton, & Wisloff, 2012). LCR are prone 
to obesity and other metabolic and cardiovascular disorders, and gain more weight on 
either a regular or a high-fat diet (Novak et al., 2010). Therefore, HCR and LCR act as 
animal models for leanness and obesity, respectively (Koch LG, 2008; Koch et al., 2011; 
Noland RC, 2007). As these rats show significantly different activity levels and EE, they 
make an ideal model to study the differences in skeletal muscle energetics and their 
influence on weight gain or loss. These rats, bred for their endurance capacity, more 
accurately represent a complex trait like obesity compared to traditional obese and non-
obese models which fail to effectively model the polygenic nature of obesity and 
metabolic diseases. Therefore, the use of HCR and LCR will help to identify obesity-
associated differences in skeletal muscle molecular and neural mechanisms which 
contribute to obesity prevalence in a metabolically diverse human population. 
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Table 1: Comparison between lean HCR and obesity-prone LCR rats 
 
High capacity runners 
(HCR) 
Low capacity runners 
(LCR) 
Aerobic Capacity 
High intrinsic aerobic 
capacity 
Low intrinsic aerobic 
capacity 
Physical activity High Low 
Economy of 
activity 
Low High 
Body composition Lean Obese 
Life span Long-lived Relatively short life span 
Metabolic profile Healthy metabolic profile 
Prone to metabolic and 
cardiovascular diseases 
Insulin resistance Sensitive Resistant  
Effect of high-fat 
diet 
Gain less weight Gain more weight 
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1.4 Hypothalamic regulation of energy balance  
Energy balance is achieved when energy intake equals energy output (energy 
expenditure, thermogenesis). Based on more than five decades of research on the 
regulation of food intake and energy expenditure in rodents and humans, but most 
importantly triggered by the discovery of leptin in early 90’s, the current model for the 
complex neuroendocrine regulation of energy balance has emerged. Based on this model, 
afferent signals continuously inform central nervous circuits about acute and chronic 
changes in energy homeostasis, which in turn integrate this information and respond with 
efferent signals to immediately initiate the appropriate adaptive changes and reestablish 
energy balance (Berthoud, 2003; Seeley & Woods, 2003; York & Bouchard, 2000).  
 
The central nervous system (CNS) controls energy intake and EE, and the 
hypothalamus plays a critical role in this. The hypothalamus is comprised of 
interconnected yet anatomically distinct nuclei that respond to changes in energy status 
by regulating the expression of specific homeostasis-related neuropeptides and 
neurotransmitters (Chari, Lam, & Lam, 2010). Circulating hormones like ghrelin, leptin, 
and insulin, depending on their concentrations, suppress or increase energy intake and 
expenditure by acting on the brain (Figure 1). Glucose, fatty acids, and amino acids also 
serve as indicators of energy state by acting on the brain and modulating food intake and 
EE (Lopaschuk, Ussher, & Jaswal, 2010). Studies over the last decade identified roles of 
various hypothalamic nuclei on food intake through actions mediated by orexigenic and 
anorexigenic hypothalamic peptides. Even though the hypothalamus has been the main 
focus of study for these orexigenic and anorexigenic peptides, hypothalamic nuclei 
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interact with other homeostatic systems, such as hindbrain nuclei and non-homeostatic 
systems to regulate food intake and EE (Grill, 2006); many of these interactions remain 
to be elucidated in detail.  
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Figure 1: Neurons in hypothalamus that process peripheral metabolic and feeding 
signals and inhibit each other. (Barsh & Schwartz, 2002) 
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The arcuate nucleus (ARC) at the base of the hypothalamus is believed to be the 
primary hypothalamic sensor nucleus for the regulation of energy and glucose 
homeostasis (Chari et al., 2010). Related to the regulation of energy balance, there are 
two distinct neurons in the ARC that process peripheral metabolic and feeding signals. 
The first set of neurons, called anorexigenic-peptide-expressing neurons, synthesizes 
proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript 
(CART). POMC is cleaved into smaller peptides including adrenocorticotropic hormone 
(ACTH) and α-melanocyte stimulating hormone (α-MSH). These act to reduce appetite 
and food intake and, to certain extent, increase EE. The second set of neurons express 
orexigenic peptides like neuropeptides Y (NPY) and agouti-related peptide (AgRP). They 
increase food intake and reduce EE. These two sets of neurons inhibit each other, and the 
opposing signals of these orexigenic and anorexigenic neuronal subsets are important in 
the regulation of energy homeostasis. These neuronal populations project to other 
hypothalamic nuclei including the paraventricular hypothalamus (PVH or PVN), 
dorsomedial hypothalamus (DMH), lateral hypothalamus (LH), and ventromedial 
hypothalamus (VMH or VMN) (Hakansson, Brown, Ghilardi, Skoda, & Meister, 1998). 
Apart from sensing circulating hormones, these neuronal subsets also detect and respond 
to changes in metabolic fuels (Figure). 
 
The PVH, situated on either side of the 3rd ventricle is involved in maintenance 
of energy homeostasis via modulating metabolism and appetite (J. W. Hill, 2012) and 
produces peptides corticotropin- and thyrotropin-releasing hormones that modulate 
energy balance, including physical activity and food intake (Sutton, Koob, Le Moal, 
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Rivier, & Vale, 1982; Valassi, Scacchi, & Cavagnini, 2008). The PVH is normally 
associated with satiety suggested from PVH lesion studies (Weingarten, Chang, & 
McDonald, 1985) as well as the effects of the PVH neuropeptides. The PVH receives a 
strong input from POMC and AgRP neurons and regulates a variety of neuroendocrine, 
behavioral, and autonomic functions (Cowley et al., 1999; Sohn et al., 2013).  
 
The DMH plays a key role in central regulation of metabolism. It has classically 
been implicated in the control of several functions, such as ingestive behavior, 
carbohydrate metabolism, reproduction, thermogenesis (Bernardis & Bellinger, 1998) 
and stress-induced and circadian corticosterone secretion (Kalsbeek et al., 1996). The 
DMH is composed of cells and fibers containing neuropeptide Y (NPY), and the 
nutritional status (starvation-refeeding) is reflected in NPY levels in the DMH (Bernardis 
& Bellinger, 1998). The DMH is involved in the final common pathway of 
corticotrophin-releasing hormone (CRH) secretion by the PVN, sympathetic nervous 
system outflow to the adrenal gland, and brown adipose tissue (BAT) thermogenesis 
(Bernardis & Bellinger, 1998). The DMH is also part of a "fear circuit" regulating 
cardiovascular responses to stress such as myocardial blood flow and the tachycardia 
associated with the defense reaction (Bernardis & Bellinger, 1998). Although exhibiting 
reduced ponderal and linear growth and hypophagia and hypodipsia, the rat with DMH 
lesions has normal body composition, anabolic hormone levels, and intermediary 
metabolism, and responds normally to numerous endocrine, nutritional, intra- and 
extracellular thirst and body weight-regulatory challenges (Bernardis & Bellinger, 1998). 
These rats shows normal efficiency of food utilization, but have an attenuated response to 
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the feeding-stimulatory effect of insulin with lesion-induced abnormalities including 
hyperprolactinemia and a disrupted circadian corticosterone rhythm (Bernardis & 
Bellinger, 1998).  
 
Neurons in the LH are the largest in the hypothalamus, and are topographically 
well organized (Bernardis & Bellinger, 1993). The LH belongs to the parasympathetic 
area of the hypothalamus, and connects with all major parts of the brain and the major 
hypothalamic nuclei (Bernardis & Bellinger, 1993). Lesions to the LH inhibit feeding, 
reducing body weight, though rats with LH lesions regulate their body weight in a 
primary manner and not because of destruction of a "feeding center". In the early stages 
of the syndrome, catabolism and running activity are enhanced, and so is the activity of 
the sympathetic nervous system (SNS) as shown by increased norepinephrine excretion 
that normalizes later on (Bernardis & Bellinger, 1993). The LH promotes glucose 
utilization and insulin release and affects neuroendocrine secretions (Bernardis & 
Bellinger, 1993). Stimulation studies show a profound role of the LH in glucose 
metabolism (glycolysis, glycogenesis, gluconeogenesis), the mechanism being 
cholinergic which does not appear to be a key player in lipolysis (Bernardis & Bellinger, 
1993). Orexin-expressing cells are located in the lateral, dorsal, and perifornical regions 
of the LH (Muroya et al., 2004). Orexin stimulates feeding, regulates appetite, arousal, 
and wakefulness (Beck, Kozak, Moar, & Mercer, 2006; Kotz, Teske, Levine, & Wang, 
2002). Microinjections of orexin into the ARC, PVH, and LH stimulate feeding and intra 
PVH microinjections of orexin increases physical activity and weight loss in rats (Dube, 
Kalra, & Kalra, 1999; Novak & Levine, 2009). 
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Studies on rats starting in the 1940’s and 50’s used electrolytic lesions to 
demonstrate that lesioning the VMH produced hyperphagia and massive obesity, while 
lesions to the LH produced aphagia and weight loss (Anand & Brobeck, 1951; 
Hetherington AW, 1940). This formed the basis for the dual-center model, whereby the 
VMH acts as the ‘satiety center’ and the LH acts as the ‘feeding center’ (King, 2006). 
According to this model, the interplay between the two regions would then be responsible 
for determining energy intake (Elmquist, Elias, & Saper, 1999). Although the lesion 
studies did conclusively demonstrate a central role for the hypothalamus in energy 
homeostasis, the dual-center model was much criticized. Gold (Gold, 1973) stated that 
lesions which extended beyond the borders of VMH, damaging ventral noradrenergic 
bundle or PVH, were responsible for the observed hyperphagia and obesity. He also 
pointed out that VMH-lesioned rats became obese even after pair-feeding them at normal 
levels of food intake, demonstrating that “VMH obesity” was not completely secondary 
to hyperphagia. Thus, anatomical studies using knockout and pair-fed rats indicate that 
VMH lesion-induced obesity alters metabolism, likely through altered regulation of the 
autonomic nervous system, parasympathetic as well as sympathetic (King, 2006).  
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Figure 2: Illustration of a coronal section of a rat brain showing ventromedial 
hypothalamus (VMH). The rat brain in stereotaxic coordinates (Watson). 
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Today, the VMH is conceptualized as a part of a pathway regulating energy 
balance through its actions on peripheral glucose and lipid allocation, modulating 
respiratory quotient (RQ or RER) and high-fat diet-induced thermogenesis (Kim et al., 
2011; Miyaki et al., 2011; Takahashi & Shimazu, 1981; Toda et al., 2009). With regards 
to the role of the VMH in energy balance, the best studied neuropeptides are 
melanocortins. The central melanocortin (MC) system plays a vital role in controlling 
energy balance, increasing EE, decreasing appetite, and modulating peripheral lipid 
metabolism (Butler, 2006; Nogueiras et al., 2007). The neuropeptide α-MSH is derived 
from the precursor polypeptide POMC and is an endogenous MC receptor agonist that 
reduces food intake and increases EE when it acts on MC3, MC4, and MC5 receptors 
(MC3R, MC4R, and MC5R). AgRP is an endogenous inverse agonist to both MC3R and 
MC4R (A. S. Chen et al., 2000; Fan, Boston, Kesterson, Hruby, & Cone, 1997; Huszar et 
al., 1997; Ollmann et al., 1997). POMC and AgRP neurons project from the arcuate 
nucleus to the VMH which express both MC3 and MC4 α-MSH (i.e., MC) receptors 
(Bagnol et al., 1999; Elias et al., 1998; Gantz et al., 1993; Haskell-Luevano et al., 1999). 
Loss-of-function mutations in MC4R are associated with hyperphagia and severe early-
onset obesity, supporting the key role for the MC system in energy homeostasis in 
rodents and humans (Huszar et al., 1997; Razquin, Marti, & Martinez, 2011; Santini et 
al., 2009). Mutations in MC3R and MC4R have been associated with decreased EE partly 
through decreased physical activity in mice and rats (Cauchi et al., 2009; Chagnon et al., 
1997; A. S. Chen et al., 2000; Mul et al., 2012). Although characterized as similar to 
MC3R and MC4R and found in the brain and other tissues, MC5R is less studied with 
respect to energy balance (Fathi, Iben, & Parker, 1995; Griffon et al., 1994).  
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Central MC controls peripheral glucose and lipid metabolism as well as 
thermogenesis in BAT (Nogueiras et al., 2007; Obici et al., 2001; Voss-Andreae et al., 
2007), demonstrating neuroendocrine control over peripheral cell metabolism, likely 
through regulation of the SNS (Rahmouni, Haynes, Morgan, & Mark, 2003). There has 
been a gradual shift in studies the on central regulation of metabolism from adipose and 
hepatic tissue towards regulation of muscle metabolism. Peripheral signals regarding the 
energy status of the individual alter the functioning of the hypothalamic nuclei which in 
turn regulate energy partitioning in muscle, possibly via a sympathetic relay (Belgardt & 
Bruning, 2010; Braun & Marks, 2011). Injection of leptin or orexin-A into the VMH 
increases glucose uptake and glycogen synthesis in skeletal muscle via the SNS, and this 
is dependent on MC signaling, as shown by studies using Melanotan II (MTII), a potent 
activator of MC3R, MC4R, and MC5R (Shiuchi et al., 2009; Toda et al., 2009). To 
summarize, the present-day view of VMH in altering energy balance includes its role in 
modulating peripheral fuel partitioning through several systems including MC.  
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Figure 3: The hypothalamic melanocortin system and the regulation of energy and 
glucose homeostasis. The hypothalamic ARC is a critical mediator of energy and 
glucose homeostasis. Two groups of ARC neurons (“first-order” neurons), the NPY and 
AgRP coexpressing neurons and the POMC expressing neurons, are proposed to play a 
major part in mediating these regulatory effects. Projections from the ARC neurons reach 
adjacent hypothalamic nuclei (“second-order” neurons) including the PVH. The 
melanocortin signaling progressing along these nuclei and to downstream brain areas is 
mediated by α-MSH, a cleavage product of POMC, which binds the melanocortin 
receptor MC4R. Inhibition of this “melanocortin tone” is mediated by (1) synaptic 
inhibition of POMC neurons by NPY/AgRP neurons (via MC3R) and of target second-
order neurons by neuropeptide Y1 receptor (Y1R) and (2) AgRP acting as an endogenous 
antagonist on MC4R. Insulin and leptin carry out their anorectic effects via inhibiting 
NPY/AgRP neurons and stimulating POMC neurons, while ghrelin activates NPY/AgRP 
neurons to promote feeding behavior. Nutrients such as LCFAs have been shown to 
downregulate the expression of AgRP to mediate the hypothalamic anorectic signal. GP, 
glucose production; FI, food intake; EE, energy expenditure (Chari et al., 2010). 
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1.5 Obesity and skeletal muscle energy expenditure  
The prevalence of obesity is rising despite treatment strategies aimed at reducing 
energy intake. Although, programs focusing on energy intake have some impact on short-
term energy balance, the bigger problem still persists and cannot be tackled by dietary 
treatments alone. Present-day programs designed to increase EE are generating mixed 
results, suggesting the need for new strategies, for example strategies to modulate 
adaptive thermogenesis, a regulated production of heat in response to environmental 
changes in temperature and diet, modulating metabolic efficiency (van den Berg, van 
Marken Lichtenbelt, Willems van Dijk, & Schrauwen, 2011). In humans, in addition to 
the putative role of the thermogenic BAT, skeletal muscle has been demonstrated to 
significantly contribute to adaptive thermogenesis (van den Berg et al., 2011). The 
capacity of skeletal muscle to contribute to whole-body EE can be related to the fact that 
muscle is composed of approximately 40% of the total body mass and accounts for 
approximately 20–30% of the total resting oxygen uptake (Zurlo F, 1990). Skeletal 
muscle is an endocrine organ which by secretion of hormone-like factors (myokines) may 
influence metabolism in tissues and organs (Pedersen, 2011). Furthermore, the 
contribution of muscle mitochondrial proton leak to resting metabolic rate can be as large 
as 20–50% (Rolfe & Brown, 1997) and in combination with heart accounts for 100% of 
increased energy consumption during exercise (Gallagher et al., 1998), demonstrating the 
large potential of skeletal muscle to increase oxygen uptake and energy use. The 
contribution of the skeletal muscle to diet-induced adaptive thermogenesis ranges 
between 35 and 67% (van Baak, 2008); also, up to 50% of adrenalin-induced 
thermogenesis was demonstrated to originate at the skeletal muscle level (Astrup, Bulow, 
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Madsen, & Christensen, 1985). Mitochondrial uncoupling, the process whereby substrate 
oxidation is uncoupled from ATP production and directed towards heat loss, is postulated 
to be an excellent target to elevate whole-body EE (Conley, Jubrias, Amara, & Marcinek, 
2007). This is mostly due to the high oxidative capacity of muscle which allows for 
significant uncoupling-related EE. The other mechanisms that contribute to skeletal 
muscle adaptive thermogenesis may also provide potential targets, although the scaling 
possibilities are limited in comparison with uncoupling (van den Berg et al., 2011). 
 
 Skeletal muscle is heterogeneous and composed of slow and fast-twitch fiber 
types. Which differ in the composition of contractile proteins, oxidative capacity, and 
substrate preference for ATP production. Slow-twitch fibers display low fatigability, high 
oxidative capacity, and a preference for fatty acids as substrate for ATP production. Fast-
twitch fibers have a higher fatigability, higher strength of contraction, lower oxidative 
capacity, and a preference for glucose as a substrate for ATP production through 
anaerobic glycolysis (Bassel-Duby & Olson, 2006; Schiaffino & Reggiani, 2011). 
Endurance or aerobic exercise increases mechanical and metabolic demand on skeletal 
muscle, resulting in a switch from a fast-twitch to a slow-twitch fiber type (Baskin, 
Winders, & Olson, 2015). Conversely, in obesity and diabetes, characterized by excess 
caloric intake without increased metabolic demand, a slow-to fast fiber type switch 
occurs in muscle, which decreases oxidative capacity (Mootha et al., 2003). Insulin 
resistance, a hallmark of metabolic syndrome and diabetes, correlates with a higher 
composition of fast-twitch muscle fibers (Simoneau, Colberg, Thaete, & Kelley, 1995). 
Resistance training also impacts skeletal muscle metabolism by increasing muscle mass 
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and enhancing the oxidative and glycolytic capacity of fast-twitch fibers (LeBrasseur, 
Walsh, & Arany, 2011). Diabetic patients on a regimen of resistance training have 
improved insulin sensitivity (Zanuso, Jimenez, Pugliese, Corigliano, & Balducci, 2010), 
and obese patients subjected to resistance training develop increased lean mass and a 
higher resting metabolic rate (Willis & Houmard, 2012). Exercise impacts systemic 
glucose and lipid homeostasis and alters muscle fiber type composition, which is 
regulated at the level of transcription (Baskin et al., 2015). 
 
1.6 A functional model of hypothalamic control of peripheral metabolism  
The hypothalamus regulates muscle glucose metabolism and insulin sensitivity 
(Shiuchi et al., 2009). For example, electrical stimulation of the VMH increases glucose 
uptake in certain peripheral tissues, including skeletal muscle, BAT, and heart of rats 
(Shiuchi et al., 2009). Intravenous (i.v.) or intracerebroventricular (i.c.v.) administration 
of leptin also induces an acute increase in both whole-body glucose turnover and glucose 
uptake by the same peripheral tissues in mice without any substantial change in plasma 
insulin or glucose level. Administration of leptin into the medial hypothalamus (MH) 
increases glucose uptake in skeletal muscle, heart, and BAT via sympathetic nerves in a 
manner that apparently is dependent on β-adrenergic receptor (β-AR) stimulation. In 
support of this, injection of leptin into the MH results in the stimulation of fatty acid 
oxidation in skeletal muscle through the activation of sympathetic nerves and of α2 
subunit-containing AMP kinase (α2AMPK) in skeletal muscle (Minokoshi et al., 2002).  
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One tissue that is targeted by the sympathetic nervous system in this process is 
skeletal muscle. Central administration of fatty acid synthase (FAS) inhibitors in both 
obese and lean mice rapidly activates fatty acid oxidation in skeletal muscle (Cha, Hu, 
Chohnan, & Lane, 2005). Skeletal muscle is the most abundant fatty-acid metabolizing 
tissue in most animals. Because fatty acids are the major physiological fuel for muscle, an 
increase in the rate of fatty acid oxidation in this tissue would be expected to have a 
major impact on whole-body EE. Moreover, evidence supports the assertion that skeletal 
muscle fatty acid metabolism is modulated by the CNS, and that the signal transmitted 
from CNS to muscle is mediated through the SNS via α-adrenergic receptors in skeletal 
muscle (Cha et al., 2005). This statement gets support from the study made by Cha et al 
(2005), where, α receptor blockade prevented the FAS inhibitor-induced increase of 
skeletal muscle uncoupling protein 3 (UCP3), whole-body fatty acid oxidation, and 
decreased skeletal muscle malonyl-CoA.  
 
A possible explanation for the increase of energy expenditure induced by intra-
hypothalamic FAS inhibition is increased thermogenesis caused by upregulation of 
skeletal muscle UCP3. UCP3 is thought to dissipate the proton gradient across the inner 
mitochondrial membrane, producing heat rather than ATP. This thermogenic response 
may contribute to whole-body EE. Because UCP3 is expressed primarily in skeletal 
muscle, which is a major energy-consuming tissue in most animals, up-regulation of 
skeletal muscle UCP3 is a likely candidate for the FAS inhibitor-induced increase in EE. 
Fatty acids most likely fuel this thermogenic response. There is a positive correlation 
between upregulation of UCP3 induced by central administration of FAS inhibitors and 
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the increase in fatty acid oxidation by skeletal muscle (Cha et al., 2005). This increase is 
the result of decreased malonyl-CoA concentration caused by the phosphorylation-
induced inactivation of acetyl CoA carboxylase (ACC) (Figure 4) (Cha et al., 2005). The 
decrease in malonyl-CoA levels in skeletal muscle normally leads to activation of 
carnitine palmitoyltransferase-1 (CPT1) in skeletal muscle, allowing translocation of fatty 
acids into the β-oxidation compartment of mitochondria. Skeletal muscle has little-to-no 
FAS, so malonyl-CoA cannot be used for fatty acid synthesis but is used primarily in the 
regulation of CPT1b, the muscle-specific CPT1, in combination with the outer-
mitochondrial tethered ACC2. Therefore, there is evidence for malonyl-CoA as a 
signaling intermediate in altering whole-body energy expenditure by acting at the level of 
skeletal muscle (Figure 4).  
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Figure 4: Proposed model for transmission of the malonyl-CoA signal from the 
hypothalamus to skeletal muscle. β3-Ad-R, β3-adrenergic receptor; ATPsynth, ATP 
synthase; ICDH, isocitrate dehydrogenase; Mito, mitochondria (Cha, Rodgers, 
Puigserver, Chohnan, & Lane, 2006). 
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Cha et al (2005) demonstrated how central sensing of lipids affects skeletal 
muscle fuel use and altered skeletal muscle energetics. Central administration of FAS 
inhibitors up-regulates the expression of the transcriptional coactivators peroxisomal 
proliferator activator γ coactivator 1α (PGC-1α) and of peroxisome proliferator activated 
receptor α (PPARα) in skeletal muscle (Cha et al., 2006). The role of these coactivators in 
skeletal muscle is to activate β-oxidation and thermogenesis, as shown by ectopic 
expression of PGC-1α in muscle cell line, which activates fatty acid oxidation and 
induces expression of UCP3 and PPARα (Cha et al., 2006). PGC-1α is known to activate 
the transcription of genes that promote adaptive thermogenesis in both brown adipose 
tissue and skeletal muscle, and it stimulates mitochondrial biogenesis (Cha et al., 2006). 
PGC-1α is a transcriptional coactivator that interacts with transcription factors like 
peroxisome proliferator activated receptor γ (PPARγ), PPARα, and thyroid hormone 
receptor by binding to the promoters of target genes which encodes proteins that carry out 
its metabolic effects. These findings reinforce the importance of these transcriptional 
regulators in the control of energy homeostasis which may mediate the effects of the CNS 
on skeletal muscle through the SNS.  
 
The studies described above support a model in which malonyl-CoA signaling in 
the brain, initiated by the central administration of a FAS inhibitor, is rapidly 
communicated to skeletal muscle via the SNS; in muscle, fatty acid oxidation and the 
expression of the genes related to this process are up-regulated (Cha et al., 2005). The 
malonyl-CoA signal appears to be transmitted by the SNS because the β-blocker, 
propranolol, and the α-blocker, phentolamine, prevent the centrally administered FAS 
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inhibitor’s effects on skeletal muscle gene expression, for example inhibiting the rise of 
UCP3 expression (Cha et al., 2005). There is a correlation between these gene expression 
patterns and increases in effectors of the β-adrenergic signaling system in muscle (namely 
norepinephrine and cAMP, the expression of the β-adrenergic receptor, and the 
phosphorylation of ACC) (Cha et al., 2005). Actions of these centrally administered FAS 
inhibitors resemble the effects of leptin, which also acts through the hypothalamic-SNS 
axis (Cha et al., 2006). Both FAS inhibitors and leptin trigger the expression of the genes 
encoding a group of enzymes involved in mitochondrial fatty acid oxidation and 
oxidative phosphorylation in skeletal muscle (Figure 4).  
 
In addition to above mentioned systems, there are other brain systems in the 
hypothalamus, for instance orexin, that effect SNS and skeletal muscle. The orexin-
containing neurons are activated during motivated behaviors and active waking and they 
regulate sympathetic tone, metabolic rate, and blood glucose concentration as well as 
food intake, wakefulness, and reward seeking (Shiuchi et al., 2009). Furthermore, orexin 
transgenic mice were recently found to exhibit enhanced insulin sensitivity with regard to 
whole-body glucose metabolism. Effects of orexin-A on skeletal muscle appear to be 
mediated through β-adrenergic rather than α-adrenergic pathway. Stimulation of 
sympathetic nerves and subsequent β2-AR signaling results in activation of the insulin 
signaling pathway in skeletal muscle (Shiuchi et al., 2009). Insulin delivery to skeletal 
muscle cells via blood vessels plays a key role in whole-body glucose disposal. Both β2-
ARs in blood vessels and insulin stimulate vascular relaxation. (Shiuchi et al., 2009). 
Orexin-A injection into the VMH induced greater effect on glucose uptake in red type of 
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skeletal muscles (e.g., soleus) than in white type of muscles (e.g., quadriceps). Red type 
muscles have many mitochondria, a key organelle for thermogenesis (Shiuchi et al., 
2009). It is also possible that the orexin-VMH-SNS axis regulates muscle glucose 
metabolism during fasting. Although the activity of sympathetic nerves in tissues such as 
BAT decreases markedly in response to fasting, that in skeletal muscle does not (Shiuchi 
et al., 2009). The β2-adrenergic receptor in both myocytes and nonmyocyte cells of 
skeletal muscle is involved in this regulation. Collectively, these data suggest that the 
VMH modulates skeletal muscle energetics and associated thermogenesis via multiple 
pathways, one of which is modulated by hypothalamic peptides including orexin. 
 
At present, pharmacological, genetic, and physiological evidence clearly 
demonstrates that discrete sets of hypothalamic neurons modulate peripheral lipid 
metabolism by integrating the signaling effects of hormones (such as leptin and ghrelin) 
and neuropeptidergic systems (such as melanocortins and NPY). It is very likely that 
other peripheral signals and central neuropeptides may also control peripheral lipid 
metabolism. There is lot of attention lately on the role of BAT in EE, but skeletal muscle 
can be a better target organ, as it is larger tissue in animals, burns more calories, and is 
more relevant to whole body insulin sensitivity. But first, it is necessary to elucidate 
which nuclei and neuropeptides in the brain are important for the regulation of peripheral 
metabolism. It is also necessary to look at the tissues like skeletal muscle that can be a 
good target system for pharmacological interventions that are aimed at changing EE to 
treat over-weight and obesity which lead us to the designing and development of efficient 
drugs for the treatment of obesity and its related disorders. 
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1.7 Uncoupling proteins, metabolism, and obesity  
The uncoupling proteins 1, 2, and 3 (UCP1, UCP2, and UCP3) are members of 
the super family of anion carrier proteins located in the inner membrane of mitochondria. 
UCP1 is found only in brown fat mitochondria of mammals (Fisler & Warden, 2006). 
Studies beginning in the 1960s, identified the function of UCP1 in providing heat and 
decreasing energy efficiency through dissipation of the proton electrochemical gradient 
across the inner mitochondrial membrane of brown adipose tissue without the generation 
of ATP (Nicholls, 2001). Thus, the function of UCP1 was known before the gene was 
cloned. On the other hand, UCP2 (Fleury et al., 1997) and UCP3 (Boss et al., 1997; 
Vidal-Puig, Solanes, Grujic, Flier, & Lowell, 1997), were identified in 1997 by reverse 
cloning (i.e., by 'mining' databases of expressed sequence tags or from similarity to UCP1 
in cDNA libraries). UCP2 and UCP3 have 59% and 57% identity, respectively, with 
UCP1, and 73% identity with each other (Krauss, Zhang, & Lowell, 2005). These 
uncoupling proteins have several hypothesized functions including thermogenesis in 
certain tissues, protection from reactive oxygen species (ROS), mediation of insulin 
secretion, neuroprotection, and export of fatty acids. Several of these functions are either 
directly or indirectly linked to the etiology of the metabolic syndrome. The major protein 
involved in the process of mitochondrial uncoupling is UCP1, which is primarily 
associated with BAT (Ribeiro MO, 2010). Homologues of UCP1 include UCP2 and 
UCP3; UCP2 has been demonstrated to be expressed in a variety of tissues, but UCP3 
expression is mainly limited to the skeletal muscle (Azzu, Jastroch, Divakaruni, & Brand, 
2010). 
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Figure 5: Action of the electron transport chain leading to the build-up of a proton 
gradient across the inner mitochondrial membrane. Protons can cross the inner 
mitochondrial membrane via the F0F1 complex, thereby providing energy for the 
conversion of ADP to ATP. Alternatively, the proton gradient can be reduced by 
uncoupling proteins (UCP), either by direct transport of protons from the intermembrane 
space to the matrix or by transport of fatty acid anions in the opposite direction. Cyt c, 
cytochrome c. Q, coenzyme Q (Schrauwen & Hesselink, 2002). 
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Energy wastage and protection from obesity were initially suggested to be 
significant functions of UCP2 and UCP3 due to their homology to UCP1 and their 
distribution in tissues, such as in white adipose tissue and muscle, which could dissipate 
energy. Gene expression of UCP2 and UCP3 increases during fasting (Cadenas S, 1999), 
however, the opposite of what would be expected for a thermogenic compound. Also, 
neither UCP2 nor UCP3 knockout mice are obese (Arsenijevic et al., 2000; Gong et al., 
2000), providing evidence against these proteins contributing to whole-body 
thermogenesis. Transgenic mice over-expressing a UCP2/UCP3 construct, however, are 
leaner than wild type mice (Fuller, Warden, Barry, & Fuller, 2000; Horvath, Diano, 
Miyamoto, et al., 2003) and those overexpressing only UCP3 in skeletal muscle are 
leaner despite hyperphagia (Clapham et al., 2000). However, even though uncoupling in 
over-expression studies does not reflect the native function of the protein in the cell, they 
cannot negate UCP2 or UCP3’s whole-body thermogenic function and protection against 
obesity. 
 
Evidence suggests that, under specific conditions, these UCP homologues can 
have a thermogenic function. UCP2 mRNA was positively associated with higher 
temperatures within certain areas of the brain, suggesting that UCP2 could function as a 
thermogenic protein in the microenvironment of the brain (Horvath, Diano, & Barnstable, 
2003; Horvath et al., 1999). In UCP3 knockout mice, the thermogenic response to the 
drug MDMA (ecstasy) is significantly reduced, suggesting that UCP3 in muscle can 
affect whole body thermogenesis in this non-physiological condition (Mills, Banks, 
Sprague, & Finkel, 2003). The contribution of higher rates of skeletal muscle 
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mitochondrial uncoupling to thermogenesis has been demonstrated in mouse models (Li 
et al., 2000). Evidence for beneficial effects of skeletal muscle uncoupling comes from 
UCP1 muscle-specific overexpressing mice that have a higher degree of whole-body EE 
and skeletal muscle mitochondrial uncoupling, and are protected against high-fat diet 
induced obesity as well as glucose intolerance (van den Berg et al., 2011). Similarly, 
UCP3 overexpression protects mice from high-fat diet-induced obesity and insulin 
resistance (C. S. Choi et al., 2007). Stimuli such as cold and leptin administration 
increase skeletal muscle uncoupling and total EE (Rousset et al., 2004). UCP3 mRNA 
expression in skeletal muscle is upregulated after thyroid hormone treatment which is 
known to increase thermogenesis both in rodents (Gong, He, & Reitman, 1999) and 
humans (Schrauwen et al., 2000). Skeletal muscle expression of UCP3 is rapidly 
upregulated after cold exposure with levels reaching peak after 1 day, but prolonged 
exposure leads to a reduction in UCP3 mRNA expression (B. Lin, Coughlin, & Pilch, 
1998). Mice overexpressing UCP3 eat considerably more than their wild type littermates, 
but do not become obese, suggesting that metabolic rate is increased in these animals 
(Clapham et al., 2000). This implies that UCP3 plays role in uncoupling oxidative 
phosphorylation, dissipating energy as heat. In conclusion, muscle mitochondrial 
uncoupling lowers body weight and plays a key role in adaptive thermogenesis. In 
addition, because of the large potential physiological impact of elevating EE in skeletal 
muscle, increasing skeletal muscle mitochondrial uncoupling may be an effective 
treatment against obesity. 
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UCP3 has been proposed to be a transporter of fatty acid anions out of 
mitochondria (Himms-Hagen & Harper, 2001) analogous to UCP1 in BAT. The fatty 
acid cycling model, proposed for UCP1 in 1996 (Garlid, Orosz, Modriansky, Vassanelli, 
& Jezek, 1996), suggests that UCP3, by transporting fatty acids out of mitochondria, 
protects the mitochondria from the toxic effects of fatty acid anions or peroxides 
(Schrauwen & Hesselink, 2004) (Figure 6). The hypothesis is attractive in that it is 
consistent with observations that UCP3 expression is correlated with improved fatty acid 
oxidation when fatty acid supplies are high, for example with fasting or a high-fat diet 
(Krauss et al., 2005). Also, muscle UCP3 protein levels are increased when rats are fed a 
diet high in long-chain triglycerides but not a diet high in medium-chain triglycerides 
which are oxidized via a different pathway (Schrauwen et al., 2003), again linking fatty 
acid oxidation with UCP3. Results from UCP3 knockout mice are not consistent, 
however, some showing reduced rates of fatty acid oxidation and others finding no effect 
(Krauss et al., 2005). Thus, the proposal that UCP3 protects against fatty acid toxicity in 
the mitochondria remains to be confirmed.  
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Figure 6: Hypothesis for the function of uncoupling protein-3 (UCP3): fatty acid 
anions are transported out of the mitochondrial matrix to prevent accumulation of fatty 
acid anions inside the matrix. FA, fatty acid; CoA, coenzyme A; FAS, fatty acyl-CoA 
synthetase; CPT1, carnitine palmitoyl transferase-1; CPT2, carnitine palmitoyl 
transferase-2;Δ H+, proton gradient (Schrauwen & Hesselink, 2002).   
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UCP2 and UCP3 expression levels are elevated during fasting (Samec, Seydoux, 
& Dulloo, 1999) as well as in other states including feeding of high-fat diets, where 
circulating fatty acid levels are elevated and there is a shift from carbohydrate to lipid 
oxidation (Fisler & Warden, 2006). Up-regulation of UCP expression depends on strain 
and tissue type: a high-fat diet increased UCP3 mRNA expression in skeletal muscle of 
C57BL/6J mice (Gong et al., 1999) and rats (Kusunoki et al., 2005) but increases UCP2 
expression only slightly in white adipose tissue of AKR mice and not at all in C57BL/6J 
mice (Gong et al., 1999) or in rats (Kusunoki et al., 2005). The up-regulation of UCP3 
protein by a high-fat diet also occurs in human skeletal muscle (Hesselink et al., 2003). 
Similarly, within the brain, a high-fat, ketogenic diet increases UCP2 mRNA and protein 
levels and reduces ROS production (Sullivan, Rippy, et al., 2004; Sullivan, Springer, 
Hall, & Scheff, 2004). Conversely, substitution of a low-fat diet to immature rats reduces 
UCP2 levels and increases ROS production and seizure-induced excitotoxicity (Sullivan, 
Dube, Dorenbos, Steward, & Baram, 2003). Thus, a ketogenic diet may be 
neuroprotective by diminishing ROS production through activation of UCP2 in the brain 
(Sullivan, Rippy, et al., 2004). Indeed, UCP2 up-regulation in the brain is proposed as the 
mechanism by which a ketogenic diet reduces pediatric seizures (Fisler & Warden, 2006). 
 
Features of the metabolic syndrome include central adiposity, increased plasma 
triglycerides and free fatty acids, insulin resistance, hyperglycemia, increased 
inflammation and hypertension, leading to increased risk of type-2 diabetes, 
atherosclerosis, and stroke. Several of these features are influenced by UCP2 and/or 
UCP3 (Fisler & Warden, 2006). Genetic association of natural polymorphisms with 
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phenotypes in humans provides an independent method to determine the in vivo functions 
of UCP2 and UCP3. Thus, one can demonstrate the influence of UCP2 on type-2 diabetes 
or BMI in an association study even without proving the underlying biochemical reaction 
carried out by these proteins (Fisler & Warden, 2006). Indeed, genetic studies can be 
used to guide biochemical investigations towards understanding the biochemistry of 
UCP2 and UCP3 (Fisler & Warden, 2006). 
 
A review of human genetic studies examining expression of UCP2 or UCP3 and 
the propensity to obesity suggested that some obesity related phenotypes are significantly 
associated with these UCPs. A UCP2 insertion/deletion variant was associated with BMI 
in 4 studies, and polymorphisms of UCP3 were associated with BMI in 2 studies 
(Schonfeld-Warden & Warden, 2001). These authors concluded that since the UCP2 
insertion/deletion variant association with BMI was observed in a variety of ethnic 
groups, the variant itself underlies the association with BMI (Schonfeld-Warden & 
Warden, 2001). Population studies showed that a common polymorphism in the UCP2 
promoter, -866G/A, was associated with a reduced risk of obesity in Caucasian 
Europeans (Esterbauer et al., 2001; Krempler et al., 2002). However, the data suggesting 
an effect of UCPs on obesity remains uncertain, with papers reporting no linkage or 
association with UCP2 or UCP3 alleles, while another reports an association of UCP3 
alleles with measures of body composition in women (Fisler & Warden, 2006). 
 
Insulin resistance in type-2 diabetes and obesity involves muscle, liver, and 
adipocytes. UCP2 knockout mice show increased insulin sensitivity and are protected 
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against dietary fat-induced insulin resistance (Joseph et al., 2002). Conversely, data from 
in vitro studies in L6 muscle cells suggest that UCP3 functions to facilitate fatty acid 
oxidation and minimize mitochondrial ROS production, perhaps thereby reducing muscle 
insulin resistance (MacLellan et al., 2005). Higher expression of UCP2 in white adipose 
tissue and skeletal muscle are associated with reduced risk of developing obesity 
(Schrauwen & Hesselink, 2002). The data presently available suggest that UCP2 up-
regulation has opposing effects on different components of type-2 diabetes. Increased 
UCP2 results in β-cell dysfunction, impaired insulin sensitivity, and earlier, more severe 
diabetes, but may protect from diabetic neuropathy (Fisler & Warden, 2006). Thus, UCP2 
is proposed as a diabetes gene (Marx, 2002). Increased UCP3 may, on the other hand, 
reduce muscle insulin resistance (Fisler & Warden, 2006).  
 
1.8 ATP-sensitive potassium channels (K+ATP), metabolism, and obesity 
ATP-sensitive potassium (K+ATP) channels, a family of weak inward rectifiers 
inhibited by intracellular ATP that couple cellular energy metabolism to membrane 
electrical activity, have perhaps been the most widely explored K+ channels in terms of 
therapeutic potential (S. J. Ashcroft & Ashcroft, 1990). Various types of ion channels are 
involved in the regulation of electrical activity in the pancreatic β-cell, and of these, the 
K+ATP channel plays a critical role; these are also found in the sarcolemmal, 
mitochondrial, and nuclear membranes (sarc, mito, and nuclear K+ATP). In pancreatic β-
cells opening the K+ channels leads to membrane hyperpolarization and consequently 
suppression of insulin secretion (Shieh, Coghlan, Sullivan, & Gopalakrishnan, 2000). The 
K+ATP channels predominantly determine the resting potential of β-cell and couple 
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cellular metabolism to electrical activity (F. M. Ashcroft & Rorsman, 1989; Dukes & 
Philipson, 1996). When plasma glucose is elevated, increases in intracellular ATP/ADP 
ratio lead to closure of K+ATP channels and membrane depolarization that, in turn, leads to 
the activation of voltage-dependent Ca2+ channel, a rise in intracellular Ca2+, and insulin 
secretion. 
 
The subunit composition of K+ATP channels is tissue specific and is regulated by 
tissue energetics. The molecular structure of sarc K+ATP channels has been clarified by 
cloning members of the inwardly rectifying K+ channel subfamily Kir6.0 (Kir6.1 and 
Kir6.2) and the receptors for sulfonylureas (SUR1, SUR2A and SUR2B) (Inagaki et al., 
1995; Seino, 1999). Evidence indicates that an integrated sarc K+ATP molecule is an 
octameric complex composed of four Kir subunits and four SUR subunits. The Kir 
subunits have two transmembrane domains and form the pore. The SUR subunits belong 
to members of the ATP-binding cassette (ABC) protein superfamily. They have three 
transmembrane domains and two nucleotide-binding domains (NBD1 and NBD2) on the 
cytoplasmic side (Seino & Miki, 2003). The SUR functions as regulatory subunit 
(Aguilar-Bryan et al., 1998), conferring sensitivities of the channel to regulators like 
sulfonylureas, MgADP and some channel openers (Enkvetchakul, Loussouarn, Makhina, 
& Nichols, 2001). The subunit composition of sarc K+ATP channels is tissue specific: in 
the pancreatic β-cell,  K+ATP consists of SUR1 and Kir6.2 subunits; in the cardiac and 
skeletal myocytes, it is composed with SUR2A and Kir6.2; in vascular smooth muscle 
cells, with SUR2B and Kir6.1, and in non-vascular smooth muscle cells, with SUR2B 
and Kir6.2 (Seino & Miki, 2003). 
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Cell energy metabolism regulates the expression of K+ATP channels present in 
sarcolemma, mitochondria, and the nuclear membrane; alteration of cell metabolism 
leads to changes in channel number (Zhuo, Huang, Liu, & Liang, 2005). High glucose 
uptake leads to significant decrease in kir6.2 mRNA expression level in pancreatic islets. 
This effect is reversed by exposure to low glucose (Moritz, Leech, Ferrer, & Habener, 
2001). Diabetes (Ren, Xu, & Wang, 2003) and hormones like glucocorticoids 
(Hernandez-Sanchez, Ito, Ferrer, Reitman, & LeRoith, 1999) and estrogen (Ranki, Budas, 
Crawford, & Jovanovic, 2001), which alter cell metabolism, can regulate KATP gene 
expression. KATP gene transcription responds dynamically to cell energy metabolism. 
Some of the products of energy metabolism like ATP and ADP can directly regulate the 
channel activity. 
 
Sarc K+ATP can prevent intracellular Ca
2+ overloading into cells which would 
result in reduction in contraction and energy sparing, demonstrated in the case of kir6.2 
knockout mice (Suzuki et al., 2001). Mito K+ATP protect mitochondria from disturbances 
like over-production of free radicals, imbalance in trans-membrane ion transport by 
controlling mitochondrial Ca2+ ion concentration, and matrix swelling. Opening of mito 
K+ATP restores membrane potential, allowing extrusion of H
+ ions, creating a more 
favorable electrochemical gradient for ATP synthesis (Szewczyk, 1996; Y. Wang & 
Ashraf, 1999; Xu, Wang, Ayub, & Ashraf, 2001). But Garlid (2000) proposed that 
opening of mito K+ATP induces matrix swelling which maintains architecture and 
permeability of mitochondrial membranes (Garlid, 2000). Matrix swelling can activate 
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fatty acid oxidation, respiration, and ATP production (Halestrap, 1989). In case in energy 
crisis, depletion of intracellular ATP and consequently Ca2+ inflow will activate some of 
the K+ATP channels, which then results in the opening of all the K
+
ATP channels to initiate 
a coordinated metabolic response, with sarc K+ATP decreasing cell excitability and 
reducing energy cost, mito K+ATP channels maintaining the homeostasis of intra-
mitochondrial environment and keeping the production of ATP to provide constant 
energy supply, and nuclear K+ATP regulating genes that are related with energy 
metabolism (Zhuo et al., 2005). 
 
The homeostatic role of K+ATP channels has been demonstrated by using KCNJ11 
gene (encodes Kir6.2)-deficient mice to demonstrate the effects of the skeletal muscle-
specific ablation of K+ATP activity (Alekseev et al., 2010). These mice showed a higher 
rate of oxygen consumption under sedentary conditions, reflecting increased EE and heat 
production, and did not show any deficit in food intake or blood energy substrates 
(Alekseev et al., 2010). Data from a different study using a low-level exercise regimen 
revealed that the K+ATP deficiency amplifies energy use through an extra cost of physical 
activity, primarily determined by physical activity performance (Ghanassia, Brun, 
Mercier, & Raynaud, 2007), resembling animal models overexpressing mitochondrial 
uncoupling proteins in skeletal muscle (Li et al., 2000). By modulating exercise 
thermogenesis and NEAT (Alekseev et al., 2010), sarc K+ATP channels could also 
contribute to heat production during acute cold exposure through muscle shivering. The 
enhanced energy use in K+ATP channel-deficient skeletal muscles, resulting in limited 
body weight gain and compromised physical endurance (Alekseev et al., 2010), 
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implicates K+ATP as an important energy-sparing system that defines muscle thermogenic 
response through optimization of energy use. 
 
1.9 Mediator of RNA polymerase II transcription subunit 1 (MED1) 
Mediator, a large multisubunit protein complex consisting of nearly 30 subunits, 
plays an essential role in the transcription of all RNA polymerase II-transcribed genes in 
eukaryotic cells (W. Chen & Roeder, 2011) thus serving as a bridge between DNA-bound 
activators and the general transcription machinery to facilitate formation and/or function 
of the preinitiation complex (W. Chen, Zhang, Birsoy, & Roeder, 2010). In particular, in 
vitro studies have established ligand-dependent Mediator coactivator functions that 
involve ligand-dependent binding of Mediator, through the MED1 subunit, to nuclear 
receptor AF2 domains. A subsequent study showed that MED1 is essential for PPARγ–
mediated differentiation of mouse embryonic fibroblasts to adipocytes and for associated 
PPARγ-dependent transcription events (Ge et al., 2002), and an earlier study of a liver-
specific MED1 knockout mouse demonstrated a role for MED1 in PPARα-mediated 
oxidation of fatty acids (Jia et al., 2004). As a major site for the regulation of fatty acid 
and glucose metabolism, skeletal muscle plays a significant role in the control of obesity, 
diabetes, and cardiovascular disease; nuclear receptors (Desvergne, Michalik, & Wahli, 
2006; Smith & Muscat, 2005) and coregulators (Feige & Auwerx, 2007; J. Lin, 
Handschin, & Spiegelman, 2005) play key roles as the critical regulators of 
transcriptional programs that govern the processes of normal muscle maintenance and 
function.  
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Muscle-specific MED1 knockout (MED1 MKO) mice exhibit enhanced insulin 
sensitivity and improved glucose tolerance and are resistant to high-fat diet-induced 
obesity despite a similar food intake to control mice, possibly through increased EE (W. 
Chen et al., 2010). Med1 MKO mice also exhibit increased mitochondrial density and 
increased expression of genes specific to type I and type IIA fibers in white muscle, 
indicating a switch toward slow fibers, as well as increased expression of BAT-specific 
genes involved in energy expenditure through uncoupled respiration (W. Chen et al., 
2010). These results strongly suggest that MED1 acts in the muscle to regulate glucose 
and energy metabolism as observed in Med1 MKO where around 140 genes were 
upregulated in skeletal muscle (W. Chen et al., 2010). Of these, more than half are 
involved in metabolic pathways particularly involved in EE and may account, at least in 
part, for the enhanced glucose tolerance and insulin sensitivity of the knockout mice as 
well as the associated protection from high-fat diet-induced obesity (W. Chen et al., 
2010). This study indicates a strong suppressive function of MED1 on energy 
expenditure pathways in muscle and also has significant implications for therapeutic 
approaches to metabolic and muscle diseases. 
 
1.10 AMP-activated protein kinase (AMPK) 
AMP-activated protein kinase (AMPK) is a heterotrimeric complex consisting α 
subunit (catalytic), β, and γ (regulatory subunits). Activation of this kinase into pAMPK 
is through AMP and occurs by three independent mechanisms: 1) allosteric activation of 
the phosphorylated enzyme; 2) promotion of phosphorylation of Thr-172 by an upstream 
kinase; 3) inhibition of dephosphorylation of Thr-172 by protein phosphatases (Hardie, 
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Hawley, & Scott, 2006). All these three mechanisms make the AMPK system very 
effective because a small change in the concentration of AMP can induce a large change 
in the kinase activity of the complex. ATP inhibits the activation of AMPK by 
antagonizing binding of AMP. Almost all eukaryotic cells express enzyme adenylate 
kinase which converts ADP to AMP and ATP. This makes AMP to ATP ratio a better 
indicator of cellular energy status than ADP to ATP ratio, and AMPK a better sensor for 
the cellular energy levels (Hardie et al., 2006).  
 
In skeletal muscle, the degree of activation of AMPK is dependent of the 
metabolic stress caused by contraction. The response to metabolic stresses, such as 
energy depletion, is probably the key role for AMPK in single celled eukaryotes but it is 
now becoming clear that during the course of evolution of multicellular organisms, 
hormones and cytokines have acquired the ability to regulate AMPK system. It is 
activated by the adipokine, leptin in skeletal muscle and by adiponectin in skeletal muscle 
and liver (Minokoshi et al., 2002; Tomas et al., 2002; Yamauchi et al., 2002). This 
increases EE in muscle by increasing fatty acid oxidation and up-regulating 
mitochondrial biogenesis. Conversely, leptin inhibits AMPK in the hypothalamus, 
consistent with the ability of the adipokine to inhibit food intake, which suggests that 
hypothalamic AMPK also has a key role in the regulation of body weight and whole body 
energy balance (Minokoshi et al., 2002).  
 
The first targets of AMPK to be identified were acetyl-CoA carboxylase (ACC) 
and HMG-CoA reductase, activation of AMPK (i.e., pAMPK) caused inhibition of fatty 
 
 
43 
 
acid and cholesterol synthesis in hepatocytes (Corton, Gillespie, Hawley, & Hardie, 
1995; Henin, Vincent, Gruber, & Van den Berghe, 1995). AMPK activation also inhibits 
muscle glycogen synthesis via phosphorylation of glycogen synthase (Jorgensen et al., 
2004). In skeletal muscle it stimulates glucose uptake both via translocation of the 
glucose transporter 4 (GLUT4) to the plasma membrane and by increasing its expression 
(Holmes, Kurth-Kraczek, & Winder, 1999; Kurth-Kraczek, Hirshman, Goodyear, & 
Winder, 1999; Merrill, Kurth, Hardie, & Winder, 1997). By phosphorylating ACC, 
AMPK lowers malonyl-CoA, relieving the inhibition of uptake of fatty acids into 
mitochondria via the carnitine carrier system, and thus stimulating fatty acid oxidation 
and up-regulating mitochondrial biogenesis (Merrill et al., 1997; Winder et al., 2000). 
 
1.11 Peroxisome proliferator-activated receptors (PPARs) 
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
transcription factors involved in the transcriptional regulation of key metabolic pathways 
including lipid metabolism, adipogenesis, and insulin sensitivity. As these nuclear 
receptors are activated by extracellular signals and control multiple gene targets of 
metabolism, PPARs can be viewed as a system that control multiple inputs and outputs 
involved in energy balance. They are of three isotypes: PPARα, PPARδ, and PPARγ. 
Their activation is initiated by specific ligand binding to the ligand-binding domain 
which is specific to isotype. Each of the three PPAR subtypes is expressed in a distinct, 
tissue-specific pattern. PPARα is highly expressed in liver, heart, kidney, skeletal muscle, 
and BAT, tissues that are metabolically very active. PPARγ is most-highly expressed in 
white and brown adipose tissue, large intestine, and spleen. In contrast to PPARα and 
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PPARγ, which are abundantly expressed in just a few tissues, PPARδ is expressed in 
virtually all tissues at comparable levels (Berger, Akiyama, & Meinke, 2005).  
 
PPARα plays an important role in regulating the β-oxidation of fatty acids, a 
major source of cellular energy. PPARα target genes include multiple proteins essential 
for fatty acid uptake, intracellular transport, and β-oxidation, including fatty acid 
transport protein, fatty acid translocase, long-chain fatty acid acetyl-coenzyme A 
synthase, and CPT1 (Evans, Barish, & Wang, 2004). PPARα activation induces 
expression of lipase, which hydrolyzes triglyceride rich lipoproteins, the major source of 
circulating fatty acids. Fasting potently induces PPARα expression, which underlines the 
importance of this transcription factor in energy balance (Kersten et al., 1999).  
 
PPARγ also regulates genes involved in lipid metabolism, including lipoprotein 
lipase, acyl-coenzyme A synthetase, and aP2, and glucose control such as the GLUT4 
and phosphoenolpyruvate carboxykinase (PEPCK) (Lehrke & Lazar, 2005; Spiegelman, 
Hu, Kim, & Brun, 1997). PPARγ regulates signaling molecules like leptin that are 
secreted from adipose and affect glucose utilization and/or production in other tissues 
(Kliewer, Xu, Lambert, & Willson, 2001). PPARγ agonists reduce serum concentrations 
of both esterified and nonesterified fatty acids, presumably by promoting their uptake and 
storage in adipocytes (Kliewer et al., 2001). PPARγ is expressed at low levels, in both 
skeletal muscle and liver. Thus, PPARγ agonists may have direct effects on glucose 
utilization or production in both of these tissues (Kliewer et al., 2001). In liver, PPARγ 
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agonist treatment results in decreased expression of phosphoenolpyruvate carboxykinase, 
which encodes the rate-limiting step in hepatic gluconeogenesis (Kliewer et al., 2001).  
 
Selective overexpression of a constitutively active form of PPARδ in mouse 
adipose tissue induces significant weight loss and protects against obesity and 
dyslipidemia induced by a high-fat diet (Y. X. Wang et al., 2003). This PPARδ effect 
correlated with activation of genes involved in fatty acid oxidation and adaptive 
thermogenesis. Importantly, PPARδ did not have an effect on genes involved in lipid 
storage and thus appears to be involved primarily in energy consumption in adipose 
tissue. This enhancement of fatty acid oxidation also was found in genetically altered 
mice that overexpress PPARδ in skeletal muscle. In the presence of a PPARδ agonist, the 
mouse skeletal muscle fibers reportedly switch from type II “glycolytic/fast twitch” to 
type I “oxidative/slow twitch.” (Y. X. Wang et al., 2004) This change explains why these 
PPARδ overexpressed mice can run twice the distance of control mice. The muscle fiber 
type switch also confers resistance to obesity. 
 
1.12 Peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC1-α) 
The transcriptional coactivator PGC1-α is highly expressed and interacts with 
nuclear receptor PPARγ in oxidative tissues like BAT, heart, and slow-twitch skeletal 
muscle where it regulates mitochondrial function and metabolism (Finck & Kelly, 2006). 
PGC1 co-activators affect biological processes that regulate cellular responses to meet 
energy demands according to their environment by increasing mitochondrial biogenesis, 
cellular respiration, and energy substrate uptake and utilization. The expression and 
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activity of PGC1-α is linked to a number of upstream signaling pathways which include 
beta adrenergic/cAMP pathway and AMPK, particularly in BAT and skeletal muscle 
(Finck & Kelly, 2006). 
 
Forced expression of PGC-1α at high physiologic levels in mice resulted in an 
increased proportion of oxidative or type I muscle fibers coincident with an increase in 
the expression of mitochondrial markers, red muscle coloration, increased expression of 
contractile protein characteristic of type I fibers, and resistance to electrically stimulated 
fatigue (J. Lin et al., 2002). These results indicated that PGC-1α is sufficient to drive the 
slow-twitch skeletal muscle program. Recent evidence also implicates PGC-1α in the 
regulation of muscle glucose metabolism. Studies demonstrate that PGC-1α robustly 
activates expression of GLUT4 in skeletal muscle cells in culture and represses glucose 
oxidation in muscle cell lines by activating the expression of the gene encoding pyruvate 
dehydrogenase kinase 4 (Michael et al., 2001; Wende, Huss, Schaeffer, Giguere, & 
Kelly, 2005). These results suggest that PGC-1α controls muscle fuel selection by 
increasing fatty acid oxidation while temporarily shutting down glucose oxidation — a 
gene regulatory equivalent of the fatty acid-glucose cycle (Finck & Kelly, 2006). 
 
1.13 Fatty acid synthase (FAS) 
Fatty acid synthase (FAS) is a key enzyme in fatty acid synthesis from acetyl 
CoA, which is expressed at high levels in liver and adipose tissue, but at low levels in 
other tissues including skeletal muscle (Weiss et al., 1986). FAS catalyzes the last step in 
fatty acid biosynthetic pathway and is believed to be a determinant of the maximal 
 
 
47 
 
capacity of a tissue, and in particular to synthesize fatty acids by de novo lipogenesis 
(Aye & Izaguirre, 1991). Liver-specific FAS knockout mice possess a similar phenotype 
to control animals when fed normal chow, and did not show protection against the 
development of fatty liver but rather exacerbated it under specific nutritional conditions 
(Chakravarthy et al., 2005). Indeed, when fed a low-fat/high-carbohydrate diet for 4 
weeks, these mice developed hepatic steatosis due to a reduction in β-oxidation, increased 
hepatic malonyl-CoA concentrations, and a significant decrease in blood ketone bodies 
(Chakravarthy et al., 2005). In fact, this mouse model led to the novel and interesting 
concept that “new fat” synthesized via FAS activity would specifically activate nuclear 
receptors like PPARα and would in turn lead to enhanced β-oxidation.  
 
1.14 Fatty acid translocase (FAT/CD36) 
Long-chain fatty acids (LCFAs) cross the plasma membrane via a protein-
mediated mechanism involving one or more LCFA-binding proteins. Among these, 
FAT/CD36 has been identified as key LCFA transporter in the heart and skeletal muscle, 
where it is regulated acutely and chronically by insulin (Bonen, Tandon, Glatz, Luiken, & 
Heigenhauser, 2006). FAT/CD36 is expressed ubiquitously to varying extents among 
metabolically active tissues such as the heart, skeletal muscle, liver, and adipose tissue 
where, along with CPT1, it regulates fatty acid transport and oxidation in the 
mitochondria (Bonen et al., 2006; Holloway, Bonen, & Spriet, 2009). In skeletal muscle, 
FAT/CD36 expression and/or its subcellular distribution is altered in obesity and type-2 
diabetes (Bonen et al., 2006; Love-Gregory & Abumrad, 2011). FAT/CD36 response to 
metabolic disturbances can differ in muscle and adipose tissue. Unlike muscle 
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FAT/CD36, adipose tissue FAT/CD36 expression was not altered in an animal model of 
type-1 diabetes and in contrast, in the insulin-resistant obese rats, adipose tissue, but not 
muscle, FAT/CD36 expression was increased (Bonen et al., 2006). 
 
1.15 Sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) 
A thermogenic system has evolved for the specific purpose of protecting a tissue 
or organism from the cold in the myocytes (Kozak & Young, 2012). This system is based 
on the cycling of Ca2+ by the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 
(SERCA)—a pump that transfers Ca2+ into the sarcoplasmic reticulum upon ATP 
hydrolysis and there by generating heat (Kozak & Young, 2012). The SERCA pump is 
encoded by a highly conserved multigene family whose function is to transport Ca2+ ions 
and regulate intracellular calcium homeostasis. Their presence is ubiquitous and they are 
the only mechanism to maintain SR/ER calcium stores in muscle and non-muscle cells 
(Periasamy & Kalyanasundaram, 2007). The SERCA pump regulates the cytosolic 
calcium level tightly and controls many cellular functions, from muscle contraction to 
cell signaling responsible for growth and differentiation (Periasamy & Kalyanasundaram, 
2007).  
 
The diversity of SERCA pump isoforms and pump expression level imparts 
tissue- and cell specific Ca2+ transport capacity. Furthermore, this diversity can be better 
understood in skeletal muscle, where the SERCA1 isoform with faster kinetics is 
expressed several-fold higher in fast-twitch skeletal muscle, whereas SERCA2a is 
expressed at a lower level in cardiac and slow-twitch skeletal muscle (Periasamy & 
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Kalyanasundaram, 2007). The differences in the function of individual SERCA pump 
isoforms can be further amplified by their cellular environment and the presence of 
SERCA regulatory proteins (inhibitors) phospholamban (PLB) and sarcolipin (SLN) 
which provide additional regulation of SERCA pump activity and contribute to Ca2+ 
homeostasis in cardiac and skeletal muscle (Periasamy & Kalyanasundaram, 2007).  
  
In humans, this muscle-based thermogenic Ca2+ cycling is also the basis of a 
pathological condition, malignant hyperthermia, caused by a mutation of the ryanodine 
receptor that results in uncontrolled leakage of Ca2+ into the cytoplasm, causing heat 
generation as Ca2+ passes down its concentration gradient (similar to uncoupling protein-
associated heat generation) (Kozak & Young, 2012). Stimulation of Ca2+ cycling, 
uncoupled to muscle contraction, with ATP hydrolysis by SERCA activity is therefore a 
powerful thermogenic mechanism. SLN induces non-shivering thermogenesis (NST) by 
regulation of SERCA in skeletal muscle to maintain core body temperature when mice 
are exposed to cold, even in the absence of BAT and shivering thermogenesis, and 
protects these mice from developing diet-induced obesity, suggesting this thermogenesis 
system has a role in energy balance and has potential as a target to induce fat burning to 
treat obesity (Bal et al., 2012).  
 
1.16 Summary 
The alterations in the peripheral energy homeostatic mechanisms leading to 
phenotypic differences may have a central origin. The hypothalamus, particularly the 
VMH, along with the central MC system, plays an important role in determining fuel 
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partitioning and usage in peripheral tissues. Activation of MC receptors in the 
hypothalamus increases EE by increasing SNS activity and may engage molecular 
mediators of energy homeostasis in the periphery, including in skeletal muscle. Although 
numerous studies show the importance of the VMH, central MC, and SNS in obesity 
resistance, there is lack of an effective model to describe function of VMH-central MC-
SNS-skeletal muscle pathway and its potential relevance in promoting the lean 
phenotype.  
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CHAPTER 2
 
As described in the introduction in Chapter 1, lean HCR have high total daily EE, 
high physical activity, and are less prone to metabolic disorders, whereas their 
counterparts, LCR, are prone to metabolic and cardiovascular diseases and have low total 
daily EE and low physical activity. This high EE in HCR is consistent even when 
matched by body weight suggesting these HCR have low economy of activity. I wanted 
to see which component of EE was altered in these HCR/LCR rats. I took the approach of 
partitioning EE data into resting and non-resting EE to test the hypothesis that there is 
higher activity-related EE in HCR, and that this high activity EE is due to heightened 
daily activity plus low economy of activity in HCR, implying that there may be excess 
calories used by skeletal muscle during activity. I proposed that this high activity EE and 
low economy of activity arises through differential skeletal muscle thermogenesis and 
enhanced expression of molecular and neural intermediates in lean (HCR) vs. obesity-
prone rats (LCR). One strategy to compare EE between phenotypes that differ in 
bodyweight and composition is to compare EE by obtaining animals that overlap in body 
weight or lean mass. Here, I used female HCR and LCR rats, as the male HCR and LCR 
have minimal overlap in body weight and composition between the groups. 
 
I tested the hypothesis that the lean HCR have heightened activity-related EE and 
low economy of activity due to increased sympathetic drive to peripheral tissues which in 
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turn increase mediators of EE. I quantified EE using indirect calorimetry and used 
norepinephrine turnover to determine the level of sympathetic drive to peripheral tissues. 
Quantitative RT-PCR and western blotting were performed to evaluate the mRNA and 
protein expression of mediators of energy balance. 
 
2.1 Methods 
Animals 
Adult female HCR/LCR rats (selection generation 25, N=13/group; 10-12 months 
of age and overlapping in body weights) were obtained from the University of Michigan. 
Each rat was housed individually on a 12:12 light:dark cycle with lights on at 0700 EST. 
Rats received rodent chow (5P00 MRH 3000, T.R. Last Co. Inc) and water ad libitum. 
All studies were conducted according to the rules and approval of the Kent State 
University IACUC. 
 
Body composition 
I measured body composition using EchoMRI-700 (Echo Medical Systems, 
Houston, TX) to determine the fat and lean mass (in grams) of each rat the day before 
test. This did not interfere with temperature transponder function (see transponder 
implantation below). 
 
Measurement of total energy expenditure (TEE) and its components 
After body composition determination, adult female HCR and LCR rats were 
measured for total EE and 24-hr physical activity using small-animal indirect calorimetry 
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(4-chamber Oxymax FAST system, Columbus Instruments, Columbus, OH). Rats were 
acclimated to the calorimetry chamber (7.5 in x 12 in x 9 in) and room for 24-48 hrs prior 
to testing; this is sufficient to avoid novelty-induced increases in physical activity. On the 
day of calorimetry, rats were weighed and placed in the chamber with food and water; the 
chamber was then sealed. The calorimeter was calibrated using primary gas standards. 
Air was pumped into the chamber at 1.9-3.1 lpm, depending on the weight of the rat, and 
chamber air was sampled at 0.4 lpm. Measurement of gas exchange took place every 30 
sec throughout the 24-hr period except for a 3.5-min room-air reference and settle period 
after each 60-sample interval. Physical activity data were collected using infrared beam-
break counts, collected every 10 sec uninterrupted throughout the 24-hr period, in the X 
and Z axes; the first hour of data was not included in the analysis. Data collected from 
1200 (EST) on day 1 through 1200 on day 2 were analyzed. EE data (VO2, VCO2, RER, 
kcal/hr) were averaged, and physical activity data were expressed as mean beam breaks 
per minute. Body weight and food intake data indicate that rats were in homeostatic 
energy balance during EE measurements and body weight did not change significantly 
(within and between groups) compared to home-cage days.  
 
Next, I separated the non-resting EE and resting EE components of total EE data 
described above using Columbus Instruments software (CLAX). Using the data set 
described above, resting EE was defined as the lowest level of EE, excluding the lowest 5 
episodes (i.e., short sequences of consecutive data points) to eliminate potential error due 
to variation in gas exchange values that can occur during the switch from sample to 
reference air measurement. This same method was used to define resting EE during the 
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treadmill test (see below). Because each rat had two separate resting EE values calculated 
within a short period of time (one for 24-hr EE, one before treadmill walking), we 
compared the two values for each rat to validate our method. The two resting EE 
measurements were very similar (data in Results). Non-resting EE is defined as (TEE) – 
(resting EE). 
 
As previously reported (Gavini et al., 2014; Novak CM, 2009), resting and 
physical activity EE were directly assessed by measuring gas exchange once every 10 sec 
during a treadmill activity test. At least one day after a 15-min treadmill acclimation 
period, rats were placed in the treadmill and allowed to acclimate without food for 2 hrs. 
Over the course of this 2-hr period, rats showed a predictable pattern of behavior: 
physical activity and EE rise markedly then fall gradually, reaching a steady state. After 
the 2-hr resting period, the treadmill was started at 7 m/min for 30 min, during which 
time steady-state activity EE data were collected. Rats that did not show adequate resting 
or activity (walking backward on the treadmill, sitting on the treadmill or shocker) were 
measured at a later date. 
 
All EE data from HCR/LCR rats were analyzed using t-tests, ANOVA, and 
analysis of covariance (ANCOVA). Because our previous studies suggested the 
hypothesis that EE was elevated in HCR, we compared resting and non-resting EE 
between weight-matched or lean-mass-matched HCR and LCR using a 1-tailed paired t-
test. An unpaired 1-tailed t-test was used to compare treadmill gas exchange values 
between groups based on our previous results. Lastly, total EE, resting EE, and non-
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resting EE were analyzed using analysis of covariance (ANCOVA) with either body mass 
or lean mass as the covariate; interaction terms were removed from the analysis if not 
significant. While lean mass is regarded as the best covariate for analyzing resting EE or 
total EE (Tschop et al., 2012) activity EE is better evaluated using body weight 
(Schoeller & Jefford, 2002). Thus resting and non-resting EE were analyzed using each 
lean mass and body weight as covariates in separate analyses to allow full comparison. 
  
Transponder implantation 
Adult female HCR/LCR (n=7/group, a subset of actual group mentioned above) 
rats were anesthetized using isoflurane. A short incision was made on both hind legs. 
Sterile temperature transponders IPTT-300 (Bio Medic Data Systems, Inc.) were 
implanted adjacent to the gastrocnemius (gastroc) muscle group of both hind limbs to 
measure the heat generated by skeletal muscle during activity. Care was taken to place 
the transponders so as not to disrupt locomotor function. Rats were allowed to recover for 
a week before the graded treadmill test was performed. Implant placement was examined 
during tissue harvest and data from inaccurately placed transponders were omitted from 
final analyses. 
 
Graded treadmill test 
To determine skeletal muscle heat dissipation during controlled physical activity, 
we measured the temperatures of the gastroc muscle group using a graded treadmill 
exercise test. The rats were acclimated to the treadmill for 10 minutes in the days prior to 
the test as well as immediately before the test. Gastroc temperatures in each leg were 
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recorded at baseline and at set intervals during a 5-level graded treadmill test.  Starting at 
7 m/min, 0⁰ incline, temperature was measured at 2, 5, and 10 minutes, 15 minutes (9 
m/min at 0⁰ incline), 20 minutes (9 m/min, 10⁰ incline), 25 minutes (11 m/min, 10⁰ 
incline), and 30 minutes (11 m/min, 20⁰ incline). The test was stopped at end of 35 
minutes; however some LCR were not able to complete all 5 levels of activity.  
 
Muscle gene expression 
Skeletal muscle (gastroc and quadriceps (quad)) was collected from adult female 
HCR/LCR rats (from a separate group, generation 25, N = 8 or 7/group) after euthanasia 
by rapid decapitation without anesthetic agents after several weeks without exercise. 
Muscle samples were homogenized and total mRNA was extracted using an Ambion 
ribopure kit following manufacturer’s instructions. The purity of mRNA was measured 
using NANODROP (ND-1000) (Nanodrop technologies) and A260/280 ratio to be 
ranging from 1.8 – 2.1.This mRNA was used to prepare cDNA using an Applied 
Biosystems kit and thermal cycling at 25⁰C for 10 minutes, 48⁰C for 30 minutes, 95⁰ C 
for 5 minutes and holding at 4⁰C. The cDNA was used for quantifying the expression of 
uncoupling proteins 2 and 3 (UCP2, UCP3), ATP-dependent potassium channel (K+ATP 
subunits Kir6.1, Kir6.2), Mediator of RNA polymerase II transcription subunit 1 
(MED1), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, used as a control). 
The relative expression was calculated using comparative Ct method (ΔCt). Data are 
expressed as a percent expression using the HCR as the reference value (defined as 
100%), and groups were compared using a 2-tailed t-test. 
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Western blotting 
UCP2, UCP3, and the K+ATP subunits Kir 6.1 and Kir 6.2  and MED1 were 
examined in skeletal muscle (gastroc and quad) from adult female HCR/LCR rats (same 
group of generation 25 rats used for muscle gene expression, N = 5 or 4/group), using 
actin as a loading control for protein expression. Skeletal muscle samples were 
homogenized with ice-cold RIPA buffer (Thermo Scientific) containing a protease 
inhibitor cocktail (Roche Diagnostics). The supernatant from the homogenization and 
subsequent centrifugation was used for the analysis. Equal quantities of supernatant and 
sample buffer (150mM tris-HCl pH 6.8, Trizma-base for pH, 6% SDS, 30% glycerol, 
0.03% pyronin-Y, DTT) were mixed and tubes were heated at 90⁰C for 3 minutes. 
Samples containing equal quantity of protein were loaded on to a gradient gel (4-15%) 
(Bio Rad) and electrophoresed using SDS running buffer (0.384M glycine, 0.05M Trizma 
bas, 0.1% SDS) at constant voltage (150V) for 30 minutes. The gel was blotted on to a 
PVDF membrane using semi-wet blotting apparatus and Otter et al. transfer buffer 
(49.6mM Trizma base, 384mM glycine, 17.5% methanol, 0.01% SDS) (Otter, King, & 
Witman, 1987) at constant current (400mAmp). The blot was incubated overnight in a 
blocking solution of 5% milk (Blotto) in 1xPBST (Phosphate buffered saline; 84mM 
sodium hydrogen phosphate, 16mM sodium dihydrogen phosphate, 100mM sodium 
chloride, tween20), then rinsed using 1xPBST. Primary antibodies for UCP2, UCP3, 
actin, MED1 (Abcam Inc. ab67241, ab3477, ab1801, ab60950 respectively), and for Kir 
6.1, Kir 6.2 (Santa Cruz Biotechnology, Inc. sc-11224 and sc-11230 respectively) were 
diluted in blocking solution at ratio of 1:1000 (Kir 6.2, Kir 6.1, and MED1 at 1:500) and 
incubated with the blot overnight. Secondary antibodies were diluted in blocking solution 
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in the ratio 1:5000 and incubated for 1 hour at room temperature. After washing, the blots 
were developed using a chemiluminiscence detector using an Amersham kit (GE 
Healthcare, UK). The expression levels relative to actin were plotted as a percent of the 
reference value (with HCR as 100%), and groups were compared using a 2-tialed t-test. 
 
Norepinephrine turnover (NETO) 
Adult male HCR/LCR rats (generation 30, N= 13 HCR, 12 LCR) were used to 
assess sympathetic drive to skeletal muscle (including quad, lateral and medial gastroc, 
and soleus) and BAT. They were individually housed on a 12:12 light:dark cycle with ad 
libitum access to standard rodent chow and water and acclimated to daily handling for a 
week. Level of sympathetic drive to peripheral tissues was determined by norepinephrine 
(NE) turnover (NETO) method using α-methyl-p-tyrosine (aMPT) (Gavini et al., 2014; 
Shi, Bowers, & Bartness, 2004). aMPT is a competitive inhibitor of tyrosine hydroxylase, 
the rate limiting enzyme in catecholamines biosynthesis. After aMPT administration, the 
endogenous tissue levels of NE decline at a rate proportional to the initial NE 
concentrations. The rats were divided into 2 sub-groups per group (aMPT, control). On 
the day of study, rats receiving aMPT were injected with aMPT (125 mg aMPT/kg of 
BW, 25 mg/ml) and with a booster dose at same concentration 2 hours later. All rats were 
euthanized by rapid decapitation between 1200 and 1500, 4 hours after first aMPT 
injection. Tissues were rapidly dissected and snap-frozen in liquid nitrogen.  
 
Briefly, tissue was thawed and homogenized in a solution containing 
dihydroxybenzylamine (DHBA, internal standard) in 0.2M perchloric acid (PCA) with 1 
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mg/ml ascorbic acid (AA). Following centrifugation for 15 min at 7,500 g at 4°C, 
catecholamines were extracted from the homogenate with alumina and were eluted into 
the PCA/AA. The catecholamines were assayed using an HPLC system with 
electrochemical detection (Coulochem III), MDTM mobile phase and reverse phase MD 
150x3.2 column. NETO in quad, lateral and medial gastroc, soleus, and BAT were 
calculated using the following formula (Gavini et al., 2014; Shi et al., 2004):  
k = (lg[NE]0 – lg[NE]4)/(0.434 x 4)  
K = k[NE]0  
k is the constant rate of NE efflux (also known as fractional turnover rate),  
[NE]0 is the initial NE concentration or from 0-hr group (control),  
[NE]4 is the final NE concentration or from 4-hr group (aMPT), and  
K = NETO. 
Difference in NETO of HCR and LCR tissues were compared using 1-tailed, unpaired t-
test for each tissue. 
 
2.2 Results 
Rats of the lean, high-activity phenotype have higher total EE and non-resting EE, 
but not consistently high resting EE. 
As shown in Figures 7, 8, and 9, female HCR have significantly higher total EE 
when rats were matched for either body weight (Figure 7) or for lean mass (Figure 8), or 
when analyzed as a group (Figure 9). To parse the components of total EE (i.e., resting 
EE + non-resting EE), I first validated our method to estimate resting EE from the 24-hr 
calorimetry dataset using the 2 hr treadmill test described above (Novak CM, 2009). The 
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two methods of calculating resting EE did not significantly differ (t = -0.64; p = 0.53), 
supporting the validity and accuracy of our resting EE calculation from total EE data. 
After matching for body weight, total energy cost of activity (treadmill walking) was 
higher in HCR (3.09±0.10 kcal/hr) compared to the LCR (2.88±0.08 kcal/hr).  
 
Resting EE over the 24-hr test did not differ between female HCR and LCR, 
neither as a group (without matching; Figure 9) or when matched for lean mass (Figure 
8). Non-resting EE was significantly higher in female HCR in every analysis 
performed—after matching for either lean mass or body weight, or without matching 
(Figures 7, 8, and 9). The heightened non-resting EE in the lean, high-capacity phenotype 
(HCR) was not secondary to a higher workload as fat mass and/or total mass were higher 
in the LCR in each analysis. Physical activity, both horizontal and ambulatory activity, 
was also higher in female HCR than LCR in every analysis performed (Figures 7, 8, and 
9). ANCOVA analyses of EE data from female HCR/LCR revealed that body weight or 
lean mass were the dominant determinants of resting EE, as resting EE was consistently 
higher in rats with greater body weight or lean mass (Figure 10). Lastly, non-resting EE 
increased with higher body weight or lean mass, and HCR consistently had higher non-
resting EE compared to LCR, even after body weight or composition were considered 
using ANCOVA (Figure 10).  
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Figure 7: Lean high-capacity rats have higher total energy expenditure and physical 
activity when matched by body weight. High-capacity runners (HCR) have heightened 
total energy expenditure (TEE) and non-resting energy expenditure (NREE), but not 
resting energy expenditure (REE), when matched for body weight. Daily physical activity 
was higher in HCR when matched for body weight. HCR and low-capacity runners 
(LCR) show significant differences in fat mass (FM) but not in lean mass (LM) when 
weight matched.*p<0.05 (HCR≠LCR). All data are means ± SEM. (N = 8/group) 
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Figure 8: Lean high-capacity rats have higher total energy expenditure and physical 
activity when matched by lean mass. High-capacity runners (HCR) have heightened 
total energy expenditure (TEE) and non-resting energy expenditure (NREE), but not 
resting energy expenditure (REE), when matched for lean mass (LM). Daily physical 
activity was higher in HCR when matched for LM. HCR and low-capacity runners (LCR) 
show significant differences in fat mass (FM) and body weight when matched for 
LM.*p<0.05 (HCR≠LCR). All data are means ± SEM. (N = 8/group) 
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Figure 9: Lean high-capacity rats have higher total energy expenditure and physical 
activity. High-capacity runners (HCR) have heightened total energy expenditure (TEE) 
and non-resting energy expenditure (NREE), but not resting energy expenditure (REE), 
when analyzed by group. Daily physical activity was higher in HCR when analyzed by 
group. HCR and low-capacity runners (LCR) show significant differences in fat mass 
(FM) but not in lean mass (LM) or body weight when analyzed by group.*p<0.05 
(HCR≠LCR). All data are means ± SEM. (N=13/group) 
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Figure 10: Body weight or lean mass are the dominant determinants of energy 
expenditure. In all rats, non-resting energy expenditure (NREE) increased along with 
body weight (A) and lean mass (B); NREE was significantly higher in the lean phenotype 
(high-capacity runners, HCR) compared to low-capacity runners (LCR), even after lean 
mass and body weight were factored out. Resting EE (REE) also increased with body 
weight (C) and lean mass (D), but did not significantly differ between female HCR and 
LCR. (N = 13/group) *p<0.05, HCR>LCR.  
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Table 2: Physical activity and body composition in rats of the lean (HCR) and 
obesity-prone (LCR) phenotype 
  
Body 
weight (g) 
Lean 
mass (g) 
Fat mass 
(g) 
Total 
counts 
Ambulatory 
counts 
All rats 
HCR 
293.4 ± 
12.8 
206.27 
± 7.92 
*39.39 ± 
4.29 
*11.82 ± 
0.55 
*4.93 ± 0.35 
LCR 
303.3 ± 
12.0 
194.26 ± 
8.32 
61.32± 
6.16 
6.92 ± 
0.31 
2.7 ± 0.23 
Matched 
by body 
weight 
HCR 
 
295.99 ± 
11.5 
 
*204.96 
± 6.91 
 
*41.85 ± 
5.58 
 
*11.49 ± 
0.75 
 
*4.86 ± 0.5 
LCR 
 
296.06 ± 
11.9 
 
190.33 ± 
5.73 
 
58.66 ± 
6.7 
 
7.04 
± 0.43 
 
2.9 ± 0.34 
Matched 
by lean 
mass 
HCR 
 
*264.74 ± 
11.44 
 
188.95 ± 
6.3 
 
*32.77 ± 
3.97 
 
*10.99 ± 
0.69 
 
*4.44 ± 0.42 
LCR 
 
307.89 ± 
12.13 
 
189.12 ± 
6.11 
 
70.2 ± 
7.74 
 
7.09 ± 
0.38 
 
2.94 ± 0.33 
HCR, High-capacity runners; LCR, Low-capacity runners. *p<0.05, HCR≠LCR 
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High activity energy expenditure is accompanied by skeletal muscle energy 
dissipation as heat. 
Our analysis of EE clearly implicated non-resting EE (composed primarily of 
activity EE), more than resting EE, as the predominant contributor to the heightened total 
EE seen in the lean phenotype. This, along with previous data showing decreased 
economy of activity in HCR (Novak CM, 2009), strongly implicates differential skeletal 
muscle energy use as an underlying cause of differences in non-resting EE and, therefore, 
total EE. The question remained as to how the HCR dispose of these additional calories. 
Here, I tested the hypothesis that HCR ultimately expend calories through heat 
dissipation in skeletal muscle. This hypothesis was tested by measuring gastroc 
temperature during a graded exercise treadmill test equalizing workload between rats 
(matched by body weight). HCR showed significantly higher gastroc temperatures, and 
their maximal rise in temperature was significantly higher in HCR compared to LCR 
(Figure 11), demonstrating that HCR have heightened skeletal muscle heat dissipation 
compared to LCR. 
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Figure 11: High-capacity runners (HCR) have heightened muscle heat dissipation 
during physical activity. (A) Mean gastrocnemius (gastroc) temperature during a graded 
treadmill exercise test. HCR show higher gastroc temperatures throughout the test period 
compared to low-capacity runners (LCR) with exception of resting. (B) Maximal rise in 
gastroc temperature was significantly higher in HCR compared to LCR during the graded 
treadmill test. *p<0.05 (HCR>LCR). All data are means ± SEM. (N=7/group) 
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Lean, high-activity rats have higher expression of mRNA and proteins involved in 
energy expenditure, and lower expression of energy conserving processes in both 
quadriceps and gastrocnemius. 
To determine the source of the calorie use and heat dissipation in HCR skeletal 
muscle, we examined mRNA and protein expression of molecular endpoints known to 
alter energy use in quad and gastroc of HCR and LCR; for energy conservation, MED1 
and K+ATP (subunits Kir6.1, Kir6.2); for energy expenditure, we examined UCP2 and 
UCP3. The mRNA content of UCP2 and UCP3 were found to be higher in HCR 
compared to LCR; that of potassium channel subunits Kir6.1 and 6.2, as well as MED1, 
were higher in LCR compared to HCR (Figure 12). Protein expression levels of proteins 
involved in energy expenditure (UCP2, 3) were found to be higher in HCR compared to 
LCR in both quad and gastroc. Protein expression levels of MED1 were higher in LCR 
compared to HCR in both quad and gastroc (Figure 13). No differences were found in 
protein levels of K+ATP subunits Kir6.1 and 6.2 in the quad. 
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Figure 12: Lean high-capacity rats have higher mRNA expression of mediators of 
energy expenditure than energy conservation. Compared to low-capacity runners 
(LCR), high-capacity runners (HCR) have lower mRNA expression of molecular 
mediators of energy conservaiton in skeletal muscle [quadriceps (quad) and 
gastrocnemius (gastroc)], including (A) Mediator of RNA polymerase II transcription 
subunit 1(MED1), and subunits of the ATP-gated K+ channels (K+ATP) Kir6.1 (B) and 
Kir6.2 (C); (D, E) Uncoupling protein 2 and 3 (UCP2, UCP3) mRNA expression was 
significantly higher in skeletal muscle of HCR compared to LCR. *p<0.05 (HCR>LCR 
for UCP2, UCP3; and HCR<LCR for Kir6.1, Kir6.2, and MED1). All data are means ± 
SEM. (N=8/group) 
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Figure 13: Lean high-capacity rats have higher protein expression of mediators of 
energy expenditure than energy conservation. Compared to low-capacity runners 
(LCR), high-capacity runners (HCR) have lower protein expression of molecular 
mediators of energy conservaiton in skeletal muscle [quadriceps (quad) and 
gastrocnemius (gastroc)], including (A) Mediator of RNA polymerase II transcription 
subunit 1(MED1), and subunits of the ATP-gated K+ channels (K+ATP) Kir6.1 (B) and 
Kir6.2 (C). Compared to HCR, Kir6.1 and Kir6.2 protein levels were higher in LCR 
gastroc, but not quad. (D, E) Uncoupling protein 2 and 3 (UCP2, UCP3) protein levels 
were significantly higher in skeletal muscle of HCR compared to LCR. *p<0.05 
(HCR>LCR for UCP2, UCP3; and HCR<LCR for Kir6.1, Kir6.2, and MED1). All data 
are means ± SEM. (N=5/group) 
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Lean rats have elevated sympathetic drive to skeletal muscle. 
As illustrated in Figure 14, compared to LCR, HCR had higher NETO in several 
skeletal muscle groups, including medial (D) and lateral gastroc (C), quad (A), and soleus 
(B), indicating higher sympathetic drive to skeletal muscle, potentially modulating their 
economy of activity. Higher NETO was also found in interscapular BAT in HCR 
compared to LCR (E). 
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Figure 14: Lean rats have heightened sympathetic drive to peripheral metabolic 
tissues. Compared to low-capacity runners (LCR), high-capacity runners (HCR) have 
elevated sympathetic drive indicated by higher norepinephrine turnover (NETO) in 
skeletal muscle groups: (A) quadriceps (Quad), (B) soleus, (C) lateral gastrocnemius 
(lat.gastroc) (D) medial gastrocnemius (med.gastroc), and (E) brown adipose tissue 
(BAT). *p<0.05 (HCR>LCR). All data are means ± SEM. (N= 7 HCR, 6 LCR) 
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2.3 Discussion 
It is known that lean people and lean animals have higher daily physical activity 
levels (Johannsen, Welk, Sharp, & Flakoll, 2008; Levine et al., 2005; Novak CM, 2009; 
Novak & Levine, 2007) and that this is a biologically regulated trait (Joosen et al., 2005; 
Levine & Kotz, 2005). It was not known, however, whether or not this physical activity 
energy expenditure, or NEAT, meaningfully contributes to total EE. Here, I use a rat 
model of a lean phenotype to demonstrate that lean rats show heightened total EE, and 
that this is primarily due to elevated non-resting EE. Taken together with previous studies 
(Novak CM, 2009; Novak et al., 2010), I have shown that the amplified NEAT 
characteristic of this lean phenotype is predominantly due to increased daily activity 
levels combined with increased fuel cost of that activity (Gavini et al., 2014). The 
increased calorie use may be secondary to heightened function of muscle UCPs, 
combined with decreased function of K+ATP and MED1, potentially driven by 
sympathetic outflow to skeletal muscle. 
 
Relative to female LCR, female rats of the lean, high-capacity phenotype (HCR) 
did not show significantly elevated resting EE. Instead, the lean, high-capacity rats 
consistently displayed significantly heightened non-resting EE (Figures 7, 8, and 9). This 
persisted when the groups were matched for body weight or lean mass, or without 
matching (Figures 7, 8, and 9; Table 2). This was consistent with ANCOVA analyses, 
which demonstrated that non-resting EE was consistently higher in female HCR, even 
after body weight and lean mass were considered as covariates, without any detectable 
difference in resting EE (Figure 10). Overall, this gives little support for the hypothesis 
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that there is a meaningful deficiency in resting metabolic rate in the obese. Rather, my 
results support the assertion that non-resting EE, including physical activity EE, is 
consistently elevated in the lean phenotype associated with high aerobic capacity even 
after individual differences in body mass and composition are taken into account. This is 
in line with elevated activity EE observed in other models of leanness (Kotz, Teske, & 
Billington, 2008).  
 
It is conceivable that economy of activity is differentially modulated in HCR than 
in LCR, potentially by sympathetic outflow, resulting in greater variance in activity EE in 
HCR. The difference in non-resting EE persists even when body weight and composition 
are nearly identical (Figures 7, 8, and 9), indicating that lower daily physical activity 
levels in LCR are not due to the any difficulty in locomotion incurred by greater body 
mass, but are inherent to the obesity-prone, low aerobic capacity phenotype. This reflects 
what many studies have established regarding leanness in humans, namely the link 
between high aerobic capacity, high physical activity and NEAT, and favorable 
metabolic health (Ekelund et al., 2005; Levine et al., 1999; Novak et al., 2010; Simmons 
et al., 2008).  
 
NEAT (i.e., activity EE) is the component of total EE that consistency differs 
between lean and obesity-prone individuals, and this is elevated in obesity-resistant rats 
through higher levels of physical activity combined with decreased fuel economy of 
activity (Levine & Kotz, 2005; Novak et al., 2010) (Figures 7, 8, and 9; Table 2). Skeletal 
muscle is the major contributor to activity EE, and also significantly impacts resting EE 
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(Zurlo F, 1990). Therefore, the logical next step was to investigate cellular and molecular 
mechanisms that differentially regulate NEAT in skeletal muscle of these phenotypes. 
Specifically, what is the fate of the “extra” calories being burned during NEAT in HCR 
(Novak et al., 2010)? In an attempt to answer this question, I hypothesized that excess 
calories used during the less-economical NEAT in the lean, high-capacity phenotype are 
being dissipated as heat, analogous to the fuel inefficiency that occurs during BAT 
thermogenesis (Kozak, 2010; Rothwell & Stock, 1979). Hind-limb gastroc muscle 
temperature was significantly higher in HCR than LCR during physical activity of 
equivalent workload (treadmill speed and incline, similar body weight (Figure 11)). This 
supports the hypothesis that the “wasted” calories utilized for non-resting EE are being 
used by muscle, specifically for NEAT, and at least some of the energy is being 
dissipated as heat. This is consistent with the work of others demonstrating relatively 
inefficient coupling in HCR mitochondria specifically in HCR skeletal muscle (Lessard 
et al., 2009; Lessard et al., 2011; Naples et al., 2010; Stephenson, Stepto, Koch, Britton, 
& Hawley, 2012b; Tweedie et al., 2011). This is also consistent with reports that, relative 
to LCR, HCR have enhanced muscle glucose uptake, glucose and lipid oxidation, and 
higher muscle glycogen (Rivas et al., 2011). Obesity-related differences in walking or 
running economy in humans is a matter of some contention. Studies in both athletes and 
non-athletes, however, support the idea that those with higher VO2max (i.e., aerobic 
capacity) have lower economy of activity (Lucia, Hoyos, Perez, Santalla, & Chicharro, 
2002; Sawyer et al., 2010). This relative inefficiency may be a trade-off for enhanced 
aerobic capacity. 
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I predicted that the lean vs. obesity-prone phenotypes would exhibit differential 
expression of molecular mediators of energy consumption in myocytes. I examined K+ATP 
channels, which are important in determining the metabolic state of the cell by 
maintaining potential gradient for ATP synthesis (Alekseev et al., 2010; Nichols, 2006). 
Given that mice deficient in of K+ATP channels are lean and have lower fuel economy of 
activity (Alekseev et al., 2010), similar to HCR, I predicted that lean, high-NEAT HCR 
would show low expression of K+ATP channels in skeletal muscle compared to obesity-
prone LCR. Consistent with the hypothesis, Kir6.2, the predominant subtype of the K+ATP 
channel in muscle (Aguilar-Bryan et al., 1998), showed dampened levels of expression in 
gastroc of HCR (Figures 12 and 13). In addition, a component of mediator cofactor 
complex, MED1, also showed lower levels of expression in the muscle of HCR than 
LCR, particularly in gastroc (Figures 12 and 13). This component of mediator cofactor 
complex is associated with several nuclear receptors involved in the transcription of 
genes involved in fatty acid oxidation (Kodera et al., 2000; Yuan, Ito, Fondell, Fu, & 
Roeder, 1998), and is hypothesized to mediate myocyte fuel conservation (W. Chen et al., 
2010). Low levels of both MED1 and K+ATP channels are consistent with the 
compromised economy of activity and increased heat generation of HCR muscle, likely 
through altered control of fatty acid oxidation (Alekseev et al., 2010); assessments of 
channel function are needed to directly test this hypothesis, however. 
 
Similar to BAT, skeletal myocytes express uncoupling proteins (UCP2 and 3). 
UCPs play an important role in uncoupling ATP generation and in proton leak across 
mitochondrial membranes, opposing the function of K+ATP channels in the cell. Here, I 
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find that lean rats have consistently heightened expression of both UCP2 and UCP3 in 
skeletal muscle (both quad and gastroc) compared to the obesity-prone LCR (Figures 12 
and 13), consistent with what has been reported by others in rats (Lessard et al., 2009; 
Lessard et al., 2011; Stephenson et al., 2012b). There is no consensus on the role of 
UCPs, especially UCP 3, in skeletal muscle, though they are hypothesized to facilitate 
fatty acid translocation or mitigation of ROS (Harper et al., 2001; Samec, Seydoux, & 
Dulloo, 1998). It is unknown whether the uncoupling affects efficiency or thermogenesis. 
Altogether, the data support a theoretical model in which the myocytes of the lean 
phenotype have increased use of metabolic fuels, particularly fatty acids, through 
heightened UCP function along with reduced ability to conserve fuel through MED1 and 
K+ATP channels.   
 
My findings using a contrasting genetic model system support a role for 
differential activity-related skeletal muscle thermogenesis in maintaining leanness, and 
identify potential molecular mechanisms underlying this; the data also identify a potential 
source of these differences. It is possible that the central nervous system modulates 
muscle fuel efficiency through the SNS in a fashion analogous to what has been 
documented in other systems such as BAT (Cannon & Nedergaard, 2004). As illustrated 
in Figure, compared to LCR, HCR were found to have significantly higher skeletal 
muscle NETO, an indicator of SNS drive (Bartness, Vaughan, & Song, 2010). It is 
possible that muscle fuel uptake and utilization is modulated through the SNS, controlled 
by central nervous system effectors (Nogueiras et al., 2007; Shiuchi et al., 2009), possibly 
including brain orexigenic and anorexigenic peptides that are known to act in the 
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paraventricular nucleus to affect muscle uncoupling protein levels (Kotz, Wang, Levine, 
& Billington, 2002; Kotz, Wang, Briggs, Levine, & Billington, 2000; C. Wang, 
Billington, Levine, & Kotz, 2000). Brain melanocortins have been found to impact 
muscle lipid mobilization and glucose uptake (Nogueiras et al., 2007; Tanaka et al., 2007; 
Toda et al., 2009) and the lean and obesity-prone rats show differences in central 
melanocortins (Shukla, Britton, Koch, & Novak, 2012), a system recognized to modulate 
SNS drive (Sohn et al., 2013). Taken together with previous evidence, these data are 
consistent with a model in which brain systems (e.g., melanocortins) modulate SNS 
outflow and myocyte beta adrenoreceptors to increase myocyte glucose and fatty acid 
uptake and utilization, amplifying energy expenditure of activity (i.e., NEAT) (Miyaki et 
al., 2011; Shiuchi et al., 2009; Tanaka et al., 2007; Toda et al., 2009) which will be 
discussed in the next chapters. Similar to skeletal muscle, I also found that NETO was 
higher in brown adipose tissue of HCR compared to LCR. Effects of BAT thermogenesis 
on EE would not be expected to preferentially affect non-resting EE, however. The data 
described here support a theoretical model where the modulation of metabolic fuel use of 
skeletal myocytes, potentially through enhanced SNS drive, results in increased or 
decreased fuel efficiency during locomotion. This hypothesis will be tested further in the 
subsequent studies.  
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CHAPTER 3
 
The preponderance of data supports the assertion that the hypothalamus, 
particularly the ventromedial hypothalamus (VMH), plays an important role in 
modulating energy homeostasis, thermoregulation, food intake, peripheral metabolic fuel 
allocation, RER, and high-fat diet-induced thermogenesis via the modulation of SNS. As 
explained above, the MC system is a well-studied system that impacts the control of 
feeding, body weight, and thermogenesis. Melanocortins are also associated with 
increased EE and physical activity. Decreased expression and loss-of-function mutations 
in MCR are associated with increased calorie intake, decreased EE, and severe early-
onset obesity in humans and rodents. Skeletal muscle, a major fuel-burning tissue, is 
often neglected as a target for obesity treatments. Based on these studies on the VMH and 
central MC, I propose the existence of an axis between VMH and skeletal muscle, 
modeled on the hypothalamic control of BAT via the SNS.  
 
To test this hypothetical model, I examined the ability of VMH MC receptor 
activation to increase activity-related thermogenesis and EE, as well as SNS drive to 
muscle. I also measured the expression of molecular mediators of EE in other peripheral 
metabolically active tissues like BAT, liver, and white adipose tissue (WAT) along with 
skeletal muscle. BAT remains the primary target for studies on enhancing EE through 
central regulatory mechanisms such as activation of MC receptors. Heightened mRNA 
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and protein expression of EE mediators in BAT explains the majority of MC receptor-
induced increase in EE via SNS. Liver and WAT are important for providing fuel to other 
tissues, both during activity and resting, and receive a significant autonomic relay. 
Integrating the changes in these metabolically active tissues after intra-VMH MC 
receptor activation will help determine the scope of the influence of central MC on 
peripheral metabolism and in generation of lean and obese phenotypes. 
 
3.1 Methods 
3.1.1 Study 1: Examine the effects of VMH MC receptor activation on activity-related 
EE. I predicted that activation of VMH neurons with a MCR agonist will alter skeletal 
muscle energetics and thus activity-related EE. I also predicted that activation of MCR in 
the VMH will increase EE, and decrease RER, switching fuel use to fats. I will focus 
primarily on changes in EE as well as changes in heat dissipation at the level of skeletal 
muscle, after activation of VMH MC receptors. 
 
Design 
Preliminary study: A dose-response study was conducted using Sprague-Dawley rats to 
determine optimal concentration of MTII (10, 20, 50, and 100pmoles) required to induce 
VMH MC receptor activation-induced changes in temperature and calorimetric 
parameters. 
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3.1.1.1 Study 1a: Measure changes in EE and other calorimetric parameters (RER) upon 
VMH MC receptor activation with MTII in freely moving and activity-controlled rats. 
(N=12)  
Day -10 – 0: Arrival of animals, separation, and housing.  
Day 1 – 4: Stereotaxic surgeries to implant guide cannula aimed at VMH. 
Day 5 – 11: Recovery.  
Day 11: Divided into groups (MTII or vehicle), total 3 cohorts (4/cohort, two from each 
group), making sure each of them goes into both treatments at some point.  
Day 12: Acclimation of animals to calorimetry chamber and test cages.  
Day 13: 0900 – 1300 - Measured EE and other calorimetric parameters using Oxymax 
FAST system (Columbus Instruments, Columbus, Ohio) of cohort 1 for 4 hrs post-
injection with MTII (20pmoles/200nl) or vehicle. (based on preliminary study).  
Day 13: 1400 – 1800 – Repeated for cohort 2.  
Day 14: 0900 – 1300 – Repeated for cohort 3. Removed the animals from calorimetry 
chamber and return to the animal facility.  
Day 17 - 19: Repeated day 12-14 by changing the treatment.  
Day 22: Acclimated cohorts 1, 2, and 3 in calorimetry chamber for treadmill run 
(controlled activity). Trained rats to run on a treadmill.  
Day 23: Each cohort was subdivided into MTII- or vehicle-treatment groups. Rats were 
injected with MTII (20pmoles/200nl) or aCSF and allowed to run on a treadmill 105 - 
120 minutes after injection for 30 minutes and changes in EE and other calorimetric 
parameters were measured. 
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Day 24: Repeated the same with remaining rats. Removed the rats from the chamber 
after completion of run.  
Day 27 – 29: Repeated day 22 – 24 by changing treatment (no treadmill training 
necessary). 
 
3.1.1.2 Study 1b: Measure skeletal muscle heat dissipation after VMH MC receptor 
activation with MTII in these rats during light phase in their regular cages and during a 
graded treadmill test. (N=8)  
Day -10 – 0: Arrival of animals, separation, and housing.  
Day 1 – 4: Stereotaxic surgeries to implant guide cannula aimed at VMH and transponder 
implants adjacent to gastroc in both hind limbs and adjacent to BAT.  
Day 5 – 11: Recovery.  
Day 12: Divided into MTII- and vehicle-treatment groups. Injection of MTII 
(20pmoles/200nl) or vehicle (aCSF) and measured heat dissipation at the level of skeletal 
muscle and BAT every 15 minutes for 4 hrs post-injection.  
Day 17: Repeated day 12 by changing treatment (day 12 MTII group gets vehicle on day 
17).  
Day 21: Trained rats to walk on treadmill.  
Day 22: Rats were divided into two groups (MTII- or vehicle-treatment groups). Rats 
were injected with MTII (20pmoles/200nl) or aCSF; 105 – 120 minutes post-injection, 
rats were allowed to walk on a treadmill at varying intensities for 30-40 minutes. Gastroc 
temperatures were measured at regular intervals.  
Day 23: Repeated the same with remaining rats.  
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Day 27-28: Repeated the process by changing the treatment.  
 
3.1.2 Study 2: Examine the effects of VMH MC receptor activation on the SNS and how 
this pathway alters skeletal muscle energetics. I predicted that activation of MC receptors 
in the VMH will increase sympathetic drive to peripheral tissues. I also predicted that this 
higher sympathetic drive will increase fuel utilization and molecular mediators of EE. 
 
Design 
3.1.2.1 Study 2a: Measure the level of sympathetic drive to peripheral tissues after VMH 
MC receptor activation with MTII. 
Day -7 – 0: Arrival of animals, separation, housing and acclimate. (n=24)  
Day 1 – 4: Stereotaxic surgeries to implant guide cannula aimed at VMH  
Day 5 – 11: Recovery  
Day 11: Divided into groups depending on treatment.  
Day 12: Day of study  
t hrs: Euthanized zero time point group (to obtain baseline tissue NE content) 
(n=8) and injected remaining with aMPT (125 mg aMPT/kg BW). (n=16, 
8/group)  
t+0.5hrs: Injected with either MTII (20pmoles/200nl) or aCSF (200nl) depending 
on the group (n=8/group).  
t+2hrs: Injected all remaining animals with second dose of aMPT (125 mg 
aMPT/kg BW). (n=16, 8/group)  
t+4hrs: Euthanized the rats and harvest tissue. 
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3.1.2.2 Study 2b: Measure the expression of molecular mediators of EE in peripheral 
tissues after VMH MC receptor activation with MTII. 
Day -7 – 0: Arrival of animals, separation, housing and acclimate. (n=18)  
Day 1 – 4: Stereotaxic surgeries to implant guide cannula aimed at VMH  
Day 5 – 11: Recovery  
Day 11: Divided into groups depending on treatment.  
Day 12: Day of study  
t hrs: Injected with either MTII (20pmoles/200nl) or aCSF (200nl) depending on 
the group (n=9/group).  
t+4hrs: Euthanized the rats and harvest tissue. 
 
Animals 
Male Sprague-Dawley (SD) rats (N=62; 8 weeks, ~ 250g) were obtained from 
Harlan labs. Each rat was housed individually on a 12:12 light:dark cycle with lights on 
at 0700 EST. Rats received rodent chow (5P00 MRH 3000, T.R. Last Co. Inc.) and water 
ad libitum. All studies were conducted according to the Guide for the Care and Use of 
Laboratory Animals ("National Research Council (US) Committee for the Update of the 
Guide for the Care and Use of Laboratory Animals," 2011) and approval of the Kent 
State University IACUC.  
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Stereotaxic surgeries  
After the rats were acclimated to the housing conditions, stereotaxic surgeries 
were performed to chronically implant guide cannulae (PlasticsOne) aimed at VMH. The 
rats were anesthetized using isoflurane and mounted on a stereotaxic apparatus. The 
following coordinates obtained from “The rat brain in stereotaxic coordinates” 
(Watson), were used for VMH: anterior-posterior, -2.5mm; medial-lateral, +0.5mm; 
dorsal-ventral, -6mm (from dura); and an injection needle with 3mm projection (final 
dorsal-ventral, -9mm (from dura)). The guide cannulae were attached to the skull using a 
sterile wound clip and dental cement. The rats were then allowed to recover with periodic 
monitoring before the start of the study.  
 
Site checks 
After the completion of all data collection, placement of the cannula was 
determined at the end of the study by histologically examining its anatomical placement. 
The brains were removed and fixed in 10% phosphate buffered formalin and then placed 
in 10% phosphate buffered formalin with 30% sucrose. Brains were sectioned at 50 μm 
using a cryostat and mounted onto slides (Fisher Superfrost Plus); slides were 
dehydrated, stained using cresyl violet, and the injection sites were determined using a 
microscope. Only rats whose guide cannulae were within 250μm of the VMH were used 
for data analysis.  
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Transponder implantation  
A group of male Sprague-Dawley rats (n=10, a subset of actual group mentioned 
above) received transponder implants during the stereotaxic surgery. A short incision was 
made on both hind legs and near the interscapular region. Sterile temperature 
transponders IPTT-300 (Bio Medic Data Systems, Inc.) were implanted on interscapular 
BAT and also adjacent to the gastrocnemius (gastroc) muscle group of both hind limbs to 
measure the heat generated by skeletal muscle during activity. Care was taken to place 
the transponders so as not to disrupt locomotor function. Rats were allowed to recover for 
a week before the graded treadmill test was performed. Implant placement was examined 
during tissue harvest and data from inaccurately placed transponders were omitted from 
final analyses.  
 
Body composition  
Body composition was measured using EchoMRI-700 (Echo Medical Systems, 
Houston, TX) to determine the fat and lean mass (in grams) of each rat the day before 
test. This did not interfere with temperature transponder function. 
 
Measurement of energy expenditure  
After body composition determination, adult male Sprague-Dawley rats were 
measured for their EE and physical activity using small animal indirect calorimetry (4-
chamber Oxymax FAST system, Columbus Instruments, Columbus, OH) with 24-48hrs 
of acclimation in their testing cage at thermoneutral conditions to avoid any novelty-
induced alterations in calorimetric parameters, as previously reported (Gavini et.al, 
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2014). On the day of calorimetry, rats were weighed and injected either with a 
nonspecific MC receptor agonist MTII (Phoenix Pharmaceuticals, Mountain View, CA) 
(20pmoles/200nl) or vehicle (aCSF, 200nl) over a period of 30 seconds and holding in 
place for another 30 seconds to avoid back-flush, and then placed in the chamber with 
food and water; the chamber was then sealed. The calorimeter was calibrated using 
primary gas standards. Air was pumped into the chamber at 1.9-3.1 lpm, depending on 
the weight of the rat, and chamber air was sampled at 0.4 lpm. Measurement of gas 
exchange took place every 30 sec throughout the 4-hr period except for a 3.5-min room-
air reference and settle period after each 60-sample interval. Physical activity data were 
collected using infrared beam-break counts, collected every 10 sec uninterrupted 
throughout the 4-hr period, in the X and Z axes; the first 15min of data were not included 
in the analysis. EE data (VO2, VCO2, RER, kcal/hr) were averaged, and physical activity 
data were expressed as mean beam breaks per minute. Four days after the first injection, 
the same was repeated with rats now receiving the other treatment (day1 MTII rats 
receiving vehicle on day5 and vice versa). This way each rat acted as its own control 
thereby nullifying the effects of body composition and other individual differences on 
calorimetric parameters (Schoeller & Jefford, 2002; Tschop et al., 2012). 
  
As previously described (Gavini et al., 2014; Novak et al., 2010), physical activity 
EE were assessed by measuring gas exchange once every 10 sec during a treadmill 
activity test. At least one day after a 15-min treadmill acclimation period, rats were 
placed in the treadmill after weighing them and injecting with either MTII 
(20pmoles/200nl) or vehicle (aCSF) and allowed to acclimate without food for 2hrs. 
 
 
90 
 
After the 2-hr resting period, the treadmill was started at 7 m/min for 30 min, during 
which time physical activity EE data were collected. The same was repeated after 4 days 
with rats now receiving the counterbalanced injection. Because all rats received both 
injections, we compared EE between MTII and vehicle treatments using a 2-tailed paired 
t-test. A paired 2-tailed t-test was also used to compare treadmill gas exchange values 
between the treatments.  
 
Home cage muscle temperature  
To determine whether activation of MC receptors in VMH has any effect on the 
thermogenics of skeletal muscle, I measured skeletal muscle heat dissipation for 4hrs 
after intra-VMH MTII or vehicle microinjection. The activation of BAT thermogenesis 
was measured as a control process during this study. Rats were weighed and the injected 
either with MTII or vehicle, placed in their home cage and temperature data from the 
transponder implants on the gastroc and BAT were collected every 15min over a period 
of 4hrs and analyzed the data using a repeated-measures ANOVA. All rats received both 
injections.  
 
Graded treadmill test  
To determine skeletal muscle heat dissipation during controlled physical activity 
after MC receptor activation in VMH, I measured the temperatures of the gastroc muscle 
group using a graded treadmill test. The rats were acclimated to the treadmill for 10 
minutes in the days prior to the test as well as immediately before the test. The rats 
received microinjection of either MTII or vehicle 1.5 hrs prior to the test, with the test 
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repeated after 4 days in order for each rat to receive each treatment. Gastroc temperatures 
in each leg were recorded at baseline (before injecting and right before start of the test) 
and at set intervals during a 5-level graded treadmill test as reported previously in chapter 
2 (Gavini et al., 2014). The test was stopped at after 35 minutes and the data were 
analyzed using a 2-tailed paired t-test, with the time-course of temperature changes 
analyzed using a repeated-measures ANOVA.  
 
Gene expression  
Skeletal muscle (gastroc and quad), liver, WAT and BAT were collected from 
adult male Sprague-Dawley rats (N = 18, a different subset of above mentioned number) 
4hrs after intra-VMH microinjection of either MTII or vehicle (N = 9/group) after 
euthanasia by rapid decapitation without anesthetic agents. Tissue samples were 
homogenized and total mRNA was extracted using an Ambion ribopure kit following 
manufacturer’s instructions. The purity of mRNA was measured using NANODROP 
(ND-1000) (Nanodrop technologies) and A260/280 ratio to be ranging from 1.8 – 
2.1.This mRNA was used to prepare cDNA using an Applied Biosystems kit and thermal 
cycling at 25⁰C for 10 minutes, 48⁰C for 30 minutes, 95⁰ C for 5 minutes and holding at 
4⁰C. The cDNA was used for quantifying the expression of UCP1, UCP2, UCP, Kir6.1, 
Kir6.2, MED1, PPARα, PPARδ, PPARγ, PGC-1α, SERCA1, SERCA2, β2-AR, β3-AR, 
and GAPDH (used as a control). The relative expression was calculated using 
comparative Ct method (ΔCt). Data are expressed as a percent expression using the 
vehicle treated as the reference value (defined as 100%), and groups were compared 
using a 2-tialed t-test.  
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Western blotting  
Tissues samples from adult Sprague-Dawley rats (same group of rats used for 
gene expression, N =18, 9/group), were homogenized with ice-cold RIPA buffer (Thermo 
Scientific) containing a protease inhibitor cocktail (Roche Diagnostics). The supernatant 
from the homogenization and subsequent centrifugation was used for the analysis. Equal 
quantities of supernatant and sample buffer (150mM tris-HCl pH 6.8, Trizma-base for 
pH, 6% SDS, 30% glycerol, 0.03% pyronin-Y, DTT) were mixed and tubes were heated 
at 90⁰C for 3 minutes. Samples containing equal quantity of protein were loaded on to a 
gradient gel (4-15%) (Bio Rad) and electrophoresed using SDS running buffer (0.384M 
glycine, 0.05M Trizma bas, 0.1% SDS) at constant voltage (150V) for 30 minutes. The 
gel was blotted on to a PVDF membrane using semi-wet blotting apparatus and Otter et 
al. (1987) transfer buffer (49.6mM Trizma base, 384mM glycine, 17.5% methanol, 
0.01% SDS) at constant current (400mAmp). The blot was incubated overnight in a 
blocking solution of 5% milk (Blotto) in 1xPBST (Phosphate buffered saline; 84mM 
sodium hydrogen phosphate, 16mM sodium dihydrogen phosphate, 100mM sodium 
chloride, tween20), then rinsed using 1xPBST. Primary antibodies were diluted in 
blocking solution at ratio recommended by manufacturer and incubated with the blot 
overnight. Secondary antibodies were diluted in blocking solution in the ratio 1:5000 and 
incubated for 1 hour at room temperature. After washing, the blots were developed using 
a chemiluminiscence detector using an Amersham kit (GE Healthcare, UK). The 
expression levels relative to actin were plotted as a percent of the reference value (with 
vehicle treatment as 100%), and groups were compared using 2-tailed t-tests.  
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Norepinephrine turnover (NETO)  
Adult male Sprague-Dawley rats (N= 24, 8/group, a subset of above mentioned 
number) were used to assess sympathetic drive to peripheral tissues – liver, heart, BAT, 
skeletal muscle (including quad, lateral and medial gastroc, extensor digitorum longus 
(EDL) and soleus) and different WAT depots (mesenteric WAT (MWAT), gluteal WAT 
(GWAT), retroperitoneal WAT (RWAT), inguinal WAT (IWAT) and epididymal WAT 
(EWAT)) . Rats were individually housed on a 12:12 light:dark cycle with ad libitum 
access to standard rodent chow (5P00 MRH 3000, T.R. Last Co. Inc.) and water, and 
acclimated to daily handling for a week after stereotaxic surgery. Level of sympathetic 
drive to peripheral tissues was determined through the norepinephrine (NE) turnover 
(NETO) method using α-methyl-p-tyrosine (aMPT) as previously reported (Gavini et al., 
2014; Shi et al., 2004). The rats were divided into 3 groups (aMPT/MT-II, aMPT/vehicle, 
control). On the day of study, rats receiving aMPT were injected with aMPT (125 mg 
aMPT/kg of body weight, 25 mg/ml) and with a second dose at same concentration 2 
hours later. 30 minutes after first aMPT injection, rats received intra-VMH 
microinjection of either MTII (20pmoles/200nl) or vehicle (aCSF) depending on their 
group. All rats were euthanized by rapid decapitation between 1200 and 1500, 4 hours 
after first aMPT injection. Tissues were rapidly dissected and snap-frozen in liquid 
nitrogen.  
 
Briefly, tissue was thawed and homogenized in a solution containing 
dihydroxybenzylamine (DHBA, internal standard) in 0.2M perchloric acid (PCA) with 1 
mg/ml ascorbic acid (AA). Following centrifugation for 15 min at 7,500 g at 4°C, 
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catecholamines were extracted from the homogenate with alumina and were eluted into 
the PCA/AA. The catecholamines were assayed using an HPLC system with 
electrochemical detection (Coulochem III), MDTM mobile phase and reverse phase MD 
150x3.2 column. NETO in peripheral tissues was calculated using the following formula 
(Gavini et al., 2014; Shi et al., 2004):  
k = (lg[NE]0 – lg[NE]4)/(0.434 x 4)  
K = k[NE]0  
k is the constant rate of NE efflux (also known as fractional turnover rate),  
[NE]0 is the initial NE concentration or from 0-hr group (control),  
[NE]4 is the final NE concentration or from 4-hr group (aMPT), and  
K = NETO.  
Difference in NETO of intra-VMH MTII-microinjected and vehicle-microinjected rat 
tissues were calculated with respect to control-group rats and compared using 1-tailed 
paired t-test for each tissue. 
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Figure 15: Cresyl violet stained brain section showing site specific injection into the 
ventromedial hypothalamus (VMH). 
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3.2 Results  
Intra-VMH MTII induced a dose-dependent rise in energy expenditure and skeletal 
muscle and BAT heat dissipation (preliminary study) 
A dose-response study using SD rats (N=8) to examine skeletal muscle heat 
dissipation after intra-VMH microinjections of the MCR agonist MTII showed a direct 
proportionality between dose and response. All rats received intra-VMH microinjections 
of MTII at increasing doses (10, 20, 50, 100pmoles/200nl) and vehicle (aCSF, 200nl) in 
random order. Based on my analysis, using only the rats that had cannulae successfully 
aimed at the VMH, the data showed a significant MTII-induced increase in muscle and 
BAT heat dissipation, compared to vehicle injection (Figures 16 and 17). The change in 
temperature was directly proportional to the dose of MTII used where higher doses 
induced a greater change in heat dissipation. Compared to vehicle-treated rats, 
temperatures of BAT of MTII-treated rats increased significantly between 30 - 105 
minutes, and that of muscle starting around 120 minutes after MTII treatment to the end 
of study at 240 minutes. The temperatures of both BAT and skeletal muscle showed a 
clear dose-dependent pattern where higher doses (50 and 100pmoles) induced 
supraphysiological responses.   
 
Next, I examined the changes in EE and physical activity upon activating MC 
receptors in the VMH. EE and physical activity were measured using an Oxymax FAST 
system in a calorimetry chamber for 4 hours post-injection. Compared to vehicle 
microinjection, both doses of intra-VMH MTII (20 and 50pmoles) induced a significant 
increase in EE, oxygen uptake (VO2), and physical activity, and a significant decrease in 
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RER (p<0.05) (Figure 18), suggesting a shift in fuel preference to fat. At 50pmoles, the 
MTII-induced increases in EE, VO2, and physical activity and decrease in RER were 
significantly higher than the 20pmoles dose of MTII. 
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Figure 16: Intra-VMH MTII induced a dose-dependent rise in brown adipose tissue 
thermogenesis. Brown adipose tissue (BAT) temperatures after intra-VMH 
microinjection of the mixed melanocortin receptor agonist MTII at increasing doses (10, 
20, 50, 100pmoles, aCSF (vehicle)). Compared to vehicle administration, MTII injection 
induced a significant increase in the temperature of BAT. (A) BAT temperature, (B) 
change in BAT temperature from baseline after intra-VMH MTII microinjection. All 
values are means ± SEM for that particular time. 
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Figure 17: Intra-VMH MTII induced a dose-dependent rise in skeletal muscle heat 
dissipation. Gastrocnemius (gastroc) temperatures after intra-VMH microinjection of the 
mixed melanocortin receptor agonist MTII at increasing doses (10, 20, 50, 100pmoles, 
aCSF (vehicle)). Compared to vehicle administration, MTII injection induced a 
significant increase in gastroc temperature. (A) Gastroc muscle temperature, (B) change 
in gastroc temperature from baseline after intra-VMH MTII microinjection. All values 
are means ± SEM for that particular time. 
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Figure 18: Calorimetric parameters after intra-VMH MTII microinjections. Rats 
with intra-VMH MTII microinjection (both 20 and 50pmoles) showed a significant 
increase in oxygen uptake (VO2) (A), physical activity (D), and energy expenditure (C), 
with a significant decrease in RER (B). *significantly different from vehicle, p<0.05. All 
data are means ± SEM. 
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Rats with intra-VMH MTII microinjection have higher energy expenditure (Study 
1a).  
As shown in Figure 19, compared to vehicle microinjection, rats administered 
intra-VMH MTII have significantly higher EE, higher oxygen consumption (VO2) and 
lower RER. All rats received microinjections of both vehicle and MTII thereby acting as 
their own controls during the study and eliminating the effects of body composition on 
calorimetric parameters (Schoeller & Jefford, 2002; Tschop et al., 2012). There was no 
significant difference in body weight, lean mass, or fat mass between the two sets of 
injections. Compared to vehicle, MTII-injection significantly increased rats’ physical 
activity, both horizontal and ambulatory activity.  
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Figure 19: Intra-VMH MTII induced a significant increase in energy expenditure, 
oxygen uptake, and physical activity, with a significant decrease in respiratory 
exchange ratio. Oxygen uptake (VO2), respiratory exchange ratio (RER), energy 
expenditure and physical activity 4hrs after intra-VMH MTII and vehicle administration. 
Compared to vehicle, MTII microinjections significantly increased VO2 (A), energy 
expenditure (C) and physical activity (D) and decreased RER (B). (*significantly 
different from vehicle, p<0.05) 
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Intra-VMH MTII microinjection increases energy expenditure during controlled 
activity (Study 1a).  
To demonstrate that increase in these calorimetric parameters is not dependent on 
the increase in physical activity after intra-VMH microinjection of MTII, a controlled 
treadmill activity study was performed. EE was measured during a low-grade treadmill 
exercise test to control for rats’ workload. Again animals were compared to themselves – 
a within-animal design – to eliminate potentially confounding effects of individual 
differences, for example in body weight. As shown in Figure 20, compared to vehicle 
microinjection, rats receiving intra-VMH microinjection of MTII had higher EE, higher 
VO2, and lower RER during a controlled treadmill activity. Therefore, the altered EE and 
calorimetric parameters after intra-VMH MTII treatment was not dependent on increased 
physical activity. As each rat acted as its own control and considering the lack of 
significant changes in body weight, lean mass, or fat mass between treatments, the 
potential confounding effect of differential workload during activity is negligible.  
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Figure 20: Intra-VMH MTII-induced alterations in energy expenditure and 
respiratory exchange ratio persisted during controlled treadmill activity. Oxygen 
uptake (VO2), respiratory exchange ratio (RER), energy expenditure during controlled 
treadmill activity after intra-VMH MTII and vehicle administration. Compared to 
vehicle, MTII microinjections significantly increased VO2 (A), energy expenditure (C) 
and decreased RER (B). No significant change was seen in body weight (D) between the 
treatments. (*significantly different from vehicle, p<0.05) 
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High activity energy expenditure after intra-VMH MTII microinjection is 
accompanied by skeletal muscle energy dissipation as heat (Study 1b).  
Based on above results, intra-VMH MTII injection resulted in additional calories 
being used for the identical activity, indicating that intra-VMH MC receptor activation 
lowers economy of activity. Along with literature showing the association between VMH 
MC receptors and skeletal muscle fuel use and allocation, this implicates melanocortin-
induced alteration of skeletal muscle energetics and thermogenesis as the underlying 
cause. To test this, I microinjected these rats with MTII or vehicle and measured BAT 
and gastroc temperatures under home-cage resting conditions as well as during a graded 
treadmill activity. During resting, compared to vehicle, MTII treatment induced higher 
BAT temperatures, and the rise in temperature from baseline was significantly higher 
after MTII treatment between 30min and 105min after injection (Figure 21). Compared to 
vehicle, intra-VMH MTII injection induced higher gastroc muscle temperatures and the 
rise in temperature from baseline was significantly higher compared to vehicle between 
90min and 240min of the testing period (Figure 21).  
 
Next, I tested the hypothesis that MTII injection decreases economy of activity as 
the rats expend calories through heat dissipation in skeletal muscle during activity. This 
was tested by measuring gastroc temperature during a graded exercise treadmill test. All 
rats received both sets of injections and there were no significant differences in body 
weight, lean mass, or fat mass observed between treatments. Compared to vehicle 
treatment, MTII injections induced a significant increase in gastroc temperature, and the 
maximal increase in temperature from baseline was also significantly higher after MTII 
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compared to vehicle (Figure 22), demonstrating overall that intra-VMH MC receptor 
activation lowers the economy of activity and that those surplus calories are dissipated as 
heat by skeletal muscle.  
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Figure 21: Intra-VMH MTII induced a significant increase in both brown adipose 
tissue and gastrocnemius temperatures compared to vehicle microinjection during 
the light phase. Change in temperature of gastrocnemius (gastroc) (B) and brown 
adipose tissue (BAT) (A) from baseline in rats after intra-VMH microinjections of MTII 
and vehicle. Change in temperature was significantly greater after MTII microinjection 
compared to vehicle between 105 min and 240 min for gastroc, and between 30 min and 
105 min for BAT. (*MTII significantly higher than vehicle, p<0.05) 
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Figure 22: Intra-VMH MTII increased gastrocnemius temperature during a graded 
treadmill exercise test. Temperature (A) and change in temperature from baseline (B) of 
gastrocnemius (gastroc) in rats after intra-VMH microinjections of MTII and vehicle. 
Temperature was higher after MTII microinjection compared to. Change in temperature 
from baseline was significantly greater after MTII microinjection compared to vehicle. 
(*MTII significantly higher than vehicle, p<0.05) 
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Intra-VMH MT-II microinjection elevates sympathetic drive to metabolic tissues 
(Study 2a).  
The SNS is likely to play a crucial role in the transmission of signals from 
hypothalamic nuclei downstream to peripheral metabolic tissues modulating fuel use and 
production. As illustrated in Figures 23, 24, and 25, compared to vehicle, intra-VMH 
MTII-microinjected rats had higher NETO in all tissues analyzed, indicating higher 
sympathetic drive to these tissues; this included skeletal muscle, different WAT depots, 
BAT, heart, and liver. This implicates a MC regulated pathway in the hypothalamus, 
particularly the VMH, in the regulation of SNS drive, potentially modulating muscle fuel 
storage and utilization. 
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Figure 23: Intra-VMH MTII induced a significant increase in skeletal muscle 
NETO. Norepinephrine turnover (NETO) in skeletal muscle of intra-VMH MTII and 
vehicle microinjected rats in (A) extensor digitorum longus (EDL), (B) quadriceps 
(Quad), (C) lateral gastrocnemius (Lat.gastroc), (D) medial gastrocnemius (Med.gastroc), 
and (E) soleus. Compared to vehicle, intra-VMH MTII induced a significant increase in 
NETO (*MTII>vehicle, p<0.05). 
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Figure 24: Intra-VMH MTII induced a significant increase in NETO of different 
white adipose depots. Norepinephrine turnover (NETO) of intra-VMH MTII- and 
vehicle-microinjected rats in different white adipose depots (WAT): (A) epididymal 
WAT (EWAT), (B) retroperitoneal WAT (RWAT), (C) mesenteric WAT (MWAT), (D) 
inguinal WAT (IWAT), and (E) gluteal WAT (GWAT). Compared to vehicle, intra-
VMH MTII induced a significant increase in NETO in all WAT depots (*MTII>vehicle, 
p<0.05). 
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Figure 25: Intra-VMH MTII induced a significant increase in NETO of brown 
adipose tissue (BAT), heart, and liver. Norepinephrine turnover (NETO) of intra-VMH 
MTII and vehicle microinjected rats in (A) BAT, (B) heart, and (C) liver. Compared to 
vehicle, intra-VMH MTII induced a significant increase in NETO (*MTII>vehicle, 
p<0.05). 
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Intra-VMH MT-II microinjection elevates expression of mRNA of mediators of 
energy expenditure, with a trend towards lower expression of energy conserving 
processes in peripheral metabolic tissues, with some alteration in the protein content 
(Study 2b). 
 To determine the source of calorie use and heat dissipation in the muscle of MTII-
treated rats, I examined the levels of mRNA expression of potential molecular mediators 
of energy balance – UCP1, UCP2, UCP3, Kir6.1, Kir6.2, MED1, PPARα, PPARδ, 
PPARγ, PGC-1α, Ca2+-ATPase (SERCA), β2-AR, and β3-AR in the skeletal muscle 
including quad and gastroc, BAT, WAT, and liver. I found that, compared to vehicle 
administration, rats with intra-VMH MTII microinjections have elevated expression of 
UCP1, PGC-1α, PPARδ, PPARγ, and a trend  (1.0>p>0.05) toward an increase in PPARα 
in their BAT (Figure 26). There were also trends toward an increase in intra-VMH MTII-
treated rats in PPARγ, PPARα, and PPARδ in WAT (Figure 27). Intra-VMH MTII-
treated rats showed a significant increase in mRNA expression of UCP2, PPARα, and 
PPARδ and a trend for PPARγ in the liver (Figure 28). Quadriceps of MTII-
microinjected rats showed a significant increase in mRNA expression of UCP2, UCP3, 
PPARδ, SERCA1, and SERCA2 and a trend toward an increase in expression of PPARα, 
PPARγ, and β2-AR (Figure 29). Quadriceps of intra-VMH MTII-treated rats also showed 
a reduction in mRNA expression of Kir6.1, Kir6.2, and MED1. Compared to vehicle, 
gastroc muscle of intra-VMH MTII rats had significantly higher mRNA expression of 
UCP2, UCP3, PGC-1α, PPARα, PPARδ, PPARγ, SERCA2, and β2-AR (Figure 30). 
Gastroc muscle also showed a significant decrease in Kir6.2 and a trend toward a 
decrease in Kir6.1 and MED1 (Figure 30). 
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 Protein expression of some mediators of EE were altered by intra-VMH MTII, but 
did not consistently change in accordance with mRNA expression. Compared to vehicle, 
BAT of intra-VMH MTII-treated rats showed significantly increased expression of 
UCP1, PGC-1α, pAMPK, and pACC, and trend toward increased expression of PPARγ, 
PPARα, β3 AR, PPARδ, CPT1, and CD36/FAT (Figure 31). In WAT, no significant 
differences were observed except in expression of pAMPK, which was significantly 
elevated in MTII-treated rats (Figure 33). Similar to this was liver of MTII-microinjected 
rats, which showed a significant increase in pAMPK and a trend for increased expression 
of PPARγ, UCP2, β2-AR, and PGC-1α (Figure 34). Compared to vehicle, quadriceps of 
MTII-treated rats showed a significant increase in pAMPK and pACC and a trend for 
increased expression of CD36/FAT, PPARα, PGC-1α, PPARδ, UCP3, UCP2, PPARγ, 
and SERCA1 (Figure 35). Compared to vehicle, gastroc muscle of intra-VMH MTII-
microinjected rats showed a significant increase in expression of PGC-1α, PPARα, 
pAMPK, and pACC (Figure 37). Gastroc muscle also showed increasing trends in several 
proteins including SERCA1, SERCA2, β2-AR, PPARγ, PPARδ, UCP2, UCP3, CPT1, 
and CD36/FAT (Figure 37).  
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Figure 26: Intra-VMH MTII microinjection enhanced mRNA expression of 
mediators of energy expenditure in the brown adipose tissue (BAT). Compared to 
vehicle administration, rats with intra-VMH MTII microinjections have elevated 
expression of UCP1, PGC-1α, PPARδ, and PPARγ in BAT. (*significantly higher than 
vehicle, p<0.05) 
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Figure 27: Intra-VMH MTII microinjection did not significantly alter mRNA 
expression of mediators of energy expenditure in the white adipose tissue (WAT). 
Compared to vehicle administration, rats with intra-VMH MTII microinjections showed a 
trend toward an increase in PPARγ, PPARα, and PPARδ.  
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Figure 28: Intra-VMH MTII microinjection enhanced mRNA expression of 
mediators of energy expenditure in the liver. Compared to vehicle administration, rats 
with intra-VMH MTII microinjections have elevated expression of UCP2, PPARα, and 
PPARδ and a trend toward higher PPARγ in the liver. (*significantly higher than vehicle, 
p<0.05) 
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Figure 29: Intra-VMH MTII microinjection enhanced mRNA expression of 
mediators of energy expenditure in the quadriceps with a trend towards lower 
expression of energy conserving processes. Compared to vehicle administration, rats 
with intra-VMH MTII microinjections have elevated expression of UCP2, UCP3, 
SERCA1, SERCA2, and PPARδ and a trend toward higher PPARα in the quadriceps 
(quad). Quad of intra-VMH MTII-treated rats also showed a trend toward reduction in 
mRNA expression of MED1. (*significantly different from vehicle, p<0.05) 
 
 
 
 
121 
 
 
Figure 30: Intra-VMH MTII microinjection enhanced mRNA expression of 
mediators of energy expenditure in the gastrocnemius with a trend towards lower 
expression of energy conserving processes. Compared to vehicle administration, rats 
with intra-VMH MTII microinjections have elevated expression of UCP2, UCP3, 
SERCA2, PGC-1α, β2-AR, PPARδ, PPARα, and PPARγ in the gastrocnemius (gastroc). 
Gastroc of intra-VMH MTII-treated rats also showed a significant reduction in mRNA 
expression of Kir6.2 and a trend toward decreased Kir6.1 and MED1. (*significantly 
different from vehicle, p<0.05) 
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Figure 31: Intra-VMH MTII microinjection induced a trend toward an increase in 
protein expression of some mediators of energy expenditure in the brown adipose 
tissue (BAT). Compared to vehicle administration, rats with intra-VMH MTII 
microinjections have elevated expression of UCP1, PGC-1α, pAMPK, and pACC and a 
trend in PPARα, PPARδ, CD36/FAT and CPT1 in BAT. (*significantly greater than 
vehicle, p<0.05) 
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Figure 32: Representative western blot images showing the expression of molecular 
mediators of energy balance in brown adipose tissue (BAT). Uncoupling protein 1 
(UCP1), peroxisomal proliferator activator γ coactivator 1α (PGC-1α), p-acetyl-CoA 
carboxylase (pACC), p-AMP-activated protein kinase (pAMPK), and actin as the loading 
control.  
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Figure 33: Intra-VMH MTII microinjection did not alter protein expression of 
mediators of energy expenditure in white adipose tissue (WAT). Compared to vehicle 
administration, rats with intra-VMH MTII microinjections had a significant increase in 
activation of AMPK (i.e., pAMPK) in WAT. (*significantly greater than vehicle, p<0.05) 
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Figure 34: Intra-VMH MTII microinjection did not significantly alter protein 
expression of mediators of energy expenditure in the liver. Compared to vehicle 
administration, rats with intra-VMH MTII microinjections have elevated expression of 
pAMPK in the liver. (*significantly greater than vehicle, p<0.05) 
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Figure 35: Intra-VMH MTII microinjection induced a trend toward an increase in 
protein expression of mediators of energy expenditure in the quadriceps. Compared 
to vehicle administration, rats with intra-VMH MTII microinjections have elevated 
expression of pAMPK and pACC in the quadriceps (quad). Quad of intra-VMH MTII-
treated rats also showed a trend toward an increase in expression of UCP2, UCP3, PGC-
1α, CD36/FAT, PPARα, PPARδ, PPARγ, SERCA1, SERCA2, and β2-AR. 
(*significantly greater than vehicle, p<0.05) 
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Figure 36: Representative western blot images showing the expression of molecular 
mediators of energy balance in the quadriceps (Quad). p-acetyl-CoA carboxylase 
(pACC), p-AMP-activated protein kinase (pAMPK), and actin as the loading control.  
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Figure 37: Intra-VMH MTII microinjection induced a significant increase in 
protein expression of some mediators and a trend toward an increase in other 
mediators of energy expenditure in the gastrocnemius. Compared to vehicle 
administration, rats with intra-VMH MTII microinjections have elevated expression of 
PGC-1α, pAMPK, PPARα, and pACC in the gastrocnemius (gastroc). Gastroc of intra-
VMH MTII-treated rats also showed a trend toward an increase in expression of UCP2, 
UCP3, CD36/FAT, PPARδ, PPARγ, SERCA1, SERCA2, CPT1, and β2-AR. 
(*significantly greater than vehicle, p<0.05) 
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Figure 38: Representative western blot images showing the expression of molecular 
mediators of energy balance in the gastrocnemius (Gastroc). Peroxisomal proliferator 
activator γ coactivator 1α (PGC-1α), peroxisome proliferator activated receptor α 
(PPARα), p-acetyl-CoA carboxylase (pACC), p-AMP-activated protein kinase 
(pAMPK), and actin as the loading control.  
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3.3 Discussion 
I found a dose-dependent increase in EE and decrease in RER after site-specific 
microinjections of MC3R/MC4R non-specific agonist MTII into the VMH. These 
changes in calorimetric parameters were seen even when activity level and workload 
were controlled for using a low-level treadmill activity test, suggesting that intra-VMH 
MC receptor activation lowers the economy of activity. Central MTII also induced an 
increase in skeletal muscle heat dissipation as well as BAT temperature values in freely 
moving animals (Figure 21), suggesting that part of increased EE is due to energy being 
dissipated as heat through these tissues. As with MTII-induced EE, the increase in muscle 
temperature persisted during controlled treadmill activity (Figure 22), ruling out 
differences in physical activity levels. Altogether, this supports the hypothesis that the 
activation of MC receptors in the VMH increases EE, lowers RER by switching fuel use 
to fatty acids, and at the same time lowers the economy by increasing heat production in 
peripheral tissues, particularly skeletal muscle. I also found that, compared to vehicle 
administration, intra-VMH MC receptor activation induced an increase in sympathetic 
drive to the peripheral metabolic tissues as indicated by increased NETO. This increased 
SNS stimulation of skeletal muscle is a likely mechanism through which EE and fuel 
utilization is altered as it known to modulate cellular energy mediators, including in 
muscle (Shiuchi et al., 2009). Altogether, these results support the function of a brain-
muscle pathway where activation of MC receptors in the hypothalamus, particularly in 
the VMH, activate SNS outflow, increasing sympathetic drive to skeletal muscle, 
modulating fuel allocation and use through activation of molecular mediators of energy 
homeostasis potentially to enhance performance.  
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The central MC system plays a key role in the modulation of SNS outflow to 
peripheral tissues. Activation of MC receptors in the hypothalamus increases WAT 
lipolysis and thermogenesis at the level of BAT by modulating fuel allocation and uptake 
(Rossi et al., 2011; Shrestha et al., 2010). I considered the VMH and MC because of 
functional evidence supporting their role in modulating SNS outflow to muscle and 
altering metabolism. Stimulation of the VMH increases skeletal muscle fatty acid 
oxidation and glucose uptake, which is mediated by MC receptors (Miyaki et al., 2011; 
Shiuchi et al., 2009; Tanaka et al., 2007; Toda et al., 2009). This is consistent with my 
results where MC receptor activation in VMH increased total EE of the animal and this 
persisted even when activity was controlled. Even though functional studies show the 
importance of the VMH in the regulation of skeletal muscle metabolism, there were some 
unanswered questions regarding the neuroanatomical substrates underlying this. A 
limited number of VMH neurons were identified that innervate muscle through a multi-
synaptic SNS pathway (Babic, Purpera, Banfield, Berthoud, & Morrison, 2010). More 
recently, however, it was found that SF-1 neurons of the VMH that impact metabolism 
project to the rostral ventrolateral medulla which controls SNS activity (Barnes & 
McDougal, 2014; Y. H. Choi, Fujikawa, Lee, Reuter, & Kim, 2013; Lindberg, Chen, & 
Li, 2013). Although results from immunostaining of the VMH show little presence of 
MC receptors, it has been shown to have high MC binding, and activity of the VMH but 
not the surrounding regions was found to be critical for the modulation of exercise-
induced fatty acid oxidation (Haskell-Luevano et al., 1999; Miyaki et al., 2011; 
Mountjoy, Mortrud, Low, Simerly, & Cone, 1994; Trivedi et al., 2003). Taken together 
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with these studies, my findings support a role for an axis between the VMH and skeletal 
muscle via the SNS as a mediator of hypothalamic modulation of peripheral metabolism.  
 
Evidence points to the assertion that skeletal muscle fatty acid metabolism is 
modulated by CNS, and that the signal is transmitted from CNS to muscle through the 
SNS via adrenergic receptors (Cha et al., 2005). Previous studies have shown that 
activation of hypothalamic MC receptors using MTII increases sympathetic drive to 
peripheral tissues including BAT and WAT (Brito, Brito, Baro, Song, & Bartness, 2007; 
Shi et al., 2004). Centrally administered MTII induced differential sympathetic drive to 
different WAT depots and BAT (Brito et al., 2007). Here, I found that, compared to 
vehicle treatment, activation of MC receptors through non-specific agonist MTII in the 
VMH, increased the sympathetic drive to peripheral metabolic tissues including muscle 
as well as WAT, BAT, and liver. This intra-VMH MC receptor-induced increase in 
sympathetic drive to peripheral tissues supports observed changes in calorimetric 
parameters like physical activity and EE, with the SNS promoting fatty acid uptake and 
use, and WAT providing fuel through lipolysis. Intra-VMH MC receptor activation also 
increased the activation of BAT thermogenesis, but was observed only for a limited 
duration signifying that the increase in EE and muscle temperatures are not entirely due 
to BAT thermogenesis.   
 
  As discussed before, the molecular pathways involved in EE and in energy 
conservation play an important role in determining an individual’s propensity for obesity. 
Energetics at the level of metabolically active tissues like skeletal muscle help determine 
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the overall peripheral energy balance. I have shown that there is a significant increase in 
the expression of several of these mediators of EE at the level of both mRNA (Figures 
26-30) and protein (Figures 31-37) in metabolically active tissues including muscle, and 
trends toward increases in several others. I have focused mainly on thermogenic proteins 
– UCP 1, 2, and 3, and calcium ATPase (SERCA1 and SERCA2). I analyzed proteins 
involved in fatty acid transport, metabolism, and activation – PPARα, δ, and γ, PGC1-α, 
acetyl-CoA carboxylase (ACC/pACC), fatty acid synthase (FAS), fatty acid transporter 
protein (CD36/FAT), and carnitine palmitoyltransferase 1 (CPT1). I also assessed 
indicators of cellular energy needs (AMPK/pAMPK), indicators of sympathetic 
regulation – beta adrenergic receptors (β2 and β3AR), and energy conserving proteins 
(K+ATP channel subunits and MED1). There was no significant change in mRNA or 
protein expression of mediators of conservation in all tissues analyzed. Compared to 
vehicle, intra-VMH MC receptor activation also induced a significant increase or an 
increasing trend in UCP1 in BAT (Figures 26 and 31), and UCP2 and UCP3 in oxidative 
gastroc muscle (Figures 30 and 37). UCP’s have several hypothesized functions including 
thermogenesis in certain tissues, protection from ROS, mediation of insulin secretion, 
neuroprotection, and export of fatty acids (Fisler & Warden, 2006). Regulation of several 
of these functions is either directly or indirectly linked to metabolic disorders (see 
Chapter 1 section 1.7 for complete review). The increase in UCP after intra-VMH MC 
receptor activation and downstream SNS may account for some of the changes in the 
calorimetric parameters seen here such as increased EE partially through increased BAT 
thermogenesis and skeletal muscle heat dissipation, and may also be involved in fatty 
acid transport thereby affecting RER. Increased BAT thermogenesis was observed only 
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for a short duration (~for 1 hr after MC receptor activation) indicating alterations at the 
level of skeletal muscle are more likely to play a role in the observed changes in 
calorimetric parameters seen 1-4 hours after treatment. 
 
Compared to vehicle, intra-VMH MC receptor activation induced a higher 
expression of PPAR’s and co-activator PGC-1α, involved in regulation of metabolic 
pathways including lipid metabolism and mitochondrial biogenesis (Evans et al., 2004; 
Finck & Kelly, 2006). In metabolically active tissues like muscle, liver, and BAT, 
activation of PPARs leads to increased β-oxidation of fatty acids by switching muscle 
fibers to be oxidative, and also to adaptive thermogenesis (Y. X. Wang et al., 2003; Y. X. 
Wang et al., 2004). The expression and activity of these PPAR and co-activators like 
PGC-1α depends on the energy demands of the cell thereby affecting substrate uptake 
and utilization (Finck & Kelly, 2006). I found an increase in PPAR’s and PGC-1α in 
BAT and skeletal muscle after intra-VMH MC receptor activation which likely 
contributed to the increased fatty acid oxidation as indicated by the low RER (Figure) and 
temporarily shutting down glucose oxidation. This is consistent with previous studies on 
PGC-1α altered tissue fuel selection (Finck & Kelly, 2006). 
 
Compared to vehicle administration, gastroc muscle of intra-VMH MC receptor 
activated rats showed an increasing trend in SERCA1, SERCA2, and CD36/FAT 
(Figures 30 and 37). The expression of these proteins may explain to certain extent the 
reasons behind low economy of activity and negative energy balance in MTII-treated 
rats. CD36/FAT is involved in transport of fatty acids to heart and skeletal muscle for 
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oxidation in the mitochondria and its expression differs according to the metabolic 
challenges (Bonen et al., 2006). The SERCA pump regulates the cytosolic calcium level 
tightly and controls many cellular functions, from muscle contraction to cell signaling 
responsible for growth and differentiation (Periasamy & Kalyanasundaram, 2007). 
Increase in these calcium pumps involved in heat generation after intra-VMH MC 
receptor activation suggests their potential role in increased heat dissipation through 
muscle. In all tissues analyzed, intra-VMH MC receptor activation induced a trend 
toward increases in protein expression of mediators of EE, potentially because the 
relatively short amount of time after central MC receptor activation was insufficient for 
translation of proteins. Regardless, the significant increase in temperature at this time 
(4hrs after injection) indicates that there are functional differences in the cell. 
 
Unlike the protein expression pattern observed above, intra-VMH MC receptor 
activation increased the expression of pAMPK and pACC in all tissues analyzed. In 
skeletal muscle, the degree of activation of AMPK is dependent of the metabolic stress 
caused by contraction. This MTII-induced increase in activation by phosphorylation of 
AMPK (pAMPK) may be responsible for increased expression of proteins involved in 
fuel allocation and utilization. Under basal conditions, leptin or adiponectin increases the 
expression of pAMPK in skeletal muscle and liver by increasing sympathetic drive to 
these tissues (Minokoshi et al., 2002; Tomas et al., 2002; Yamauchi et al., 2002). This 
increases energy expenditure in muscle by increasing fatty acid oxidation and up-
regulating mitochondrial biogenesis (Minokoshi et al., 2002). pAMPK also inhibits ACC 
by phosphorylation (pACC) thereby inhibiting fatty acid synthesis (Corton et al., 1995; 
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Henin et al., 1995). MTII-induced activation of pAMPK would increase pACC, lowering 
malonyl-CoA concentration. This in turn, relieves the myocyte of inhibition for the 
uptake of fatty acids into mitochondria via the carnitine carrier system, thus stimulating 
fatty acid oxidation and also up-regulating mitochondrial biogenesis (Merrill et al., 1997; 
Winder et al., 2000). 
 
The current results from my data demonstrate that melanocortins act in the VMH 
to activate SNS outflow, increasing sympathetic drive to skeletal muscle to modulate fuel 
allocation and use through differential activation of molecular mediators of energy 
homeostasis. One or more of these molecular pathways likely increases EE and lowers 
fuel economy during activity, dissipating wasted calories as heat while increasing free 
fatty acid uptake and use as fuel. Altogether, these results are consistent with the role of 
MC receptor activation in the VMH and their regulation of peripheral metabolism 
particularly in tissues like BAT and skeletal muscle via increased sympathetic drive 
(Shiuchi et al., 2009).  These results suggest that the VMH is important for the regulation 
of peripheral metabolism, and that tissues like skeletal muscle can be a good target 
system to change EE to treat over-weight and obesity. Based on these studies on the 
VMH, central MC, and skeletal muscle, I proposed that functioning of this axis is 
heightened at every level in lean HCR compared to the obesity-prone LCR and may 
account for the individual differences in obesity propensity, which will be discussed in 
the next chapter. 
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CHAPTER 4
 
4.1 Introduction 
            As described before in Chapters 1 and 2, compared to LCR, HCR have elevated 
total EE, and this is predominantly due to heightened non-resting EE (rather than resting 
EE). This activity-related EE is not completely secondary to elevated physical activity as 
it persists even during controlled activity, indicating low economy of activity in these 
rats. Low economy of activity suggests wasting of calories to a greater extent in HCR 
than LCR, possibly through skeletal muscle thermogenic mechanisms. I found this 
wastage is in the form of heat, which is potentially regulated through molecular mediators 
of energy conservation and expenditure, and possibly a result of the enhanced 
sympathetic drive observed in these HCR. Under baseline conditions, compared to obese 
LCR, lean HCR rats showed heightened sympathetic drive to skeletal muscle and 
enhanced expression of mediators of energy expenditure and reduced expression of 
energy conservation processes, similar to what is seen after central activation of the 
brain-muscle pathway by MC receptors. 
 
The alterations in the peripheral energy homeostatic mechanisms leading to 
phenotypic differences in muscle energetics may have a central origin. The 
hypothalamus, particularly the VMH, along with the central MC system, plays an 
important role in determining fuel partitioning and usage in peripheral tissues as 
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described in Chapter 1. I have shown that activation of MC receptors in the VMH 
increases EE and physical activity, and decreases RER, switching fuel preference to fats; 
it lowers fuel economy during activity, and ‘wasted’ calories are dissipated as heat; this 
process may engage molecular mediators of energy homeostasis. I have identified several 
potential molecular mediators of EE that showed heightened expression in skeletal 
muscle of the lean phenotype. 
 
 Based on previous studies in our lab (Shukla et al., 2012), we know that HCR and 
LCR show differences in central melanocortins, a system known to modulate sympathetic 
drive (Rahmouni et al., 2003; Shiuchi et al., 2009; Toda et al., 2009). Based on these 
observations, I proposed to examine the role of MC in the VMH in altering activity-
related EE, heat dissipation, SNS drive, and molecular mediators of energy homeostasis 
in our lean and obesity-prone rats. I hypothesize that MC in the VMH is involved in 
altering skeletal muscle energetics through SNS and is responsible for the muscle work 
efficiency, contributing to the leanness that characterizes HCR. I predict that activation of 
MCR in the VMH will increase total EE, particularly activity-related EE, and lower fuel 
economy during activity, metabolizing fats in lieu of glucose. I also predict an increase in 
the expression of mediators involved in EE and fatty acid metabolism and decreased 
expression of energy conserving systems via the SNS to a greater extent in HCR than in 
LCR. Studies below were designed to investigate how VMH and downstream systems 
alter skeletal muscle EE, contributing to lean or obese phenotypes. 
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4.2 Methods 
4.2.1 Study 1: Examine the effects of MC receptor activation in the VMH on skeletal 
muscle energetics, potentially explaining the differences in activity EE between lean rats 
(HCR) and obesity-prone rats (LCR). I predicted higher overall EE and increased energy 
use during physical activity in lean rats upon activation of MC receptors in VMH 
compared to obesity-prone LCR. Based on my results from previous studies, I also 
predicted that skeletal muscle heat generation will be higher in HCR compared to LCR 
after intra-VMH MC receptor activation. 
 
Design 
4.2.1.1 Study 1a: Measure skeletal muscle heat dissipation after VMH MC receptor 
activation with MTII in these rats during light phase in their regular cages and during a 
graded treadmill test. (N=24, 12/group)  
Day -30 – 0: Arrival of animals, separation, housing and quarantine. (12/group)  
Day 1 – 4: Stereotaxic surgeries to implant guide cannula aimed at VMH and transponder 
implants adjacent to gastroc in both hind limbs and adjacent to BAT.  
Day 5 – 11: Recovery.  
Day 12: Divided into MTII- and vehicle-treatment groups. Injected MTII or vehicle 
(aCSF) and measured heat dissipation at the level of skeletal muscle and BAT every 15 
minutes for 4 hrs post-injection.  
Day 17: Repeated day 12 by changing treatment (day 12 MTII group gets vehicle on day 
17).  
Day 21: Trained rats to walk on treadmill.  
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Day 22: Rats were divided into two cohorts (half of each group); cohort1 was subdivided 
into MTII- or vehicle-treatment groups. Rats were injected with MTII or aCSF; 105 - 120 
minutes post injection, rats were allowed to walk on a treadmill at varying intensities for 
30-35 minutes. Gastroc temperatures were measured at regular intervals.  
Day 23: Repeated the same with cohort2.  
Day 27: Repeated the process by changing the treatment.  
Day 28: Repeated the same with cohort2. 
 
4.2.1.2 Study 1b: Measure changes in EE and other calorimetric parameters (RER) upon 
VMH MC receptor activation with MTII in freely moving and activity-controlled rats. 
(N=24, 12/group)  
Day -30 – 0: Arrival of animals, separation, housing and quarantine. (12/group)  
Day 1 – 4: Stereotaxic surgeries to implant guide cannula aimed at VMH and transponder 
implants adjacent to gastroc in both hind legs and adjacent to BAT.  
Day 5 – 11: Recovery  
Day 11: Divided into 6 cohorts (4/cohort, 2 from each group) and each cohort into MTII 
and vehicle treatment groups.  
Day 12: Acclimation of cohorts 1, 2, and 3 to calorimetry chamber and test cages.  
Day 13: 0900 – 1300 - Measured EE and other calorimetric parameters using Oxymax 
FAST system (Columbus Instruments, Columbus, Ohio) for cohort 1 for 4 hrs post-
injection with MTII or vehicle.  
Day 13: 1400 – 1800 – Repeated for cohort 2. After completion removed cohorts 1 and 2 
from chamber and placed in cohorts 4, 5, and 6.  
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Day 14: 0900 – 1300 – Repeated for cohort 3.  
Day 14: 1400 – 1800 – Repeated for cohort 4.  
Day 15: 0900 – 1300 – Repeated for cohort 5.  
Day 15: 1400 – 1800 – Repeated for cohort 6. Removed the animals from calorimetry 
chamber and returned to the animal facility.  
Day 17 - 20: Repeated day 12-15 by changing the treatment.  
Day 22: Acclimated cohorts 1, 2, and 3 in calorimetry chamber for treadmill run 
(controlled activity). Trained rats to run on a treadmill.  
Day 23: Each cohort was subdivided into MTII- or vehicle-treatment groups. Rats were 
injected with MTII or aCSF; at 105 – 120 minutes after injection, rats were allowed to 
walk on a treadmill for 30 minutes and changes in EE and other calorimetric parameters 
were measured. Removed cohorts 1 and 2 from the chamber and moved in cohorts 4, 5, 
and 6.  
Day 24: Repeated the same with remaining rats. Removed the rats after completion of 
run.  
Day 27 – 29: Repeated day 22 – 24 by changing treatment.  
 
After completion of the studies, rats were euthanized, and brains were harvested 
and site checks were done for both cannula and transponder implants. Brains were fixed 
in formalin (10%) and then transferred to 10% formalin containing 30% sucrose. Only 
rats in which the dye injection site corresponds to the stereotaxic coordinates within 
(250μm) of the target (VMH) and transponder implants placed correctly adjacent to 
gastroc and BAT were used for data analysis in all studies. 
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4.2.2 Study 2: Examine the effects of VMH MC receptor activation on the SNS and how 
this pathway alters skeletal muscle energetics in our lean rats compared to obesity-prone 
rats. I predict that activation of MC receptors in the VMH will increase sympathetic drive 
to a greater extent in lean rats compared to obesity-prone rats.  
Day -30 – 0: Arrival of animals, separation, housing and acclimate. (n=48, 24/group)  
Day 1 – 4: Stereotaxic surgeries to implant guide cannula aimed at the VMH.  
Day 5 – 11: Recovery.  
Day 11: Divided into groups depending on treatment.  
Day 12: Day of study  
t hrs: Euthanized zero time point group from both HCR and LCR (to obtain 
baseline tissue NE content) (n=16, 8/group) and injected remaining with aMPT 
(125 mg aMPT/kg of body weight). (n=32, 16/group)  
t+0.5hrs: Injected remaining HCR and LCR with either MTII (20pmoles/200nl) 
or aCSF (200nl) depending on the group (n=32, 16/group, 8/subgroup).  
t+2hrs: Injected remaining animals with 2nd dose of aMPT (125 mg aMPT/kg of 
body weight). (n=32, 16/group)  
t+4hrs: Euthanized rats by rapid decapitation and harvested tissue.  
 
4.2.3 Study 3: Examine the effect of MC receptor activation in VMH on skeletal muscle 
mRNA and protein expression levels of molecular targets involved in EE, fuel utilization, 
and energy conservation between HCR and LCR. I predict that compared to LCR, HCR 
will have higher expression of proteins involved in EE and lower expression of proteins 
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of energy conservation at both mRNA and protein levels upon VMH MC receptor 
activation. I also predict that I will find higher expression of proteins involved in fat 
metabolism in HCR. 
Day -30 – 0: Arrival of animals, separation, housing and acclimate. (n=24, 12/group)  
Day 1 – 4: Stereotaxic surgeries to implant guide cannula aimed at the VMH.  
Day 5 – 11: Recovery.  
Day 11: Divided into groups depending on treatment.  
Day 12: Day of study  
t hrs: Injected with either MTII (20pmoles/200nl) or aCSF (200nl) depending on 
the group (n=12/group, 6/treatment) (each group was divided into either vehicle 
or MTII sub-groups)  
t+4hrs: Euthanized the rats and harvested tissue. 
 
Animals 
Adult male HCR and LCR rats (N=96; 48/group) were obtained from the 
University of Michigan. Each rat was housed individually on a 12:12 light: dark cycle 
with lights on at 0700 EST. Rats received rodent chow (5P00 MRH 3000, T.R. Last Co. 
Inc.) and water ad libitum. All studies were conducted according to the Guide for the 
Care and Use of Laboratory Animals ("National Research Council (US) Committee for 
the Update of the Guide for the Care and Use of Laboratory Animals," 2011) and 
approval of the Kent State University IACUC.  
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Stereotaxic surgeries  
Stereotaxic surgeries were performed on the rats once they are acclimated to the 
housing conditions as described above in Chapter 3. The rats were then allowed to 
recover with periodic monitoring before the start of the study.  
 
Transponder implantation  
A group of male HCR/LCR rats (N=24, 12/group, a subset of larger group 
mentioned above) received transponder implants during the stereotaxic surgery as 
described before in Chapter 3.  
 
Body composition  
Body composition was measured using EchoMRI-700 (Echo Medical Systems, 
Houston, TX) to determine the fat and lean mass (in grams) of each rat the day before 
test. This did not interfere with temperature transponder function. 
 
Measurement of energy expenditure (EE)  
After body composition determination, adult male HCR/LCR rats were measured 
for their EE, physical activity, and other calorimetry parameters after intra-VMH 
microinjections of MTII or vehicle under freely moving and activity-controlled 
conditions as described above in Chapter 3. Four days after the first injection, the same 
test was repeated with rats now receiving counterbalanced treatment (day1 MTII rats 
receiving vehicle on day5 and vice versa). All EE data from both studies were analyzed 
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using 2x2 mixed ANOVA, with treatment as the within-subjects independent variable 
and HCR vs. LCR as the between-subjects independent variable.  
 
Home cage temperature and graded treadmill test 
To determine whether activation of MC receptors in VMH has any differential 
effect on the thermogenesis of skeletal muscle of HCR and LCR, I measured the skeletal 
muscle heat dissipation after intra-VMH MT-II or vehicle microinjection in freely 
moving rats and during a low-level graded treadmill test as described before in Chapter 3. 
The activation of BAT thermogenesis is used as a control process during this study. A 3-
way ANOVA was used to analyze the data (treatment as the within-subjects independent 
variable, HCR vs. LCR as the between-subjects independent variable, and with time as 
the other within-subjects independent variable). 
 
mRNA and protein expression  
Tissue samples were processed to evaluate mRNA and protein expression as 
described above in Chapter 2. The expression levels relative to GAPDH for mRNA and 
actin for protein were plotted as a percent of the reference value (with HCR-vehicle as 
100%), and were analyzed using 2x2 mixed ANOVA, with treatment and HCR vs. LCR 
as between-subjects independent variable. As I was specifically interested in the 
magnitude of effect of MTII in HCR vs. LCR, I did planned (a priori) comparisons using 
t-tests with Bonferroni correction (2 t-tests, 0.05/2 = 0.025, hence p<0.025). 
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Norepinephrine turnover (NETO)  
Adult male HCR/LCR rats (N= 48, 24/group, a subset of above mentioned 
number) were used to assess sympathetic drive to peripheral tissues – liver, heart, BAT, 
skeletal muscle groups, and different WAT depots. After acclimation, stereotaxic 
surgeries were performed to implant guide cannulae aimed at VMH and allowed to 
recover for a week before conducting the experiment. VMH MC receptor activation was 
achieved through microinjection of the agonist MTII (20pmoles/200nl) with aCSF as a 
control. Both groups (HCR and LCR) were sub-divided into 3 groups according to the 
treatment (aMPT/MT-II, aMPT/vehicle, control; 8/treatment). On the day of study, rats 
receiving aMPT were injected with aMPT (125 mg aMPT/kg of BW, 25 mg/ml) and with 
a booster dose at same concentration 2 hours later. 30 minutes after first aMPT injection, 
rats received intra-VMH microinjection of either MT-II or vehicle depending on their 
group. All rats were euthanized by rapid decapitation between 1200 and 1500, 4 hours 
after first aMPT injection. Tissues were rapidly dissected and snap-frozen in liquid 
nitrogen and processed for NETO as described above in Chapter 2. Difference in NETO 
of intra-VMH MTII microinjected and vehicle microinjected rat tissues were calculated 
with respect to control group rats and was represented as NETO per gram of tissue in 
question and analyzed using a 2X2 mixed ANOVA, with treatment (MTII/aCSF) as 
paired and HCR vs. LCR as between-subjects independent variable. 
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4.3 Results  
Lean HCR with intra-VMH MTII microinjection have higher energy expenditure 
compared to vehicle treated HCR and obese LCR.  
As shown in Figure 39, compared to vehicle-microinjected HCR and 
MTII/vehicle treated LCR, HCR administered with intra-VMH MTII have significantly 
higher EE, higher oxygen consumption (VO2), higher physical activity (horizontal and 
ambulatory activity), and lower RER. Compared to vehicle-treated LCR, LCR with 
microinjections of MTII, showed a higher EE, higher VO2, higher physical activity, and 
lower RER. While both groups showed a significant response to MTII, the response was 
significantly greater in the HCR. All rats received microinjections of both vehicle and 
MTII thereby acting as their own controls during the study and eliminating the effects of 
body composition and other individual differences on calorimetric parameters. This 
increase in EE in lean HCR after intra-VMH MTII was significantly higher compared to 
all other groups even when body composition was taken into account. There was no 
significant difference in body weight, lean mass, or fat mass between the two sets of 
injections within the groups although HCR weighed significantly less than LCR and had 
significantly lower fat mass and lean mass (Table 3).  
 
ANCOVA analyses of EE data from HCR/LCR revealed that body weight or lean 
mass were the dominant determinants of EE (Gavini et al., 2014), as EE was consistently 
higher in rats with greater body weight or lean mass (Figure 40). Intra-VMH MTII-
induced EE also increased with higher body weight or lean mass, and intra-VMH MTII 
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treated HCR consistently had higher EE compared to the MTII-treated LCR or other 
groups after body weight or composition were considered using ANCOVA (Figure 40).  
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Figure 39: Intra-VMH MTII induced a significant increase in energy expenditure, 
oxygen uptake, and physical activity, and a significant decrease in respiratory 
exchange ratio in high- and low-capacity runners (HCR, LCR). HCR were 
significantly more affected than LCR. (A) Oxygen uptake (VO2), (B) respiratory 
exchange ratio (RER), (C) energy expenditure, and (D) physical activity 4hrs after intra-
VMH MTII and vehicle administration. Compared to vehicle, MTII microinjections 
significantly increased VO2, energy expenditure and physical activity and decreased 
RER. MTII-induced changes in these parameters were significantly greater in HCR 
compared to LCR (*significantly greater than vehicle; # significantly greater elevation 
seen in HCR than in LCR, p<0.05). 
 
 
 
150 
 
 
Figure 40: In both high- and low-capacity runners, energy expenditure increased 
along with body weight and lean mass. Energy expenditure (EE) was significantly 
higher in the lean phenotype (high-capacity runners, HCR) compared to low-capacity 
runners (LCR), even after lean mass and body weight were taken into account. MTII-
induced EE also increased with body weight (A) and lean mass (B), and intra-VMH 
MTII-treated HCR had significantly higher EE compared to all other groups. 
(N=12/group) 
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Table 3: Body composition of lean high-capacity runners (HCR) and obesity-prone 
low-capacity runners (LCR). Within group, body weight, lean mass, and fat mass of 
HCR and LCR rats did not change between MTII and vehicle administration for tests of 
4hr energy expenditure. (*p<0.05 compared to vehicle-injected LCR, #p<0.05 compared 
to MTII-injected LCR). 
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Lean HCR with intra-VMH MTII microinjections have higher energy expenditure 
compared to vehicle-treated HCR and obese LCR during controlled activity.  
To ascertain that the increase in calorimetric parameters is not due to increase in 
physical activity after intra-VMH microinjection of MTII, a controlled treadmill activity 
study was performed. EE was measured during a low-grade treadmill exercise test 
controlling rats’ workload, and animals were compared to themselves to rule out 
individual differences in body weight. As shown in Figure 41, compared to vehicle 
microinjection, rats receiving intra-VMH microinjection of MTII had significantly higher 
EE, higher VO2, and lower RER in both HCR and LCR during controlled treadmill 
activity. The MTII-induced changes in treadmill EE and VO2 were significantly greater in 
HCR than in LCR. Therefore, the MTII-induced alterations in calorimetric parameters 
were not secondary to increased physical activity. As each rat acted as its own control 
and considering the lack of significant change in body weight, lean mass, or fat mass 
between treatments, the impact of differential workload (body weight and composition 
combined with velocity and incline) during activity is negligible (Table 4). In all rats, EE 
during treadmill activity was consistently higher with greater body weight (Figure 42), 
which is not surprising as body weight is the main determinant of energy expenditure, 
especially during activity. Intra-VMH MTII-induced EE also increased with higher body 
weight and lean mass (Figure 42). 
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Figure 41: Intra-VMH MTII-induced alterations in energy expenditure and 
respiratory exchange ratio persisted during controlled treadmill activity, indicating 
that MTII-induced metabolic changes are not secondary to enhanced physical 
activity. (A) Oxygen uptake (VO2), (B) respiratory exchange ratio (RER), and (C) energy 
expenditure (EE) during controlled treadmill activity after intra-VMH MTII and vehicle 
administration. Compared to vehicle, MTII microinjections significantly increased VO2 
and EE and decreased RER. (D) The MTII-induced change in EE was significantly 
higher in HCR compared to LCR. (*significantly greater than vehicle; # significantly 
greater elevation seen in HCR than in LCR, p<0.05). 
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Figure 42: In both high- and low-capacity runners, activity-related energy 
expenditure increased along with body weight and lean mass. In all rats, activity-
related energy expenditure increased along with body weight (A) and lean mass (B); 
MTII-induced activity-related energy expenditure also increased with body weight (A) 
and lean mass (B) (N = 12/group).  
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Table 4: Body composition of lean high-capacity runners (HCR) and obesity-prone 
low-capacity runners (LCR). Within-group body weight, lean mass, and fat mass of 
HCR and LCR rats did not differ between MTII and vehicle administration during 
controlled treadmill activity. (*p<0.05 compared to vehicle injected LCR, #p<0.05 
compared to MTII injected LCR). 
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High activity energy expenditure after intra-VMH MTII microinjection is 
accompanied by skeletal muscle energy dissipation as heat.  
The above study demonstrated that intra-VMH MTII microinjected rats utilized 
more calories to perform identical activity compared to after vehicle treatment, providing 
evidence to support the hypothesis that intra-VMH MC receptor activation lowers 
economy of activity in both the lean HCR and obesity-prone LCR, although this change 
is more prominent in HCR. This, along with my previous results and literature showing 
the association between VMH MC receptors and skeletal muscle fuel use and allocation, 
implicates alteration of skeletal muscle energetics possibly through thermogenic 
mechanisms as the underlying cause. To test this, I microinjected HCR and LCR rats with 
MTII or vehicle and measured their BAT and gastroc temperatures under resting 
conditions and during a graded treadmill activity test. During resting, compared to 
vehicle, MTII induced an increase in BAT temperature, and the change in temperature 
from baseline was significantly higher after MTII treatment (compared to vehicle) 
between 30min and 120min after injection (Figure 43). There was no difference either in 
temperature or change in temperature of BAT between HCR and LCR in response to 
MTII. In contrast to my prediction, compared to vehicle, intra-VMH MTII did not 
significantly increase gastroc muscle temperatures throughout the test duration; similarly, 
MTII did not induce a significant elevation in temperature when calculated as change 
from baseline temperature (Figure 44).  
 
Next, I determined if the compromised economy of activity induced by central 
MC receptor activation is accompanied by energy dissipation through heat in skeletal 
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muscle. This was tested by measuring gastroc temperature during a graded exercise 
treadmill test. All rats received both sets of injections, and there were no significant 
changes in body weight, lean mass, or fat mass observed within groups between 
injections. Compared to vehicle injections, MTII injections induced higher gastroc 
temperatures in both HCR and LCR rats. This MTII-induced increase in maximal 
temperature was not significantly different between the groups, however (Figure 45). 
Consistent with my previous results (Chapter 2), lean HCR had higher skeletal muscle 
heat dissipation under both vehicle- and MTII-injected conditions compared to obesity-
prone LCR whether treated with vehicle or MTII. These results demonstrate that intra-
VMH MC receptor activation may lower the economy of activity where surplus calories 
are dissipated as heat by skeletal muscle as evident by higher gastroc temperatures, but 
there was no discernable difference in its effectiveness between lean and obese groups.  
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Figure 43: Intra-VMH MTII-induced increase in brown adipose tissue temperature 
in lean high-capacity runners (HCR) and obesity-prone low-capacity runners 
(LCR). (A) Compared to vehicle treatment, intra-VMH MTII induced a moderate but 
significant increase in brown adipose tissue (BAT) temperature in both lean HCR and 
obesity-prone LCR. (B) Change in BAT temperature was significantly greater after MTII 
treatment compared to vehicle between 30min and 120 min. (*significantly elevated over 
vehicle for both HCR and LCR, p<0.05) 
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Figure 44: Gastrocnemius temperature after intra-VMH MTII in lean high-capacity 
runners and obesity-prone low-capacity runners. (A) Intra-VMH MTII-induced 
gastrocnemius (gastroc) temperature of lean HCR and obesity-prone LCR. (B) Change in 
temperature of gastroc from baseline after intra-VMH microinjections of MTII and 
vehicle.  
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Figure 45: Intra-VMH MTII increased activity-associated gastrocnemius 
temperature of high-capacity runners (HCR) and low-capacity runners (LCR) 
during graded treadmill exercise test. (A) Temperature and (B) change in temperature 
from baseline of gastrocnemius (gastroc) of lean HCR and obesity-prone LCR after intra-
VMH MTII and vehicle treatments. Compared to vehicle treatment, gastroc temperature 
was higher after MTII treatment, although the increase in temperature from baseline was 
not significantly greater after MTII microinjection compared to vehicle. The increase in 
temperature from baseline was significantly higher in HCR (both vehicle and MTII 
groups) compared to LCR in either treatment condition (*HCR>LCR, p<0.05).    
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Intra-VMH MTII microinjection differentially elevated sympathetic drive to 
metabolic tissues in lean vs. obesity-prone rats.  
Compared to vehicle microinjection, intra-VMH MT-II induced a significant 
increase in SNS drive to skeletal muscle of both lean HCR and obesity-prone LCR, 
although HCR were significantly more affected than LCR in some muscle subgroups 
(soleus, quadriceps, and gastrocnemius) (Figure 46). Intra-VMH MT-II also induced a 
significant increase in SNS drive to all white adipose depots studied, brown adipose 
tissue, heart, and liver (Figures 47 and 48). MTII-induced NETO was greater in HCR 
than in LCR for MWAT, GWAT, and IWAT (Figure 47), as well as for BAT and liver 
(Figure 48). Interestingly, both baseline and MTII-induced NETO of LCR was greater 
than that of HCR in heart (Figure 48), consistent with data suggestive of cardiovascular 
fitness associated with aerobic capacity. Compared to vehicle-treated LCR, vehicle-
treated HCR had higher NETO in skeletal muscle, liver, BAT, and WAT depots. These 
are consistent with my previous findings in the HCR/LCR rats under baseline conditions 
for skeletal muscle and BAT (Chapter 2) (Gavini et al., 2014). These results support the 
hypothesis that the brain-muscle pathway, modulated by melanocortin receptors in the 
VMH, more effectively impacts metabolism in HCR compared to LCR, potentially due to 
differential activation of SNS, modulating muscle fuel storage and utilization. 
 
 
 
163 
 
 
 
 
 
 
 
 
164 
 
Figure 46: Intra-VMH MTII induced a significant increase in skeletal muscle 
NETO. This effect was significantly greater in HCR than LCR in soleus, quadriceps, and 
gastrocnemius muscle groups. Norepinephrine turnover (NETO) in skeletal muscle of 
HCR and LCR in (A) soleus, (B) extensor digitorum longus (EDL), (C) quadriceps, (D) 
lateral gastrocnemius, and (E) medial gastrocnemius. Compared to vehicle, intra-VMH 
MTII induced a significant increase in NETO in both HCR and LCR. (*significant 
increase by MTII over vehicle; #significant interaction where the MTII-induced increase 
was greater in HCR than in LCR, p<0.05). 
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Figure 47: Intra-VMH MTII induced a significant increase in NETO of different 
white adipose depots. Norepinephrine turnover (NETO) of HCR and LCR in white 
adipose depots (WAT): (A) mesenteric WAT (MWAT), (B) inguinal WAT (IWAT), (C) 
gluteal WAT (GWAT), (D) epididymal WAT (EWAT), and (E) retroperitoneal WAT 
(RWAT). Compared to vehicle, intra-VMH MTII induced a significant increase in NETO 
in both HCR and LCR. This effect was significantly greater in HCR than LCR in 
MWAT, GWAT, and IWAT. (*significant increase by MTII over vehicle; #significant 
interaction where the MTII-induced increase was greater in HCR than in LCR, p<0.05). 
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Figure 48: Intra-VMH MTII induced a significant increase in NETO of brown 
adipose tissue, heart, and liver. Norepinephrine turnover (NETO) of HCR and LCR in 
(A) brown adipose tissue (BAT), (B) heart, and (C) liver. Compared to vehicle, intra-
VMH MTII induced a significant increase in NETO in both HCR and LCR. Change in 
NETO was higher for HCR in BAT and liver and for LCR in heart. (*significant increase 
by MTII over vehicle; #significant interaction where the MTII-induced increase was 
greater in HCR than in LCR except for heart where LCR>HCR, p<0.05). 
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Intra-VMH MTII microinjection elevated expression of mRNA of mediators of 
energy expenditure, with a trend towards lowering expression of energy conserving 
processes in peripheral metabolism. 
 To determine the source of increased EE and heat dissipation in MTII-treated rats, 
I examined levels of mRNA expression of potential molecular mediators of energy 
balance in the skeletal muscle including quad and gastroc, as well as in BAT, WAT, and 
liver as described in Chapter 3. I found that, compared to vehicle-treated HCR, HCR with 
intra-VMH MTII microinjections had significantly elevated mRNA expression of UCP1, 
PGC-1α, PPARδ, PPARγ, and PPARα in BAT (Figure 49). Obesity-prone LCR with 
intra-VMH MTII did not show a significant increase the mRNA expression of above said 
proteins in BAT (Figure 49).  
 
Intra-VMH MTII induced a significant increase in mRNA expression of PPARγ, 
PPARα, and PPARδ in WAT of intra-VMH MTII treated HCR compared to vehicle 
treatment in the same group (Figure 50). Compared to vehicle-treated LCR, intra-VMH 
MTII LCR did show significantly increased mRNA expression of PPARα and PPARδ in 
WAT with an increasing trend for UCP2, PPARγ, and β3-AR (Figure 50). Intra-VMH 
MTII-treated HCR showed a significant increase in mRNA expression of UCP2, PPARα, 
PPARδ, PPARγ, and PGC-1α and an increasing trend for β2 AR in the liver compared to 
vehicle-treated HCR (Figure 51). Compared to vehicle-treated LCR, intra-VMH MTII-
treated LCR had a significant increase in mRNA expression of PPARα, PPARδ, PPARγ, 
and PGC-1α and an increasing trend for UCP2 and β2 AR in the liver (Figure 51). 
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Quadriceps of MTII-microinjected HCR showed significantly higher mRNA 
expression of UCP2, UCP3, PPARα, PPARδ, SERCA1, and SERCA2 and an increasing 
trend in expression of PGC-1α, PPARγ, and β2 AR (Figure 52). Quadriceps of intra-
VMH MTII-treated rats also showed trend toward lower mRNA expression of Kir6.1, 
Kir6.2, and MED1 (Figure 52). Compared to vehicle-administered LCR, LCR with MTII 
showed significant higher mRNA expression of UCP2 and UCP3, and an increasing trend 
in expression of PPARα in the quad. LCR also showed trend toward lower expression of 
Kir6.1, Kir6.2, and MED1 after MTII microinjection (Figure 52). 
 
Compared to vehicle, gastroc muscle of intra-VMH MTII HCR had significantly 
higher mRNA expression of UCP2, UCP3, PGC-1α, PPARα, PPARδ, PPARγ, SERCA1, 
SERCA2, and β2 AR (Figure 53). Gastroc muscle also showed a significant decrease in 
Kir6.2 and a decreasing trend in Kir6.1 and MED1 (Figure 53). Gastroc of intra-VMH 
MTII-injected LCR showed a significant increase in expression of UCP2, UCP3, PPARα, 
PPARγ, and SERCA2. MTII-treated LCR also showed an increasing trend in mRNA 
expression of PGC-1α, and PPARδ (Figure 53), and a decreasing trend in Kir6.2 (Figure 
53). 
 
Protein expression of mediators of EE did not consistently change in accordance 
with mRNA expression. Compared to vehicle, BAT of intra-VMH MTII-treated HCR 
showed significantly higher expression of UCP1, PGC-1α, pAMPK, and pACC, and an 
increasing trend in expression of PPARα and CPT1 (Figure 54). No significant 
differences were observed in MTII-treated LCR, with trends toward higher PPARα, 
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pAMPK, PPARγ, and pACC (Figure 54). No significant differences were observed 
except in expression of pAMPK in WAT of MTII-treated HCR compared to vehicle-
treated HCR (Figure 56). Compared to vehicle-injected HCR, liver of MTII-
microinjected HCR showed significantly more pACC and pAMPK and an increasing 
trend in expression of PPARγ, UCP2, PPARδ, and PPARα (Figure 57). No significant 
differences were observed in LCR (Figure 57). 
 
Compared to vehicle-injected HCR, quadriceps of MTII-treated HCR did not 
show any significant difference in protein expression of the proteins described above, but 
showed an increasing trend in expression of pAMPK, pACC, PPARγ, and SERCA1 
(Figure 58). No significant differences or trends were found in protein expression of these 
energy mediators in MTII-injected LCR (Figure 58). Compared to vehicle-administered 
HCR, gastroc muscle of intra-VMH MTII-microinjected HCR showed a significant 
increase in the expression of PGC-1α, pAMPK, and pACC (Figure 59). Gastroc muscle 
of MTII-treated HCR also showed an increasing trend in PPARα, SERCA1, SERCA2, β2 
AR, PPARγ, PPARδ, UCP3, CPT1 and CD36/FAT (Figure 59). In LCR, no significant 
differences were observed in gastroc protein expression with MTII treatment (Figure 59). 
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Figure 49: Intra-VMH MTII-induced mRNA expression of mediators of energy 
expenditure in the brown adipose tissue (BAT) of lean high-capacity runners (HCR) 
and obesity-prone low-capacity runners (LCR). Compared to vehicle-administered 
HCR, HCR with MTII microinjections have elevated expression of UCP1, PGC-1α, 
PPARα, PPARδ, and PPARγ in BAT. Compared to vehicle-treated LCR, LCR treated 
with MTII showed only trends toward increase in some mediators of energy expenditure 
in BAT. (*significantly greater than vehicle within group; ⱡsignificantly greater than 
MTII-treated LCR; #significantly different from HCR vehicle, p<0.05). 
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Figure 50: Intra-VMH MTII microinjection increased mRNA expression of 
mediators of energy expenditure in white adipose tissue (WAT) of HCR and LCR. 
Compared to vehicle treated HCR, HCR with intra-VMH MTII microinjections have 
enhanced expression of PPARγ, PPARα, and PPARδ and a trend toward increase in β3-
AR (Beta3) in WAT. MTII also enhanced the expression of PPARα and PPARδ with a 
trend toward increase in PPARγ in LCR. (*significantly greater than vehicle within 
group; ⱡsignificantly greater than MTII-treated LCR; #significantly different from HCR 
vehicle, p<0.05).  
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Figure 51: Intra-VMH MTII enhanced mRNA expression of mediators of energy 
expenditure in the liver of HCR and LCR. Compared to vehicle-treated HCR, HCR 
with intra-VMH MTII microinjections have elevated expression of UCP2, PPARα, 
PPARγ, PPARδ, and PGC-1α and a trend toward increase in β2-AR in the liver. LCR 
treated with MTII also showed higher mRNA expression of PPARα, PPARδ, PPARγ, 
and PGC-1α and a trend toward higher β2-AR in the liver. (*significantly greater than 
vehicle within group; ⱡsignificantly greater than MTII-treated LCR; #significantly 
different from HCR vehicle, p<0.05).  
 
 
 
 
 
175 
 
 
 
 
 
 
 
 
 
 
 
176 
 
Figure 52: Intra-VMH MTII microinjection enhanced mRNA expression of 
mediators of energy expenditure in the quadriceps of high- and low-capacity 
runners (HCR, LCR). Compared to vehicle-administered HCR, HCR with intra-VMH 
MTII microinjections have elevated expression of UCP2, UCP3, SERCA1, SERCA2, 
PPARα, and PPARδ and a trend toward increase in PGC-1α and PPARγ in the quadriceps 
(quad). Quad of intra-VMH MTII-treated LCR also showed enhanced mRNA expression 
of UCP2 and UCP3. (*significantly greater than vehicle within group; ⱡsignificantly 
greater than MTII-treated LCR except for Kir6.1, Kir6.2, and MED1; #significantly 
different from HCR vehicle, p<0.05).  
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Figure 53: Intra-VMH MTII induced enhanced mRNA expression of mediators of 
energy expenditure in the gastrocnemius with a trend towards lower expression of 
energy conserving processes in high- and low-capacity runners (HCR, LCR). 
Compared to vehicle-treated HCR, HCR with MTII microinjections showed elevated 
expression of UCP2, UCP3, SERCA1, SERCA2, PGC-1α, β2-AR, PPARδ, PPARα, and 
PPARγ in the gastrocnemius (gastroc). MTII-treated HCR also showed a reduction in 
expression of Kir6.2 and a trend toward a decrease in that of Kir6.1 and MED1. Gastroc 
of intra-VMH MTII-treated LCR also showed enhanced mRNA expression of PPARα, 
PPARγ, SERCA2, UCP2, and UCP3. (*significantly greater than vehicle within group; 
ⱡsignificantly greater than MTII-treated LCR except for Kir6.1, Kir6.2, and MED1; 
#significantly different from HCR vehicle, p<0.05).  
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Figure 54: Intra-VMH MTII microinjection showed a trend toward an increase in 
protein expression of mediators of energy expenditure in the brown adipose tissue 
(BAT) of high- and low-capacity runners (HCR, LCR). Compared to vehicle 
treatment, HCR with intra-VMH MTII microinjections have elevated expression of 
UCP1, PGC-1α, pAMPK, and pACC and a trend toward increase in PPARα and CPT1 in 
BAT. Compared to vehicle injected LCR, MTII-treated LCR showed a trend toward 
increase in expression of pAMPK, pACC, and CPT1. (*significantly greater than vehicle 
within group; ⱡsignificantly greater than MTII-treated LCR; #significantly different from 
HCR vehicle, p<0.05). 
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Figure 55: Representative western blot images showing the expression of molecular 
mediators of energy balance in the brown adipose tissue (BAT) of high- and low-
capacity runners (HCR, LCR). Uncoupling protein 1 (UCP1), peroxisomal proliferator 
activator γ coactivator 1α (PGC-1α), p-acetyl-CoA carboxylase (pACC), p-AMP-
activated protein kinase (pAMPK), and actin as the loading control.  
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Figure 56: Intra-VMH MTII did not significantly alter protein expression of 
mediators of energy expenditure in white adipose tissue (WAT) of lean high- and 
obesity-prone low-capacity rats (HCR, LCR). Compared to vehicle-treated HCR, HCR 
with intra-VMH MTII microinjections had a significant increase in expression of 
pAMPK in WAT. (*significantly greater than vehicle within group; ⱡsignificantly greater 
than MTII-treated LCR; #significantly different from HCR vehicle, p<0.05). 
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Figure 57: Intra-VMH MTII induced a trend toward increase in protein expression 
of mediators of energy expenditure in the liver of high- and low-capacity rats (HCR, 
LCR). Compared to vehicle-administered HCR, HCR with intra-VMH MTII 
microinjections have elevated expression of pAMPK and pACC and a trend toward an 
increase in PPARα, PPARδ, and PPARγ in the liver. (*significantly greater than vehicle 
within group; ⱡsignificantly greater than MTII-treated LCR; #significantly different from 
HCR vehicle, p<0.05). 
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Figure 58: Intra-VMH MTII microinjection induced a trend toward an increase in 
protein expression of mediators of energy expenditure in the quadriceps of high 
capacity rats (HCR). Compared to vehicle-treated HCR, HCR with MTII 
microinjections showed a trend toward increased expression of pAMPK, pACC, PGC-1α, 
PPARγ, and SERCA1 in the quadriceps (quad). (ⱡsignificantly greater than MTII-treated 
LCR except for Kir6.2 and MED1; #significantly different from HCR vehicle, p<0.05). 
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Figure 59: Intra-VMH MTII microinjection induced a trend toward an increase in 
protein expression of mediators of energy expenditure in the gastrocnemius of high- 
and low-capacity runners (HCR, LCR). Compared to vehicle-treated HCR, HCR with 
intra-VMH MTII microinjections have elevated expression of PGC-1α, pAMPK, and 
pACC in the gastrocnemius (gastroc). Gastroc of intra-VMH MTII-treated HCR also 
showed a trend toward an increase in expression of UCP3, CD36/FAT, PPARα, PPARδ, 
PPARγ, SERCA1, SERCA2, CPT1, and β2-AR. (*significantly greater than vehicle 
within group; ⱡsignificantly greater than MTII-treated LCR except for Kir6.1, Kir6.2, and 
MED1; #significantly different from HCR vehicle, p<0.05). 
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Figure 60: Representative western blot images showing the expression of molecular 
mediators of energy balance in the gastrocnemius (Gastroc). Peroxisomal proliferator 
activator γ coactivator 1α (PGC-1α), p-acetyl-CoA carboxylase (pACC), p-AMP-
activated protein kinase (pAMPK), Sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 
(SERCA1 and 2) and actin as the loading control.  
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4.4 Discussion 
            In Chapter 2, I demonstrated that HCR have elevated total EE predominantly due 
to heightened activity-related EE. This activity-related EE is not completely secondary to 
elevated physical activity as it persists even during controlled activity, indicating low 
economy of activity in these rats. This low economy of activity suggests wasting of 
calories to a greater extent in HCR than LCR, potentially through elevated skeletal 
muscle thermogenesis, regulated through molecular mediators of energy conservation and 
expenditure, and in response to the enhanced sympathetic drive observed in these HCR. 
These phenotype-related differences were similar to those seen in response to intra-VMH 
MC receptor activation suggesting a difference in the response of VMH MC receptor-
SNS-muscle axis in the lean HCR. 
 
Indeed, I identified a phenotype-dependent increase in EE, physical activity, and 
VO2, and a decrease in RER after site-specific microinjections of MC3R/MC4R non-
specific agonist MTII into the VMH. In most cases, the changes in the calorimetric 
parameters were significantly higher in lean HCR compared to their obesity-prone LCR 
counterparts (Figure 39). Intra-VMH MC receptor activation induced greater changes in 
EE and VO2 in HCR, and this persisted even during a controlled activity test (Figure 41). 
This holds true even when body weight or body composition was taken into consideration 
(Figures 40 and 42). These changes in calorimetric parameters remained even when 
controlled for activity using a low-level treadmill activity in both HCR and LCR, 
indicating that these changes are not secondary to elevated physical activity levels after 
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MTII microinjections. Altogether, this suggests that intra-VMH MC receptor activation 
lowers economy of activity and is more effective in lean HCR.  
 
The increase in EE after central MC receptor activation is partially accompanied 
by increase in temperature of metabolically active tissues, as MTII induced an increase in 
skeletal muscle heat dissipation as well as BAT thermogenesis (Figures 43 and 44) in 
freely moving rats and an increase in gastroc muscle temperature during treadmill activity 
(Figure 45). These data support the function of the brain-muscle pathway proposed in 
Chapter 3. These findings also support the hypothesis that there may be a phenotypic 
variation in the effectiveness of intra-VMH MC receptor activation with lean HCR being 
more responsive.   
 
While differential skeletal muscle activity thermogenesis and associated 
molecular mechanisms are important in maintaining leanness, it is not possible to propose 
a fully functional theoretical model unless we identify the driving force behind these 
adaptations. As explained in this and previous chapters, the CNS, particularly the 
hypothalamus, plays an important role in maintaining energy homeostasis and peripheral 
fuel metabolism (Braun & Marks, 2011; Shiuchi et al., 2009; Toda et al., 2009). Most of 
the actions of these energy-regulating nuclei are relayed to the peripheral tissues through 
the autonomic nervous system and are likely regulated through β adrenergic receptors 
(Shiuchi et al., 2009). In muscle, this pathway plays a critical role in altering muscle 
energetics through NE, increasing blood flow and fuel uptake and utilization. I found 
that, compared to vehicle administration, there was an increase in sympathetic outflow to 
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the peripheral metabolic tissues in both HCR and LCR, as shown by increased NETO in 
intra-VMH MTII-treated rats (Figures 46-48). This SNS outflow after intra-VMH MTII 
was significantly higher in the lean HCR compared to obesity-prone LCR in many of the 
tissues analyzed. This upregulation of the SNS relay to fuel-producing tissues like liver 
and WAT may underlie the greater responsiveness seen in HCR. One observation I find 
more interesting is the NETO in heart of the MTII-treated HCR and LCR. Unlike most of 
the tissues I looked at, baseline NETO in heart of LCR is higher than that of HCR. 
Compared to HCR, central MC receptor activation induced a greater NETO in the hearts 
of obese LCR (Figure 48). This fits with studies showing that HCR are protected against 
hypertension and is consistent with the data suggestive of cardiovascular fitness 
associated with aerobic capacity in rodents (Wisloff et al., 2005). This supports the idea 
that the effects of intra-VMH MC receptors are carried to the periphery through the SNS. 
This more effectively impacts metabolic processes in HCR compared to LCR and may be 
partially responsible for the lower fuel economy and the associated changes in cellular 
energy mediators in the periphery. These suggest that the observed differences in overall 
EE upon VMH MC receptor activation are partially due to differences in SNS modulation 
of skeletal muscle energetics in our lean and obesity-prone rats. 
 
Both HCR and LCR showed a significantly increase in mRNA expression of 
proteins involved in EE and fatty acid metabolism and a trend in other energy balance 
mediators with central MC receptor activation. This applies not only to BAT and liver, 
but also to skeletal muscle which is the main focus of this work. While there were some 
instances of significant suppression of energy conserving processes, I found very little 
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effect on these processes. This may be due to the fact that the above said procedures were 
done in an acute fashion (3-4 hrs) which may not be adequate time to detect a significant 
inhibition in expression. This increase in proteins of fatty acid oxidation pathway and of 
that are involved in EE are also consistent with the observed phenotype-dependent 
changes in the activity, activity-related EE, and muscle energy use, supporting the 
proposed MC-activated VMH-SNS-muscle pathway. Although there was higher protein 
expression of mediators of EE, most of these changes were phosphorylation-related and 
did not require translation. Demonstrating protein concentration after increasing duration 
of central MC receptor activation may provide robust effects on protein expression. The 
above data affirmed my previous findings in Chapter 3, but also showed phenotype-
dependent differences in HCR and LCR. I found that HCR show heightened expression 
of EE mechanisms in skeletal muscle compared to LCR under baseline conditions 
(Figures 52-53), consistent with results from Chapter 2. This lends further support to a 
theoretical model in which myocytes of the lean rats utilize more fuel through elevated 
EE along with reduced conservation mechanisms, resulting in low economy of activity 
and dissipating excess calories as heat. As described before, the alterations in the 
peripheral energy homeostatic mechanisms leading to observed phenotypic differences 
may have a central origin that may engage molecular mediators of energy homeostasis 
through an SNS relay. I have identified several potential molecular mediators of energy 
expenditure that showed heightened expression in skeletal muscle and other 
metabolically active tissues of the lean phenotype. Energetic mediators at the level of 
metabolically active tissues like skeletal muscle play an important role in determining the 
overall peripheral energy balance. I have shown that there is a significant increase or at 
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least an increasing trend in the expression of these mediators of EE at the level of both 
mRNA (Figures 49-53) and protein (Figures 54-59) in metabolically active tissues, while 
maintaining their baseline phenotypic differences.  
 
Specifically, compared to vehicle, intra-VMH MTII-treated HCR showed a 
significant increase or an increasing trend in proteins involved in fatty acid oxidation 
pathway UCP1, UCP2, UCP3, PGC-1α, pAMPK, pACC  PPARα, PPARγ, PPARδ, and 
CPT1 in BAT (Figure 54)  and oxidative gastroc muscle (Figure 59). These changes may 
be responsible for the central MC receptor-induced increase in EE and decrease in RER.  
The increased EE and lowering RER after intra-VMH MC receptor activation can also be 
due to increased expression of the activated form of AMPK (pAMPK) in the 
metabolically active tissues, consistent with its role in upregulation of fatty acid oxidation 
and mitochondrial biogenesis through its regulation of ACC and CPT1 (Minokoshi et al., 
2002). Although central MC receptor activation did increase EE and SNS drive to 
peripheral tissues in LCR, there were no significant changes in any mediators of energy 
balance except statistical trends in PPARα, pAMPK, PPARγ and pACC (Figures 49-59). 
This suggests phenotypic differences in myocyte responsiveness to adrenergic stimuli, 
consistent with the findings of Lessard, 2009. Compared to vehicle-administered HCR, 
gastroc muscle of intra-VMH MC receptor activated HCR showed an increasing trend in 
SERCA1, SERCA2, and CD36/FAT (Figure 59). SERCA are involved in skeletal muscle 
thermogenesis by regulating calcium homeostasis through ATP hydrolysis and generating 
heat in the process. Increased expression of these calcium pumps or stimulation of Ca2+ 
cycling increases heat dissipation through skeletal muscle which is both dependent and 
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independent of physical activity (muscular contraction for activity). The elevation of 
these proteins in HCR could contribute to leanness and low economy of activity in our 
animal model. This study will help identify potential mediators that can be targeted to 
alter energy balance equation towards negative energy balance. 
 
Altogether, these findings support a role for differential activity-related skeletal 
muscle thermogenesis in maintaining leanness, recognize the importance of central 
homeostatic hypothalamic nuclei including the VMH, and identify potential molecular 
mechanisms underlying these differences. Activation of MC receptors in the VMH 
increases energy use in peripheral tissues in HCR and LCR similar to the observation in 
Chapter 2. It is likely that muscle fuel uptake and utilization is modulated through the 
SNS, affecting skeletal muscle or other metabolically active tissues. The central MC 
system, differentially expressed in the lean HCR and obese LCR is known to impact 
muscle lipid mobilization and glucose uptake in the periphery via SNS (Nogueiras et al., 
2007; Shukla et al., 2012; Sohn et al., 2013; Tanaka et al., 2007; Toda et al., 2009). Put 
together, my data demonstrate that melanocortins in the VMH activate SNS outflow, 
increasing sympathetic drive to skeletal muscle, modulating fuel allocation and use 
through differential activation of molecular mediators of energy homeostasis. This 
increases EE and lowers fuel economy during activity, dissipating wasted calories as 
heat. I also demonstrated that functioning of this axis is heightened at every level in HCR 
compared to LCR. Activating MC receptors in the VMH increased sympathetic drive to 
skeletal muscle and other metabolically active tissues, altering the expression of 
mediators of EE, resulting in decreased fuel economy and increased activity-related EE in 
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a phenotype-dependent manner. These results implicate this pathway as a potential 
mechanism underlying high-endurance-associated low economy of activity and leanness. 
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CHAPTER 5
 
5.1 General discussion 
Obesity is often considered to be a result of either excessive food intake or 
insufficient physical activity, or both. There is a great debate about which behavior 
deserves the most responsibility, an argument which has not yet produced effective 
solutions. Obesity can best be viewed in terms of energy balance. The basic components 
of energy balance include energy intake, energy expenditure, and energy storage (J. O. 
Hill, Wyatt, & Peters, 2012). Humans expend energy through resting metabolic rate, 
which is the amount of energy necessary to fuel the body at rest; the thermic effect of 
food, which is the energy cost of absorbing and metabolizing food consumed; and the 
energy expended through physical activity. Resting metabolic rate is proportional to body 
mass, particularly the amount of fat-free mass. The thermic effect of food is proportional 
to the total food consumed and, in a typical mixed diet, makes up 8% to 10% of total 
energy ingested. The energy expended through physical activity, the most variable 
component of energy expenditure, consists of the amount of physical activity performed 
multiplied by the energy cost of that activity (J. O. Hill et al., 2012). The mechanisms by 
which the body acts to achieve and maintain energy balance is not fully understood 
although available evidence points to a complex physiological control system. This 
system includes afferent signals from the periphery about the state of energy stores and 
efferent signals that affect energy intake and expenditure (J. O. Hill et al., 2012).  
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 Factors that predispose an individual to be obese or resistant to obesity in an 
obesogenic environment are not fully explained. Sitting time and non-exercise activity 
(NEAT) have been linked through epidemiological studies to rates of metabolic 
syndrome, type 2 diabetes, obesity, and cardiovascular disease (George et al., 2013; 
Levine et al., 1999; Levine & Kotz, 2005; Moore et al., 2012) . This obviously raises the 
need for interventional studies to more conclusively test for the potential benefits of daily 
non-exercise physical activity. Even though NEAT plays an important role in overall EE, 
little is known about the molecular and neural mechanisms that are involved in the 
variance among individuals. Thus, there is a need to understand the mechanisms involved 
in the modulation of EE and the influence of this on weight gain and obesity propensity. 
A key trait that predicts NEAT or spontaneous physical activity is intrinsic aerobic 
capacity in both humans and rodents (Novak CM, 2009). High physical activity and 
aerobic capacity can be mechanistically linked and could be characteristics of the lean 
phenotype (Novak CM, 2009).  
 
The CNS controls energy intake and EE, and the hypothalamus plays a critical 
role in this. Even though the hypothalamus has been the main focus of study for a long 
time, how hypothalamic nuclei interact with other homeostatic systems, such as hindbrain 
nuclei and non-homeostatic systems, to regulate food intake and EE remains to be 
elucidated in detail. I focus mainly on the VMH, part of a pathway regulating energy 
balance through its actions on peripheral glucose and lipid allocation, modulating RER 
and thermogenesis (Kim et al., 2011; Miyaki et al., 2011; Takahashi & Shimazu, 1981; 
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Toda et al., 2009). The central MC system also plays a vital role in controlling energy 
balance, increasing EE and physical activity, and decreasing appetite  and modulating 
peripheral lipid metabolism (Butler, 2006; Nogueiras et al., 2007). Central MC modulates 
peripheral glucose and lipid metabolism and thermogenesis in BAT, demonstrating 
neuroendocrine control over peripheral cell metabolism, likely through regulation of the 
SNS (Nogueiras et al., 2007; Obici et al., 2001; Rahmouni et al., 2003; Voss-Andreae et 
al., 2007).  
 
There has been a gradual shift in studies the on central regulation of metabolism 
from adipose and hepatic tissue towards regulation of muscle metabolism. Peripheral 
signals regarding the energy status of the individual alter the functioning of the 
hypothalamic nuclei which in turn regulate energy partitioning in muscle, possibly via a 
sympathetic relay (Belgardt & Bruning, 2010; Braun & Marks, 2011). Injection of leptin 
or orexin-A into the VMH increases glucose uptake and glycogen synthesis in skeletal 
muscle via the SNS, and this is dependent on MC signaling, as shown by studies using 
MTII (Shiuchi et al., 2009; Toda et al., 2009). To summarize, actions of central 
melanocortins in VMH could likely affect sympathetic drive to skeletal muscle, 
modulating energy use, potentially through molecular mediators of energy balance. The 
differences at each and every level of this pathway could be an underlying cause for the 
lean and obese phenotypes. Here, I investigate this pathway using an established rat 
model of leanness and obesity. 
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Based on my initial findings, lean HCR have higher total EE when rats were 
matched for body weight and/or lean mass. Partitioning total EE into its components 
clearly implicated the non-resting component (mostly activity-related EE) more than the 
resting component in this heightened total EE (Figures 7-9). This activity-related EE 
remained higher in HCR even when controlled for activity, showing decreased economy 
of activity in HCR (Gavini et al., 2014; Novak et al., 2010). This implicates differential 
skeletal muscle energy use as an underlying cause for differences in non-resting EE, 
which raises the question as to the fate of those ‘surplus’ calories being disposed by the 
HCR. HCR showed a significantly higher gastroc temperatures; the maximal rise in 
temperature was also significantly higher in HCR compared to LCR (Figure 11), 
demonstrating that HCR have heightened skeletal muscle heat dissipation compared to 
LCR.  
 
To establish the source of this calorie use and heat production in HCR skeletal 
muscle, I examined mRNA and protein expression of molecular intermediates known to 
alter energy use in skeletal muscle. As predicted, HCR showed relatively lower levels of 
mRNA and protein content of energy conserving mechanisms (K+ATP channel subunits 
and MED1) and higher expression of mediators of EE in muscle (Figures 12-13), 
potentially explaining the compromised economy of activity in HCR muscle. This 
suggests a theoretical model in which myocytes of the lean rats utilize more fuel through 
elevated EE along with reduced conservation mechanisms resulting in low economy of 
activity, and dissipate excess calories as heat. These changes in EE mechanisms persisted 
between the two phenotypes after intra-VMH MC receptor activation (Figures 49-59). 
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Though differential skeletal muscle activity thermogenesis and associated 
molecular mechanisms are important in maintaining leanness, it is not possible to propose 
a fully functional theoretical model unless we know what the driving force behind these 
adaptations is. Most of the actions of energy-regulating nuclei are relayed to the 
peripheral tissues through the SNS and are likely regulated through β adrenergic 
receptors (Shiuchi et al., 2009). Compared to obesity-prone rats, lean rats have a 
significantly higher sympathetic drive at least to the two tissue types I examined (Figure 
14). These data support a theoretical model in which the SNS modulates skeletal muscle 
metabolic fuel use, impacting fuel efficiency and increasing EE (mostly activity-related 
EE). Altogether, I have demonstrated that HCR and LCR differ in their total EE, 
particularly non-resting EE, and their activity-related EE is not completely secondary to 
physical activity or body weight. HCR have low economy of activity and possibly 
dispose of those ‘surplus’ calories in the form of heat through the regulation of mediators 
involved in energy balance; this may occur through higher sympathetic drive in HCR, 
altering their muscle energetics.  
 
Effects of central MC receptor activation (with the agonist MTII) on calorimetric 
parameters were similar to the endogenous elevation seen in the HCR. This led me to 
hypothesize that activation of MC receptors in the VMH affects EE in a phenotype-
dependent manner, with HCR being more responsive. I found that, intra-VMH MC 
receptor activation induced a significant increase in EE, VO2, and physical activity, and a 
significant decrease in RER, suggesting a shift in fuel preference to fat. Intra-VMH MTII 
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induced changes in these parameters were significantly higher in HCR compared to LCR 
of the same treatment and irrespective of body weight or composition (Figures 39-40). 
Even when amount of physical activity was taken out of the equation, intra-VMH MC 
receptor-induced changes in these calorimetric parameters persisted, indicating that they 
were not completely attributable to heightened physical activity levels induced by central 
MC receptor activation (Figures 41). Compared to vehicle microinjection, intra-VMH 
MC receptor activation induced a significant increase in EE and VO2 and a significant 
decrease in RER (Figures 19-20, 39, and 41) in both Sprague- Dawley and HCR/LCR 
rats, with HCR being more affected than LCR.  
 
Based on these results and on the proposed model, activation of central MC 
receptors increases EE even when activity or body composition are controlled for, 
implicating lowered fuel economy of activity. Central MC peptides modulate fuel use in 
the periphery including skeletal muscle by altering muscle energetics. This was evident 
as shown by increased heat dissipation at the level of skeletal muscle in Sprague-Dawley 
rats but not in HCR/LCR (Figures 21 and 44). This is also the case with BAT, where in 
both Sprague- Dawley and HCR/LCR, activation of central MC receptors increased BAT 
thermogenesis (Figures 21 and 43). These data support the hypothesis that melanocortins 
act in the VMH to regulate skeletal muscle EE, dissipating calories as heat, analogous to 
VMH control of BAT. This strongly supports the hypothesized role of the VMH 
melanocortins in lowering economy of activity, potentially through alterations in fuel 
allocation and usage, resulting in enhanced skeletal muscle activity-related EE.  
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Central MC receptor-mediated effects in the periphery are relayed through the 
autonomic nervous system particularly the sympathetic division. Compared to vehicle, 
intra-VMH MC receptor activation induced significantly higher sympathetic drive to 
most of the tissues analyzed in both SD and HCR/LCR. This change in sympathetic 
outflow after MC receptor activation was significantly higher in HCR compared to LCR 
in every tissue analyzed except for heart. Heart of LCR had higher sympathetic drive 
compared to HCR during both baseline and central MC receptor activation, suggesting 
HCR are protected against hypertensive effects of MTII (da Silva et al., 2008; Haynes, 
Morgan, Djalali, Sivitz, & Mark, 1999; Rahmouni et al., 2003) which is in line with 
previous results from lean animals (do Carmo, Bassi, da Silva, & Hall, 2011).  
 
These studies demonstrate that melanocortins in the VMH activate SNS outflow, 
increasing sympathetic drive to skeletal muscle, modulating fuel allocation and use 
through differential activation of molecular mediators of energy homeostasis. VMH MC 
receptor activation will also increase EE and lower fuel economy during activity, 
dissipating wasted calories as heat. The functioning of this VMH-skeletal muscle axis is 
heightened at every level in HCR compared to LCR possibly through increased 
sympathetic drive to skeletal muscle and other metabolic tissues excluding heart, altering 
the expression of mediators of EE and energy conservation. This results in decreased fuel 
economy and increased activity-related EE and heat dissipation, implicating this pathway 
as a potential mechanism underlying enhanced activity-related EE and leanness. 
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5.2 Future perspectives 
I have shown that MC in the VMH is involved in altering skeletal muscle 
energetics through the SNS and likely contributes to the leanness that characterizes HCR 
by increasing total EE, particularly activity-related EE, and lower fuel economy during 
activity, metabolizing fats in lieu of glucose. I also show an increase in the expression of 
mediators involved in EE and fatty acid metabolism and decreased expression of energy 
conserving systems via the SNS to a greater extent in HCR than in LCR. 
 
In addition to what I examined in these studies, the potential roles of other 
hypothalamic nuclei including the PVH and the DMH as well as other neuropeptides in 
the regulation of peripheral metabolism needs attention. As described earlier, the 
hypothalamus is comprised of interconnected yet anatomically distinct nuclei that 
respond to changes in energy status through hypothalamic peptides (Chari et al., 2010). 
Even though the hypothalamus has been the main target of studies in last few decades, 
the interactions of these hypothalamic nuclei with other homeostatic systems, such as 
hindbrain nuclei and other non-homeostatic systems in regulating whole body EE 
remains to be elucidated in detail. New methods like optogenetics and designer receptors 
exclusively activated by designer drugs (DREADDs) can be used to elucidate these 
pathways or a specific parts of the pathway, for example the role of VMH SF-1 neurons 
in metabolism (Y. H. Choi et al., 2013; Lindberg et al., 2013). These SF-1 neurons are 
involved in the regulation of energy balance by projecting both locally, within the VMH, 
as well as to other hypothalamic sites (Majdic et al., 2002). In particular, recent studies 
have shown that SF-1 positive neurons project to a number of autonomic centers, thus 
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regulating SNS outflow (Lindberg et al., 2013). Although my results implicate SNS as a 
mediator of central MC effects in the periphery, this needs further evaluation. Using 
pharmacological inhibitors for beta or alpha-adrenergic receptors or denervation studies 
may provide further evidence supporting this hypothesis. Understanding the signaling 
pathways involved in the regulation of mediators of energy balance (see Chapter 1) may 
present potential pharmacological targets to enhance activity EE to tackle overweight and 
obesity.  
 
Present-day programs designed to increase EE are generating mixed results, 
suggesting the need for new strategies. In humans, in addition to the thermogenic tissue 
BAT, skeletal muscle has been demonstrated to significantly contribute thermogenesis 
(van den Berg et al., 2011). Although heat production from muscle has long been 
recognized as a thermogenic mechanism, whether muscle can produce heat independently 
of contraction remains controversial. Studies in birds and mammals suggest that skeletal 
muscle can be an important site of non-shivering thermogenesis (NST) and can be 
recruited during cold adaptation (Rowland, Bal, & Periasamy, 2014). Considerable 
research on thermogenesis during the last two decades has been focused on BAT. These 
studies clearly implicate BAT as an important site of NST in mammals, in particular in 
newborns and rodents. However, BAT is either absent, as in birds and pigs, or is only a 
minor component, as in adult large mammals including humans, bringing into question 
the BAT-centric view of thermogenesis (Rowland et al., 2014). 
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 Skeletal muscle has a role as an elaborate energy production and consumption 
system that influences the whole body’s energy metabolism (Iizuka, Machida, & Hirafuji, 
2014). Skeletal muscle and exercise training have been known to bring about multiple 
benefits for human health maintenance and improvement by impacting glucose and lipid 
homeostasis and altering muscle fiber type composition, and much of this is centrally 
regulated (Braun & Marks, 2011; Iizuka et al., 2014). The mechanisms underlying the 
improvement of the human physical condition have been revealed to certain extent: 
skeletal muscle acts as an endocrine organ, synthesizing and secreting multiple factors, 
and these muscle-derived factors, so-called myokines, exert beneficial effects on 
peripheral and remote organs and skeletal muscle itself (Iizuka et al., 2014). 
Understanding the mechanisms of production and secretion of these myokines may lead 
to a new pharmacological approach for treatment of metabolic disorders. 
 
Skeletal muscle is a unique tissue and adapts in response to both use and disuse. 
In response to an increased work-load (for example, high-resistance strength training), 
the muscle used will increase in both size and strength. In contrast, muscle disuse (such 
as injury-induced immobilization or bed rest) results in muscle weakness and atrophy 
(Ehrenborg & Krook, 2009). Exercise training also leads to changes in the metabolic 
phenotype of the muscle. In response to endurance exercise, the number of mitochondria 
in muscle increases, resulting in an increased capacity of the muscle to sustain aerobic 
metabolism and increased expression of the insulin-sensitive glucose transporter, GLUT4 
(Ehrenborg & Krook, 2009). Trained muscle derives more of the energy required from fat 
and less from carbohydrate compared with untrained muscle during submaximal work 
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(work performed below the maximal oxygen utilization capacity) (Ehrenborg & Krook, 
2009). A detailed understanding of the molecular regulation of skeletal muscle 
metabolism may reveal novel therapeutic targets in the treatment of metabolic disorders. 
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Appendix 4 
 
Energy balance: role of hypothalamic fatty acids  
Hypothalamic nuclei respond to metabolic fuels like glucose, lipids, and amino 
acids. Based on what we know, the brain is heavily dependent on glucose to meet its 
energy demands and it does not use fatty acids as a primary source of energy. It has been 
demonstrated, however, that certain enzymes and intermediates of fatty acid metabolism 
contribute to the ability of the hypothalamus to monitor energy status (Chari et al., 2010). 
For example, administration of long chain fatty acids (LCFA) into the third cerebral 
ventricle of rodents induces a significant decrease in plasma insulin and glucose levels 
within short time (Obici, Feng, et al., 2002; Obici, Zhang, Karkanias, & Rossetti, 2002). 
In the same study, central LCFAs decreased food intake and decreased hypothalamic 
NPY mRNA levels compared to control rats (Obici, Feng, et al., 2002; Obici, Zhang, et 
al., 2002); this is not surprising given that NPY leads to hunger in animals. This supports 
the proposition that hypothalamic actions on metabolism are nutritionally regulated, 
specifically by central LCFAs.  
 
A possible explanation for the observed effects is that there might be an enhanced 
rate of LCFA-CoA metabolism in the hypothalamus of these overfed rats, or altered 
transport. Carnitine palmitoyltransferase-1 (CPT1) modulates the transportation of 
LCFAs into the mitochondria, where they undergo β-oxidation (Figure 61); the activity of 
this enzyme is likely a key factor in the level of cytosolic pool of LCFAs. Indeed, 
hypothalamic CPT1 activity was significantly increased in overfed rats (Chari et al., 
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2010). Inhibiting hypothalamic lipid oxidation by inhibiting CPT1 activity was sufficient 
to restore fatty acid as well as glucose homeostasis in overfed rodents. Altogether, these 
studies highlight the importance of hypothalamic fatty acid metabolism in initiating the 
behavioral and metabolic responses necessary to regulate energy and glucose 
homeostasis.  
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Figure 61: Generation of hypothalamic LCFA-CoA satiety signal. LCFA-CoAs gain 
access to the mitochondria to undergo β-oxidation via the acyltransferase CPT1, which is 
located on the outer mitochondrial membrane. Cellular fat oxidation is regulated by the 
availability of malonyl-CoA, which binds CPT1 and potently inhibits its activity. 
Malonyl-CoA, in turn, is mainly derived from acetyl-CoA—a glycolytic end-product—
via the enzyme ACC; thus, the pathway is in a prime position to accurately monitor 
cellular energy status. Finally, ACC activity is allosterically inhibited by AMPK-
mediated phosphorylation. LCFA-CoAs are also generated from LCFAs transported from 
the circulation via ACSs, the activity of which can be inhibited by triacsin C (Tri-C). 
FAS, fatty acid synthase; GP, glucose production; FI, food intake; EE, energy 
expenditure (Chari et al., 2010)  
 
 
 
 
209 
 
In the majority of tissues, cellular fat oxidation is regulated by malonyl-CoA, 
which is an end product of glycolysis by the enzyme acetyl-CoA carboxylase (ACC), and 
hence malonyl-CoA can precisely monitor cellular energy status. During fasting, the 
hypothalamic levels of malonyl-CoA rapidly decrease and act as a signal for hunger; 
during feeding, the level of malonyl-CoA in hypothalamus increases and acts as a signal 
to stop eating (Lopaschuk et al., 2010). The intracellular levels of malonyl-CoA 
determine the expression levels of AgRP/NPY and α-MSH in the ARC (Cha et al., 2005). 
This hypothesized mechanism of action is supported by studies demonstrating that 
administration of an inhibitor for FAS results in an increase in concentration of 
hypothalamic malonyl-CoA, which suppress expression of orexinergic neuropeptides 
(NYP and AgRP) and activates expression of anorexinergic neuropeptides (α-MSH) in 
the ARC. This leads to decrease in food intake and loss of body weight (Cha et al., 2005). 
The loss of body weight is not completely dependent on reduced food intake, but also 
involves increased EE (Cha et al., 2005). It is found that, within a short period after 
central administration of these inhibitors of FAS, CNS sends signals to peripheral tissues 
like skeletal muscle via the SNS to provoke increased fatty acid oxidation and expression 
of UCP3 and peroxisome proliferator activated receptor α (PPARα) in multiple peripheral 
tissues (Cha et al., 2005). To summarize, malonyl-CoA acts in hypothalamic neurons to 
control energy intake and expenditure (Figure 62) and alters the peripheral tissue 
metabolism by modulating the activity of SNS.  
 
Although malonyl-CoA has been assumed to act as an intermediate in the 
hypothalamic signaling pathway that controls feeding behavior and energy expenditure, 
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the upstream molecular events that regulate its formation are less understood. Recent 
studies suggests that the changes in hypothalamic malonyl-CoA during feeding and 
fasting cycles result from changes in the phosphorylation state and activity of ACC, 
which is mediated by AMP kinase (AMPK) (figure) (Wolfgang & Lane, 2008). Both 
ACC1 and ACC2 are found in hypothalamic neurons and are known to be target for 
phosphorylation catalyzed by AMPK. Conditions that activate AMPK in the 
hypothalamus lead to phosphorylation/inactivation of ACC (Wolfgang & Lane, 2008). 
For example, leptin, an anorexigenic hormone produced primarily by white adipocytes, 
suppresses AMPK activity in the hypothalamus. This action inhibits ACC and thereby 
increases malonyl-CoA. Central administration of an AMPK activator lowers 
hypothalamic malonyl-CoA and promotes food intake (Wolfgang & Lane, 2008). These 
findings have led to the notion that fasting increases the [AMP]/[ATP] ratio in neurons in 
hypothalamic nuclei, leading to the activation of AMPK, the inactivation of ACC, thus 
decreasing malonyl-CoA (Wolfgang & Lane, 2008).  
 
Within the hypothalamus, expression FAS and ACC is limited to specific 
populations of neurons. One possible molecular mechanism for a malonyl-CoA signal 
may be as an allosteric modifier of the neural enzyme CPT1. Specifically, CPT1a, the 
liver isoform, is found in the CNS and has been implicated in the malonyl-CoA signal 
(Obici, Feng, Arduini, Conti, & Rossetti, 2003). However, the CNS expresses a unique 
brain-specific CPT1 gene, CPT1c (Wolfgang & Lane, 2008). CPT1c is expressed in 
neurons throughout the CNS with concentrated localization in hypothalamic nuclei that 
are involved in energy homeostasis such as the ARC and the VMH (Wolfgang & Lane, 
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2008). CPT1c binds malonyl-CoA within the physiological range of malonyl-CoA in the 
hypothalamus (Wolfgang & Lane, 2008). CPT1c knockout mice showed decreased body 
weight resulting from decreased food intake, a phenotype consistent with a malonyl-CoA 
target enzyme CPT1 that controls body weight (Wolfgang & Lane, 2008). This 
phenotype is also consistent with the hypothalamic deletion of FAS, a condition in which 
mice are lean and exhibit lowered food intake and increased malonyl-CoA (Wolfgang & 
Lane, 2008). Altogether, these data support the model which states that the interaction 
between malonyl-CoA and CPT1c within the CNS is involved in nutrient sensing and 
alterations in energy intake likely affecting EE pathways.  
 
The CNS uses mainly glucose during the fed state but will switch to the utilization 
of ketones during food deprivation (Wolfgang & Lane, 2008). It is widely accepted that 
the CNS does not efficiently use long-chain fatty acids for cellular energy purposes. The 
hypothalamus is unique in this regard because the regions involved in regulating energy 
homeostasis have more access to circulating fuels than do other regions of the CNS 
(Wolfgang & Lane, 2008). The hypothesis that fatty acids (or amino acids) act as satiety 
factors is contrary to traditional thought in animal physiology because free fatty acids and 
amino acid concentrations in the blood are high during food deprivation, a time of hunger 
(Wolfgang & Lane, 2008). Consistent with the rather small contribution of fatty acid 
oxidation to CNS metabolism in adult animals, CPT1c does not catalyze fatty acyl 
transfer from fatty acyl-CoAs to carnitine, nor does it promote fatty acid oxidation. The 
inability to catalyze fatty acyl transfer to carnitine is unexpected given the high degree of 
amino acid sequence similarity between CPT1c, CPT1a, and CPT1b. Indeed, CPT1c may 
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not act as an enzyme but may function through a regulatory protein-protein interaction 
that is altered by malonyl-CoA binding (Wolfgang & Lane, 2008). An alternative 
hypothesis for the effect of malonyl-CoA has been proposed whereby malonyl-CoA acts 
as an inhibitor of CPT1a and, therefore, fatty acid oxidation (Obici et al., 2003). 
Inhibition of fatty acid oxidation might promote an increase in the cellular long-chain 
acyl-CoA concentration to activate K+ATP channels independent of the sulfonylurea 
receptor-1 subunit (Wolfgang & Lane, 2008). Therefore, malonyl-CoA could integrate 
cellular nutrient signals provided by glucose flux and AMPK activity as well as the influx 
of free fatty acid from the cerebrospinal fluid (Wolfgang & Lane, 2008). In this way, 
neuronal fatty acyl-CoAs acting on K+ATP channels might play a role in hypothalamic 
nutrient sensing.  
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Figure 62: Role of malonyl-CoA in the hypothalamic control of feeding behavior 
and energy expenditure (Wolfgang & Lane, 2008Wolfgang & Lane, 2008). 
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